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1.1 Introduction 
In this thesis, the targeted delivery (locally and systemically) of a novel group of 
inhibitors of the enzyme translutaminases (TGs) was investigated. Two types of 
delivery options were considered: 1) Factor XIIIa inhibitor was integrated into 
catheters as a new approach for the treatment of central venous catheter and other 
medical implant devices-associated thrombi and staphylococcal infections. 2) Tissue 
transglutaminase (TG2) inhibitor was incorporated into liposomes, with the aim of 
targeting the liver as a new approach to the treatment of liver fibrosis and its end stage 
disease liver cirrhosis. This chapter focuses on general background information 
regarding central venous catheters, liver fibrosis/cirrhosis, TGs and the TG inhibitors. 
Details of the delivery systems employed will be outlined in the respective chapters. 
 
1.2 Central venous catheters 
1.2.1 General introduction and background  
Although the earliest use was noted in 1982, central venous catheters were not a usual 
part of medical therapy until 1945 when plastic catheters became available (Garg et 
al., 2004).  Central venous catheters (CVCs) are defined by Morris et al. (2010) as 
long flexible catheters with single or multiple (2 - 5) lumens that enter central veins. 
These catheters are commonly introduced into the jugular, subclavian and less 
frequently the femoral veins (Figures 1.1 & 1.2). The use of CVCs allows the 
administration of fluids, blood products, medication, total parenteral nutrition and/or 
haemodynamic monitoring of critically ill patients. The application of long-term 
CVCs is of great importance for patients who require long-term medical therapy or 
multiple course of intermittent treatment (Xiang et al., 2001).  
 
CVCs are being utilised with increasing frequency in the hospital and in the 
community. In spite of the extensive experience gained in their application, CVCs are 
related to the long-term risks of catheter sheath formation, infection and thrombosis 
(of the catheter or vessel itself) during catheterisation. Such CVCs related-
complications (CRCs) are associated with increased morbidity, mortality, and 
duration of hospitalisation (Piozzi et al., 2004). Furthermore, these sequences could 
result in expensive interventions, loss of the access mechanism, or loss of access sites 
in a maximum of one-third of patients (Forauer & Theoharis, 2003). 
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1.2.2 Central venous catheter complications 
1.2.2.1 Catheter sheath formation 
The formation of a fibrin sheath around a catheter inserted into the subclavian vein 
was first reported by Motin et al (1964) and termed ‘fibrin sleeve’. A fibrin sleeve has 
been regarded a general reaction between blood and catheter and could be developed 
within 24 hours following catheterization (Hoshal et al., 1971). Approximately all 
CVCs are coated with a fibrin sheath within days of insertion (Kutter, 2004). The 
reported incidence of a “fibrin sleeve” ranges from 42 % to 100 % with variable 
length (Brismar et al., 1981; Raad II et al., 1994). The sleeve itself generally does not 
cause clinical symptoms, nevertheless has been counted as the reason of several 
catheter-related complications such as thrombosis and infection (Xiang et al., 1998). 
 
1.2.2.2 Catheter-related blood vessel thrombosis (DVT) 
One of the major complications of CVCs is thrombosis (Figures 1.3 & 1.4). 
According to the German physician, Rudolf Virchow, thrombus formation requires 
three essential components; hypercoagulability, hemodynamic changes (stasis, 
turbulence) and endothelial injury/dysfunction (Armstrong et al., 2008). A foreign 
body in the bloodstream can activate coagulation at its surface. All central venous 
catheters are basically intravascular foreign bodies. Platelets and the complement 
coagulation pathways are activated at the focal site of injury where the catheter places 
the vein or potentially at any place all along the entire catheter length. Red blood 
cells, platelets, white blood cells, fibrinogen, and fibrin attach to a catheter surface. 
Thrombus formation associated with central venous catheters can form at the tip of a 
Figure 1. 2 Central venous catheter inserted 
into subclavian vein (web image 2). 
Figure 1. 1 Multi-lumen Central Venous Catheter 
Systems (web image 1). 
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catheter, along the entire intravascular catheter and also at the site of venous entry 
(Santilli, 2002).  
 
The mural thrombi may partly or completely block the blood vessel and may involve 
12 – 74 % of all CVCs (Kutter, 2004). This wide variability is due to the diagnostic 
methods used, the difficulties in interpretation of observations, the way thrombosis is 
defined and reported (Xiang et al., 2001), variation in catheter type, position, duration 
of insertion, and the underlying diseases (Kutter, 2004). Aside from reducing the 
function of the catheter the CV-related thrombi can cause postphlebitic syndrome in 
15 – 30 % of cases and pulmonary embolism in 11 % of cases (only half of which are 
symptomatic) (Kutter, 2004).  
 
       
 
1.2.2.3 Catheter-related infection 
 
1.2.2.3 Catheter-related infection 
Infection is defined as a homeostatic imbalance between the host tissue and existence 
of microorganism (Zilberberman and Elsner, 2008). Nosocomial or hospital acquired 
infections are a major cause of morbidity and mortality among hospitalized patients. 
They concern 5 – 15 % of hospitalized patients and can lead to complications in 25 - 
50 % of those admitted to intensive care units (ICUs) (Eggimann et al., 2004). Urinary 
tract and surgical site infections, followed by respiratory and bloodstream infections 
are the most frequent infections worldwide (Eggimann, & Pittet, 2001). Methicillin-
resistant Staphylococcus aureus (MRSA) is the most common cause of nosocomial 
infections (Sisirak et al., 2010). The National Nosocomial Infection Surveillance 
Figure 1. 3 Taking out of the catheter with the 
surrounding fresh thrombus material with the 
help of a clamp (web image 3). 
Taking out of the catheter with the 
Figure 1. 4 Parts of Cava-fix catheter and 
covering thrombus surrounding it (inside), 
after removal from a patient (Figure 1.3) 
(web image 4). 
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(NNIS) (2000) system reported that the majority of nosocomial bloodstream 
infections in ICUs are related with the utilisation of intravascular access and the 
infection rates are considerably higher among patients with central venous catheters 
than among those with peripheral lines. 
 
     
                                                                                      
 
 
 
CVC-related infection has been defined in various terms by the Centers for Disease 
Control, researchers, and authors. In general it consist of any of the following 
conditions: ‘‘a catheter colonized with more than 15 colony-forming units, according 
to the Maki technique (1977), with symptoms of sepsis (hyperthermia, hypothermia, or 
hypotension); purulent drainage at the catheter site with or without bacteremia; 
symptoms of sepsis with or without bacterernia, unrelated to infection at another site, 
in the presence of an indwelling CVC; and bacteremia, unrelated to infection at 
another site, in the presence of an indwelling CVC’’ (Hoppe, 1995). 
 
Systemic and local infectious complications of CVCs include local site infection, 
catheter related blood stream infection (CRBSI), septic thrombophlebitis, 
endocarditis, and other metastatic infections such as lung abscess, brain abscess, 
osteomylitis and endophthlamitis (O’Grady et al., 2002; Garg et al., 2004) (Figures 
1.5 & 1.6). The American Centers for Disease Control and Prevention (CDC) defines 
CRBSI as the isolation of the same organism from the colonised catheter and 
Figure 1. 6 Appearance of a central venous 
catheter associated with bacteremia (web image 
6). 
 
Figure 1. 5 A tube-site infection. Most catheter-
related infections involve local cellulitis, as 
shown here, with erythema and tenderness. These 
infections frequently respond to local wound care 
and oral antibiotics (web image 5). 
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peripheral blood in a patient with clinical sepsis and no other apparent source of 
bloodstream infection (Garg et al, 2004). The most common pathogens isolated from 
hospital acquired CRBSI are coagulase negative Staphylococcus species, Gram-
negative rods and Staphylococcus aureus (Garg et al., 2004).  
 
It was first suggested by Press et al. in 1984 that thrombosis is a major risk factor for 
infection of CVCs by demonstrating that bacteremia was much more common in 
patients with documented CVCs thrombosis (Press et al., 1984). This could be due to 
the fact that all cannulated blood vessels comprise a fibrin sheath seeded with 
adherent cocci (Kutter, 2004). Figure 1.7 demonstrates the potential routes of catheter 
infection. 
 
 
 
There are two most general pathways identified in the development of catheter-related 
infections.  Initially, colonization of the external surface begins with the colonization 
of the insertion site by microorganisms that may progressively move through the 
transcutaneous part of the dermal tunnel surrounding the catheter. Skin colonization is 
a strong indicator of catheter-related infection. Secondly, colonization of the internal 
surface may occur by colonization of the hub and intraluminal surface of the catheter 
during utilization and frequent opening of the hub. The third pathways could be 
haematogenous seeding of the catheter throughout blood stream infection. 
Figure 1. 7 Potential routes of catheter infection (web image 7). 
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Nevertheless, contamination of fluids or drugs intravenously administered could be 
responsible for catheter-related infections. As a consequence, a biofilm constituted of 
host glycoproteins including fibrinogen, fibronectin, collagen and laminin may be 
formed.  This layer increases the adherence of bacteria, in particular Staphylococcus 
aureus and coagulase-negative staphylococci to the foreign material (Figure 1.7) 
(Eggimann et al., 2004). Contamination of intravenous fluid is the fourth potential 
source of CVC-related infection. This mechanism hardly ever results in bacteremia, 
however it has been associated with cases of epidemic nosocomial infections (Hoppe, 
1995). 
 
1.2.3 Epidemiology for CRBSI 
It has been found that 2.8 – 18 % of CVC patients suffer from catheter-related 
infection (Mughal, 1989). In the United States, CRBSI occurs with 3 – 7 % of 
catheters and affects more than 200,000 patients per year with a mortality of 10 - 25 
% and an extra cost to the health-care system of approximately $ 25,000 per episode 
(O’Grady et al., 2002).  
 
The epidemiology, clinical outcomes and costs associated with CRBSIs in four 
European countries (France, Germany, Italy and the UK) based on recent information 
are estimated in Table 1.1 & Figure 1.8. In the UK, approximately 6000 patients 
acquire catheter-related bloodstream infection annually with a considerable increase 
in the length of hospitalisation and medical care costs (Fletcher & Bodenham, 1999). 
The most recent CRBSI study in the UK was conducted by the Scottish Executive 
Health Department in 2005 in five hospitals in six intensive care units (ICUs). This 
pilot study using the Hospital in Europe Link for Infection Control through 
Surveillance definitions (HELICS) reported an estimate of 4.2 CRBSIs per 1000 
catheter days (95 % CI: 1.4–9.8). Based on a study performed by Plowman et al 
(2001), it was estimated (through modeling) that CRBSIs might be accountable for an 
extra length of stay (LOS) of 4.0 days (1.9 days based on observed, not modeled, 
data). The extra LOS was regarded as low and related to the considerable use of 
medical resources. This translates into an estimate of 16 980 to 35 750 days caused by 
CRBSIs, i.e. 1.9–4 days extra LOS multiplied by the 8940 CRBSIs in the UK 
(Plowman et al., 2001; Tacconelli et al., 2009). 
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Mortality rates for CRBSI are complicated to calculate due to the presence of various 
confounding factors that were observed amongst patients. In a relatively recent study 
carried out by Tacconelli et al. (2009), no information was retrieved concerning 
CRBSI-related mortality in the UK. However, rates in France, Germany and Italy 
were reported (Table 1.1). 
 
Table 1.1 Key results of a Medline literature review of published epidemiological studies, 
economic evaluations and cost studies in the field of CRBSIs. (taken from Tacconelli et al, 2009). 
ICU stands for intensive care unit; CRBSI stands for catheter-related bloodstream infections; LOS 
stands for length of stay.  
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The cost of a CRBSI episode can be determined by multiplying the extra LOS related 
to CRBSI by the daily ICU cost. Plowman et al. (2001) provided an estimation of 
additional costs per blood stream infection of ~ € 9,251 (£ 6,209) (exchange rate: £ 
1 =  € 1.49) when modeled versus € 4,392 (£ 2,949) when observed, whilst Tacconelli 
et al. (2009) expected that the costs for the National Health Service (NHS) could be 
between £ 19.1 and £ 36.2 million (€ 28.5 to € 53.9 million) (Figure 1.8). Another 
study at Blackpool Victoria Hospital, NHS Trust stated that the full cost of hospital 
acquired bacteremia in general surgical and the institutional technical unit (ITU) 
patients over a 12 month period was £ 491,984 (Garg et al., 2004). Presently this 
number is increasing rather than decreasing. 
 
 
 
Figure 1. 8 Extra costs of catheter-related bloodstream infection (CRBSI) per implanted central 
venous catheter per country (France, Germany, Italy and the UK). Results present the minimum 
and maximum estimates per country for the additional costs of CRBSIs per implanted CVC (taken 
from Tacconelli et al., 2009).  
 
1.2.3 Current treatment options for CRCs 
Many approaches have been made to reduce the incident of catheter related 
complications including:  
 
• Regular flushing with heparin and saline (Kutter, 2004). 
• Administration of warfarin or low molecular weight heparin (LMWH). 
• Use of antimicrobial coated catheters such as antispetic coated catheters 
including: chlorhexidine/ silver sulphadiazine, benzalkonium chloride, 
platinum/ silver; antibiotic coated catheters including: minocycline/ rifampin 
or teicoplanin; bonding with cefazoline. 
• Impregnation with extremely small silver particles throughout the polymer 
matrix has also been tried (Garg et al., 2004). 
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In spite of these options, prophylactic flushes with heparin or saline are insufficient to 
avoid blood vessel thrombosis (Kutter, 2004). The advantage of systemic prophylaxis 
with LMWH or warfarin has not been widely recognized. Low-dose warfarin 
prophylaxis remains debatable, although many earlier studies support the use of low-
dose warfarin, most recent studies do not. There is also a major inconvenience of daily 
subcutaneous injections of standard heparin or LMWH. Even low prophylactic doses 
of LMWH may accumulate and lead to bleeding in the asthenic or elderly cancer 
patient with a reduced glomerular filtration rate. This effect is augmented in patients 
with reduced renal function due to disease or chemotherapy. Nevertheless, in patients 
with sufficient nutrition and hepatic function, the risks of this approach seem 
negligible (Kutter, 2004). There have been debates concerning the utilization of 
antibiotic-coated catheters and the increased risk for bacterial resistance and the 
possible ineffectiveness of these agents against antibiotic resistant nosocomial 
bacteria and fungi. To date, clinical trials have not overcome this problem (Darouiche 
et al., 1999; Hanna et al., 2003).  
 
1.2.4 Transglutaminases (TGs): Nature's biological glues 
The term transglutaminase (TGs) (EC2.3.2.13) was initially described by Clarke et al. 
in 1957, while observing the transamidating activity in guinea-pig liver. Subsequent 
studies conducted by Pisano et al. (1968) on the stabilization of fibrin monomers 
during blood clotting, demonstrated that transamidation is brought about by Ca2+ and 
thiol–dependant enzymes which cross-link proteins through an acyl-transfer reaction 
between the γ-carboxamide group of peptide-bound glutamine and the ε-amino group 
of peptide-bound lysine, resulting in a ε-(γ-glutamyl) lysine isopeptide bond (Griffin 
et al., 2002) (Figure 1.9).  
 
The ε-(γ-glutamyl) lysine cross link is essentially an isopeptide bond, being found in a 
range of organisms from humans to bacteria and plasmodium (Peterson et al., 1983). 
The resultant bonds are covalent, stable, and resistant to proteolysis, thus enhancing 
the resistance of tissues to chemical, enzymatic, and physical degradation (Hiiragi, 
1999). 
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Figure 1. 9 Cross-linking reaction of transglutaminases. The enzyme forms covalent bonds between 
the γ- carboxamide group of a glutamine residue in one polypeptide chain and the ε-amino group of 
peptide-bound lysine in a second polypeptide chain with the subsequent release of ammonia (NH3) 
(web image 8). 
 
Eight distinct TGs isoenzymes have been identified at the genomic level in mammals 
(Grenard et al., 2001) (Table 1.2), however their function in a variety of physiological 
and pathological processes is still a matter of considerable research and dispute 
(Wodzinksa, et al., 2005). These enzymes are dispersed in plasma, tissues, and 
extracellular fluids, transglutaminase modified proteins are manifest all through the 
body in the fibrin network of blood clots, cell membranes, extracellular matrix, 
features of the epidermis and its appendages (callus, hair, and nail) (Greenberg et al., 
1991). They are also involved in many therapeutic applications including the use of 
FXlll substitutive therapy in a rare genetic defect due to the loss of plasma TGs, repair 
of surgical wounds, fractures and cartilage lesions, treatment of certain intestinal 
disease or reduction in tumor growth, in addition to commercial application of TGs in 
the pathogenesis of infectious diseases and in the development of novel strategies in 
vaccination for bacterial and viral infections. Nevertheless, deregulation of enzyme 
activity usually associated with main interruption in cellular homoeostatic 
mechanisms and has resulted in these enzymes contributing to various human 
diseases, including inflammatory disease, chronic neurodegenerative diseases 
(Alzheimer’s and Huntington’s disease), neoplastic diseases, autoimmune conditions, 
such as celiac disease, cancer, tissue fibrosis and diseases related to the epidermis of 
the skin (Griffin et al., 2002).  
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Table 1.2 Identified active types of TGs in mammals (taken from Griffin et al., 2002). They are 
distinguished from each other by their physical properties and distribution in the body. 
 
1.2.5 Plasma factor XIII 
Blood coagulation Factor XIII (FXIII), also known as fibrin-stabilizing factor (or 
fibrinoligase), is one of the best characterized transglutaminases, and its physiological 
role is well established (Figure 1.10). FXIII is a tetramer composed of two A subunits 
(FXIII A) and two B subunits (FXIII B) 
noncovalently associated (lorand et al., 
1986). The Factor XIII A-subunit gene 
belongs to the transglutaminase family 
(Ariens, et al., 2002). Dissimilar to many 
other TGs, it is a zymogen (proenzyme) 
that is converted into an active 
transglutaminase (FXIIIa) by the 
proteolytic action of thrombin and Ca2+ in 
the final phase of the coagulation cascade. 
Its main task is to crosslink α-, and γ-chains 
of fibrin and α2-plasmin inhibitor to fibrin. 
By this way FXIIIa strengthens fibrin and protects it from the prompt elimination by 
the fibrinolytic system (Ichinose et al., 1990). Cross-linking by FXIIIa improves the 
mechanical strength, rigidity and elasticity of the clot and increases its resistance to 
plasmin-mediated degredation (Ariens, 2002). Therefore, inhibition of FXIIIa activity 
 ?
 ??
 
Figure 1. 10 Crystal structure of human 
Factor XIII (web image 9). 
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enhances fibrin degradation mediated by plasmin in vitro and accelerates 
thrombolysis in animal models of venous and arterial thrombosis and in experimental 
pulmonary embolism (Bereczky et al., 2003; 2004).  
 
1.2.6 FXIIIa inhibitors: a new approach to the treatment of catheter-related 
infection and thrombosis 
FXIIIa, the key enzyme of the normal blood clotting process in thrombus stabilisation 
could also be exploited by Staphylococci which then become permanently attached to 
the blood clot, thus shielding them from immune attack and the antibiotics used to 
eradicate them. The link between catheter-related thrombus formation and 
Staphylococci infection is the mechanism by which Staphylococci aureus colonise 
surfaces of medical devices by binding to the host proteins (fibrin/ fibrinogen and 
fibronectin). The interaction is mediated by the production of a number of microbial 
surface components recognizing adhesive matrix molecules; in Staphylococci aureus 
these include the fibrinogen-binding clumping factors A and B and the fibronectin-
binding protein (FnbA) (Foster et al., 1998). FnbA is a substrate for FXIIIa and 
undergoes covalent cross linking to fibrinogen and fibronectin (Matsuka et al., 2003; 
Anderson et al., 2004). Staphylococci aureus becomes covalently cross-linked to 
fibrinogen and fibrin during deposition within the fibrin-platelet matrix of thrombi on 
the catheter surface; this prevents the release of bacteria into the blood during natural 
fibrinolysis and retaining the organisms in an environment protected from antibiotics 
action and host defenses (Griffin et al., 2004).  
 
Incorporation of the FXIIIa inhibitors into catheter or other medical implant devices 
could be used as a new approach to reduce the incidence of catheter sheath formation, 
thrombotic occlusion and associated infection in CVCs (Griffin et al., 2004). 
 
Recently, a novel group of transglutaminase inhibitors has been introduced by Griffin 
et al. (2004; 2008). These small, non-toxic inhibitors could prevent stabilisation of 
thrombi by FXIIIa and consequently increase the natural rate of thrombolysis. In 
addition they could reduce staphylococcal colonisation of catheters by inhibiting 
FXIIIa-mediated cross-linking of staphylococci to host proteins on the catheter 
surface (Griffin et al., 2004) (Figure 1.11, Lambert, 2007).  
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Figure 1. 12 A healthy liver in adults (left). A liver damaged 
by alcoholism shows a build up of fatty tissue (middle), and 
a liver with cirrhosis is enlarged and swollen (right) (web 
image 10). 
 
A major aim of this study was the integration of the fluorescent FXIIIa inhibitor into 
the polymeric coating of polyurethane central venous catheters or silicone central 
venous catheter, with the intent of producing CVCs with a lower incidence of 
thrombosis and related staphylococcal infections. 
 
Figure 1. 11 Effect of the FXIIIa inhibitors (R281 & R283, excising inhibitors) on release of 
Staphylococcus aureus from human thrombi. The release of Staphylococcus aureus from human 
thrombi is increased in the presence of the FXIIIa inhibitors over time (Lambert, 2007). 
 
As previously stated, TGs inhibitors could also be used for treating of liver fibrosis 
and its end stage disease cirrhosis. 
 
1.3 Liver fibrosis/ Cirrhosis  
1.3.1 General introduction and background  
The term cirrhosis, derived 
from the Greek term 
scirrhus, meaning orange, 
was first introduced by 
Laennec in 1819 to describe 
the way that cirrhotic livers 
turn from yellowish to tan in 
colour. In general, cirrhosis 
is a chronic degeneration of 
an organ resulting in the 
replacement of healthy 
tissues with extensive 
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fibrous connective tissue (Iredale, 2003). The term is most commonly used to depict a 
diseased state of the liver, the organ that is most frequently influenced by cirrhosis 
(Figure 1.12). Cirrhosis of the liver is the end stage of fibrous scarring and 
hepatocellular regeneration, distinguished by diffuse disorganization of the normal 
hepatic structure of regenerative nodules and fibrotic tissue (Ueki et al., 1999). 
Following chronic liver damage, inflammatory lymphocytes enter the hepatic 
parenchyma, some hepatocytes undergo apoptosis, and Kupffer cells become 
activated, and release fibrogenic mediators. Hepatic stellate cells (HSCs) proliferate, 
experience a substantial phenotypical activation and secrete a considerable amount of 
extracellular matrix proteins. Sinusoidal endothelial cells relinquish their 
fenestrations, and the tonic contraction of HSCs results in increased resistance to 
blood flow in the hepatic sinusoid (Figure 1.13) (Bataller and Brenner, 2005).  
 
  
Figure 1. 13 Alterations in the hepatic structure in a fibrotic liver caused by accumulation of 
ECM proteins. Normal liver (A) and advanced hepatic fibrosis (B). Following chronic liver damage, 
inflammatory lymphocytes enter the hepatic parenchyma. Some hepatocytes undergo apoptosis. 
Kupffer cells activate, and release fibrogenic mediators. HSCs proliferate, experience a considerable 
phenotypical activation and secrete a significant amount of extracellular matrix proteins. Sinusoidal 
endothelial cells relinquish their fenestrations, and the tonic contraction of HSCs results in increased 
resistance to blood flow in the hepatic sinusoid (taken from Bataller and Brenner, 2005).  
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Liver cirrhosis is the end stage of liver fibrosis (Li and Wang, 2009). Therefore the 
prevention and inversion of liver fibrosis is the approach used to cure chronic hepatic 
diseases and to improve prognosis. Liver fibrosis, the extreme accumulation of 
extracellular matrix proteins such as collagen, is a result of the wound-healing 
response of the liver to recurring injury (Figure 1.13) (Friedman, 2003; Bataller and 
Brenner, 2005; Iredale, 2007).  
 
1.3.2 Etiology of liver cirrhosis  
The common causes of liver fibrosis and cirrhosis include hepatitis B, hepatitis C, 
alcohol, immune-mediated damage, genetic abnormalities, exposure to various drugs 
and toxic chemicals and non-alcoholic steatohepatitis, which is associated with 
diabetes and metabolic syndrome (Dufour et al., 1993; Day, 2002; Adrian et al., 
2007). It is well known that alcohol consumption is a foremost contributor in deaths 
from cirrhosis and the related condition of alcoholic hepatitis (Mann et al., 2003).  
 
1.3.3 Epidemiology of liver cirrhosis in European countries 
A survey conducted by Leon (2007) between the periods 1987-1991 and 1997-2006, 
on two age groups (15-44 years old and 45-64 years) of men and women. The study 
shows that the cirrhosis mortality rate accelerated dramatically in Britain, whilst rates 
in most of Western Europe were declining, with Scotland having one of the fastest 
growing chronic liver disease and cirrhosis death rates in the world (Figure 1.14). 
Nevertheless, since the early 1950s, there has been a considerable increase in liver 
cirrhosis mortality rates in Scotland, England and Wales for both sexes. Since then 
there has been a steady increase that continued until the end of 1970, which became 
more dramatic in the 1980s, and again from 1990 to 1994, and continuing until today. 
Indeed rates in men increased five-fold in England and Wales, and six fold in 
Scotland, between the period of 1950–54 and that of 2000–2002, whilst in women 
there was a corresponding four-fold increase in mortality rates. The same pattern of 
increase was observed for both of the age groups, although the absolute rates in the 
older age-group of women were much higher. In contrast, mortality rates for both men 
and women in both age-groups rose sharply compared with the mean for other 
European countries from 1955 and peaked in the early 1970s. In Scotland, the 
mortality rates for both age groups and sexes are approximately twice that of other 
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European countries, while the mortality rate in England and Wales was equal to if not 
higher than the European average (Figure 1.14). 
 
           
 
 
 
 
          
 
Figure 1. 14 Chronic liver disease and cirrhosis mortality rates per 100,000 populations, 1950-
2006 (taken from Leon, 2007). 
 
1.3.4 Epidemiology of liver cirrhosis in United States 
In a surveillance report which was published by the National Institute on Alcohol 
Abuse and Alcoholism (NIAAA), trends in liver cirrhosis mortality in the United 
States were presented from 1970-2005. Accordingly, liver cirrhosis was considered to 
be one of the 12 major causes of death in the United States. Overall, cirrhosis 
mortality in the United States grew steadily following the end of Prohibition in 1933 
until 1973, when the age-adjusted death rate (a rate that accounts for differences in 
mortality regardless of any difference in the age distribution between populations) 
reached a peak at 18.1 deaths per 100,000 of the population. Cirrhosis mortality then 
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began an almost steady decrease which continued until 2005, the most recent year for 
which data is available (Yoon et al., 2008).  
 
1.3.5 Current options for treatment of liver fibrosis/ cirrhosis 
Contrary to the conventional view that cirrhosis is an irreversible process, recent 
evidence shows that even advanced fibrosis is reversible (Friedman, 2000 ; Arthur, 
2002 ; Bataller & Brenner, 2005). At present, there is no efficient pharmaceutical 
intervention to treat this fibrotic disease (Pinzani et al., 2005; Li & Wang, 2009). 
Currently, the cure for cirrhosis is limited to removing the underlying cause of the 
disease. The development of fibrosis can reduce after removal of the main cause of 
damage, nevertheless to accomplish complete treat of advanced liver fibrosis, medical 
intervention is required in most cases. Some of these interventions comprise 
eradicating viruses using interferon, ribavirin and nucleoside analogues in viral 
hepatitis and ultimately, liver transplantation which is a highly successful treatment 
for end stage cirrhosis (Iredale, 2003). Nevertheless, to date no effective treatment 
other than liver transplantation has been established (Adrian et al., 2007).  
 
1.3.6 Problems of current interventions in treatment of liver fibrosis/ cirrhosis 
The main problem with current antifibrotic drugs in vivo is that they are neither liver-
specific nor fibrosis-specific. Accordingly, many drugs that demonstrate potent 
antifibrotic activity in vitro frequently demonstrate only slight effects in vivo due to 
inadequate concentrations of drugs around the target cell and adverse effects on non-
target cells, particularly during chronic administration (Li & Wang, 2009). 
 
Therefore, it can be concluded that targeting therapeutics to the relevant tissue or 
disease-associated cell has several advantages over non-targeted therapies. A lower 
concentration of the therapeutic agent is required to be delivered to the site of action 
to achieve a therapeutic effect. Furthermore, altered pharmacodynamics increases the 
possibility of specific action directed at the target tissue/cell and decrease the 
probabilities of adverse effects (Elrick et al., 2005).      
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1.3.7 Tissue transglutaminase (TG2) inhibitors: a new approach to the treatment 
of liver cirrhosis.  
Tissue transglutaminase (TG2, 
transglutaminase 2, transglutaminase C, 
Gah) is the ubiquitous member of TGs 
and is also one of the most studied 
(Collighan & Griffin, 2009) (Figure 
1.15). Recent evidence supports the view 
that the enzyme has a general protective 
and stabilizing role in cells and tissues. 
However, in a pathological environment, 
the uncontrolled activation of TG2 can 
alter its protective function into a 
pathological one (Fesus and Piacentini, 
2002). TG2 is emerging as a well-characterized, multifunctional molecular agent in 
numerous diseases and processes (Aeschlimann et al., 2000) such as fibrosis and 
scarring (Johnson et al., 1999). Huntington’s disease and Alzheimer’s disease (Citron 
et al., 2001) coeliac disease (Marzari et al., 2001) thrombosis (Ariëns et al., 2002) and 
cancer (Mangala & Mehta, 2005).  
 
The development of hepatic fibrosis reflects an alteration in the normally balanced 
processes of extracellular matrix production and degradation (Friedman, 2000). Liver 
fibrosis is characterised by increased synthesis and decreased degradation of the 
extracellular matrix (ECM) molecules (Sarem et al., 2006). Covalent cross-linking of 
collagen enhances its resistance to proteolytic degradation and excessive cross-linking 
may result in destructive loss of tissue functionality (Grenard et al, 2001). 
 
Tissue transglutaminase catalysed cross-linking is a physiological mechanism for the 
stabilization of basement membranes and cartilage matrix (Aeschlimann et al., 1995). 
Transglutaminase-mediated covalent cross-linking has been implicated in the 
stabilization and accumulation of the ECM in number of fibrotic diseases (Griffin et 
al., 1979; Johnson et al., 1997, 1999; Mirza et al., 1997; Grenard et al., 2001; Skill et 
al., 2001) and in kidney fibrosis. In the latter, it has also been shown that in rats 
induced to undergo either renal scarring or development of diabetic nephropathy, 
Figure 1. 15 Overall structure of a human 
tissue transglutaminase (TG) (web image 11). 
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treatment with the site directed TG inhibitors leads to up to 80 - 90 % reduction in 
kidney scaring with preservation of kidney function (Griffin et al., 2008; Huang et al., 
2009). Shweke et al. (2008) demonstrated that TG2 knockout mice show a reduction 
of renal fibrosis induced by urethral obstruction. 
 
Thus, it can be predicted that potent and selective TG2 inhibitors would have broad 
therapeutic potential in treatment of fibrotic diseases characterised by increased ECM 
deposition and cross linking (Griffin et al., 2008, Collighan & Griffin, 2009). The 
anti-fibrosis effect of the tissue transglutaminase non-specific inhibitor, cystamine, on 
liver fibrosis has been investigated by Qiu et al (2007). Cystamine ameliorates carbon 
tetrachloride (CCl4) induced liver fibrosis via inhibition of TG2. The probable 
mechanism is linked with the reduced synthesis of the ECM caused by the inhibition 
of hepatic stellate cell activation and decreased expression of tissue inhibitor of 
metalloproteinases 1 (Qiu et al., 2007).  
 
As TG2 is assumed to participate in many essential biological processes, a number of 
researchers challenge the above view (Nardacci et al., 2003), stating that TG2 plays a 
protective role in liver injury by enhancing tissue stability and repair, therefore 
pharmacological inhibition of TG2 may have undesirable side effects. This 
hypothesis presumes that a fraction of TG2 is constitutively active in vivo, and that 
this activity is essential under normal physiological condition. One objection to this 
argument is data supporting the view that a physiological role for the catalytic 
activity of TG2 is limited. Intracellular and extracellular TG2 is catalytically inactive 
under normal physiological conditions. Nevertheless, physical or certain types of 
chemical damage can lead to rapid enzymatic activation (Siegel et al., 2008). The 
normal development and normal phenotype of TG2 knockout mice along with the 
lack of toxicity observed in mice dosed chronically with dihydroisoxazole inhibitors 
indicate that TG2 activity is not essential for survival in a stress free environment 
(Nanda et al. 2001; De Laurenzi & Melino, 2001; Choi et al., 2005; Yuan, 2006; 
Strnad, 2006; Siegel et al., 2008). Consequently, it can be argued that on the one 
hand, the mammalian body requires a reasonably non-specific cross linking enzyme 
in approximately all the organs to assist rapid tissue growth and healing. On the other 
hand, considering the extreme stability of an isopeptide linkage, uncontrolled TG2 
activity possibly yields to excessive scar tissue formation and the formation of 
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neoepitopes that could initiate an autoimmune response. Therefore, the catalytic 
activity of TG2 must be activated rapidly when required, and inactivated almost 
immediately following the completion of its task. Disruption of this sensitive balance 
may be the basis for a range of seemingly disparate diseases (Siegel et al., 2008).  
 
Recently, a novel group of specific tissue transglutaminase inhibitors has been 
described which has the advantage of targeting TG2 in the extracellular environment 
this limiting cell toxicity (Griffin et al., 2004; 2008). These inhibitors have already 
shown themselves to be successful candidates in the treatment of kidney fibrosis in 
animal models (Griffin et al., 2008), where they were delivered directly to the kidney 
via an osmotic pump. Some of these inhibitors have been shown to be TG2 specific 
and subsequently have the advantage of exclusive inhibition of the tissue 
transglutaminase (TG2) enzyme rather than other extracellular transglutaminase 
enzymes Factor XIIIa. A major aim of this study was to investigate in vivo 
pharmacokinetics and tissue biodistribution of the TG2 inhibitor and develop an 
efficient drug delivery system for site specific delivery of the novel TG2 inhibitors 
into the liver with the aim of treating liver fibrosis and its end stage disease cirrhosis.  
 
1.4 Aims and objectives 
The aim of this thesis was to establish an efficient method of effective delivery of the 
TG inhibitors for their applications such as treatment of catheter-related complications 
and liver fibrosis. 
 
The objective of this work is outlined below; 
 
• Characterisation of fluorescent derivatives as potential probes for the novel 
TG inhibitors. 
 
• Development of a controlled release polymer coats with incorporated FXIIIa 
inhibitor for polyurethane (PU) central venous catheters and quantifying the 
enzyme inhibitor release from the polymeric coating in vitro.  
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• Integration of the FXIIIa inhibitor into silicone elasotomers for sustained drug 
release and measuring the amount of inhibitor release from the elastomers in 
vitro. 
 
• Investigation of pharmacokinetics and biodistribution of the TG2 inhibitor in 
vivo. 
 
• Development of an efficient drug delivery system for site specific delivery of 
the TG2 inhibitor into the liver.  
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2.1 Introduction  
As detailed in chapter 1, transglutaminases (TG) are an extensively distributed group 
of enzymes that catalyze a calcium-dependent acryl transfer reaction between the γ-
carboxamide group of a polypeptide bound lysine residue to form an ε-(γ-glutamyl) 
lysine isopeptide bond or the formation of (γ-glutamyl) polyamine bonds through 
catalyzing the incorporation of polyamines into peptide-bound glutamine (Griffin et 
al., 2002). Nevertheless, deregulation of enzyme activity usually associated with 
major disruption in cellular homoeostatic mechanisms has caused these enzymes 
contributing to a number of human diseases, such as chronic neurodegeneration, 
neoplastic diseases, autoimmune diseases, diseases involving progressive tissue 
fibrosis and diseases related to the epidermis of the skin (Griffin et al., 2002; Lorand 
& Graham 2003). Hence, it can be expected that potent and selective TG inhibitors 
would find wide therapeutic potential (Griffin et al., 2008).  
 
Irreversible TG2 inhibitors (suicide inhibitors) prevent enzyme activity by covalently 
modifying the enzyme thereby preventing substrate binding. The majority of 
irreversible TG2 inhibitors are intended to target the active site cysteine of the TG 
enzyme, using chemical functional groups that are reactive in the presence of a 
nucleophilic atom. However, they form relatively stable chemical bonds following 
reacting (Siegel & Khosla, 2007). Several irreversible inhibitors of tissue 
transglutaminase (TG) have been published (Freund et al. 1994; Choi, et al., 2005; 
Pardin et al., 2006; Yuan et al., 2006; Siegel & Khosla, 2007). 
 
Recently, a novel group of transglutaminase inhibitors has been introduced by Griffin 
et al. (2004; 2008). These inhibitors are specific and subsequently have the advantage 
of exclusive inhibition of FXIIIa and tissue transglutaminase rather than other 
transglutaminases enzymes. Different types of TG synthesized inhibitors are detailed 
below; 
 
2.1.1 Irreversible non-fluorescent TG inhibitor (R281)  
R281 (Figure 2.1) was one of the first site-directed TG inhibitors synthesized by 
Griffin, Saint and Coutts (2004). Despite its ability to act as an enzyme inhibitor, it is 
difficult to monitor if studies are undertaken on the compound as a potential drug. For 
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example it would be difficult to easily track and follow it inside the body or to detect 
it in buffer, blood plasma or body tissues, therefore marker options were investigated. 
 
 
 
 
 
 
 
Figure 2.1 The schematic structure of irreversible non-fluorescent transglutaminase inhibitor 
(R281), with a dimethyl ulfonium group at one end and a carbobenzyloxy group (CBZ) at the N-
terminus of the peptide-based inhibitor. 
 
2.1.2 Irreversible fluorescent TG inhibitor  
The novel fluorescent inhibitors of TG are essentially R281 with a fluorescent group 
attached and prepared within the chemistry department at Aston University by Dr. 
Alexandre Mongeot and Dr. Dan Rathbone. Synthesis was based on an existing 
irreversible non-fluorescent TG inhibitor (R281). To achieve this, a fluorescence 
group (pyrene or dansyl ring) was added to replace the CBZ group (carbobenzyloxy) 
at the N-terminus of the peptide-based inhibitor, whilst the dimethylsulfonium or 
tetramethylimidazolium group was a thiol reactive warhead. The TG inhibitors 
investigated in this study were R281 with a dimetheylsulphonuim warhead and a 
phenylalanine amino acid and its derivatives with a fluorescent pyrene group, a 
dimetheylsulphonuim warhead and a phenylalanine amino acid (AM1/99) or with a 
fluorescent dansyl group, a dimetheylsulphonuim warhead and a phenylalanine amino 
acid (AM1/107) or with a fluorescent dansyl group, a tetramethylimidazolium 
warhead and a phenylalanine amino acid (AM2/97) or with a fluorescent dansyl 
group, a dimetheylsulphonuim warhead and a proline amino acid (AM2/169) (Table 
2.1).  The recently described group of TG inhibitors offer potential advantages over 
existing inhibitors (monodansylcadaverine (MDC) and cystamine) due to their 
irreversible nature, improved tolerability (so far tested only in rats and mice), 
specificity and short half-life as will be discussed. 
 
Drug product characterization is essential during the development of new drug 
substances. Appropriate characterisation enables discriminating formulations during 
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preliminary screening, monitoring drug consistency during processing, and essentially 
testing and releasing of the commercial product. Characterisation is also important for 
comparison of the drug product with other products. Therefore, in order to employ the 
fluorescent derivatives of the TG inhibitor as potential probes for novel TG inhibitors, 
physicochemical characteristics of the novel group of transglutaminase enzyme 
inhibitors were determined. 
 
2.2 Aim and objectives 
The aim of this study was physicochemical characterisation of the fluorescent 
derivatives of the TG inhibitor (R281) as potential probes for novel TG inhibitors. 
 
The objectives of this work were; 
 
• Determination of excitation/emission spectra of the fluorescent TG inhibitors. 
 
• Quantification of the TG inhibitors, using either fluorescence 
spectrophotometry or high performance liquid chromatography. 
 
• Verification of the relative efficacy of the TG inhibitors in vitro, using an 
enzyme linked sorbent assay. 
 
• Cytotoxicity studies of the TG inhibitors, by measurement of mitochondrial 
dehydrogenase activity (XTT assay) and direct cell counting (Trypan blue 
test). 
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  Table 2.1 The name, chemical structure, molecular weight and components of the fluorescent and non- fluorescent TG inhibitors investigated. 
 
Compound Structure Molecular weight (Dalton) Amino acid Protecting group Warhead 
R281 
 
 
567.5 Phenylalanine CBZ Dimethylsulphonium 
AM1/99 
 
 
703.68 Phenylalanine Pyrene Dimethylsulphonium 
AM1/107 
 
 
666.65 Phenylalanine Dansyl Dimethylsulphonium 
AM2/97 
 
 
760.79 Phenylalanine Dansyl tetramethylimidazolium 
AM2/169 
 
 
616.58 Proline Dansyl Dimethylsulphonium 
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2.3 Material  
TG inhibitors were prepared within the chemistry department at Aston University by 
Dr. Alexandre Mongeot and Dr. Dan Rathbone as previously described (Griffin et al., 
2008). Human tissue transglutaminase (hTG2) recombinant in E.coli and N-
(Biotinyl)cadaverine hydrochloride were obtained from Zedira, Germany. Human 
coagulation factor XIII was from CSL Behring, UK. Phosphate buffered saline (PBS), 
ethylenediaminetetraacetic acid (EDTA), o-phenylendiamine (OPD), TRIS-HCL, 
ExtrAvidin-peroxidase, hydrogen peroxide and Dimethyl sulfoxide (DMSO) were 
purchased from Sigma-Aldrich, UK. Fetal bovine serum was obtained from Biosera, 
UK. Bovine serum albumin (BSA) and Dimethyl casein were procured from 
Calbiochem, UK. HPLC grade water, HPLC grade acetonitrile (ACN) were from 
Fisher Scientific, UK. Tween 20 and calcium chloride (CaCl2) were acquired from 
Melford Laboratories Ltd, UK. Unless stated otherwise PBS was used at 0.01M, pH 
7.4. Doubly distilled and filtered water was used in the preparation of all solutions.  
 
Albino Swiss mouse embryo fibroblast (3T3 line) was obtained from American Type 
Culture Collection (ATCC, USA) and were routinely maintained in a Dulbecco’s 
Modified Eagle’s Medium (DMEM, Sigma-Aldrich, UK) supplemented with 10 % 
(v/v) heat inactivated fetal bovine serum (FBS, Sigma-Aldrich, UK), 2 mM glutamine 
(Sigma-Aldrich, UK), 1 % (v/v) nonessential amino acids (Sigma-Aldrich, UK) and 
100 U/ml of penicillin and 100 µg/ml of streptomycin and consistently cultured in a 
humidified atmosphere at 37 °C in a 5 % (v/v) CO2 and 95 % (v/v) air.  
 
2.4 Methods 
2.4.1 Determination of excitation/emission spectra  
Excitation and emission wavelengths for the TG inhibitors were determined using 
spectral scanning by a spectrofluorometer (Spectra Max Gemini XS, Molecular 
Devices). Initially, a stock solution of 0.1 M of the inhibitor was prepared, using 
DMSO (dimetheyl sulphoxide) as a solvent. Subsequently, different concentrations (0, 
1, 10, 100 µM) of the inhibitor solutions were prepared, using PBS (pH 7.5) as a 
diluent. Emission spectra were obtained through stepwise variation of the excitation 
wavelength from 250 to 350 nm with 10 nm intervals for each excitation wavelength. 
The emission wavelengths were always set at a minimum of 20 nm above the 
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excitation wavelength. The step increment was set to 2 nm. The emission wavelength 
was fixed subsequent to emission peak observation. The solutions were then excited at 
a point between 250 nm and 20 nm beneath the emission peak and the maximum 
excitation was measured. All measurements were carried out at 25 °C. 
 
2.4.2 Analytical method for quantification of the TG inhibitors  
The sensitivity of quantification of fluorescent TG inhibitors by fluorescence, via 
direct measurement or separation by reversed-phase chromatography with fluorescent 
detection, was applied to measure and model controlled release of the inhibitors from 
delivery systems.  
 
2.4.2.1 Fluorescence spectrophotometry 
To quantify the concentration of the TG inhibitors in buffer and to assess the amount 
of released drug from carrier systems, solutions were analyzed via fluorescence, using 
direct measurement and a drug calibration curve was obtained. First, from a stock 
solution of the inhibitors in DMSO (0.1 µM), a series of the inhibitor solutions in PBS 
were prepared. Subsequently, by setting the excitation and the emission spectrum at 
the corresponding wavelengths, the drug emission intensity within 200 µl aliquot of 
each solution was measured fluorometrically, on a 96 well microtiter plate. The 
calibration curve was then obtained by plotting the drug concentration (µM) along the 
x-axis and relative fluorescence unit (RFU) along the y-axis. Fluorescence is affected 
by temperature; consequently it was kept constant at 25 °C during each reading of the 
plate. In order to validate accuracy, precision (repeatability and reproducibility) and 
specificity of the analytical procedure, a minimum of 5 concentrations of each 
inhibitor in 3 replicate samples (15 determinations) were prepared and measured for 5 
continuous days.  
 
2.4.2.2 High performance liquid chromatography (HPLC) 
Estimation of the drug in blood and tissues was performed by fluorimetric estimation 
using high performance liquid chromatography (HPLC). Reverse phase HPLC 
analysis of the inhibitor was performed on an AKTA Purifier (Amersham 
Biosciences) HPLC system, with a fluorescence detector (Cecil Instruments Limited, 
CE 4500 fluorescence detector) on a Bio-Rad Hi-Pore C4 HPLC column (250 X 4.6 
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mm) (Richmond, CA, U.S.A). A linear gradient elution of two solvent systems, 
solvent A and B, was optimised. Solvent A was composed of 1 % (trifluoroacetic 
acid) TFA in water; while solvent B was acetonitrile (ACN). The modified gradient 
procedure had a flow rate of 1 ml/min, a 20 µL sample loop and the following 
gradient: 100 % A held for 6 minutes, 5 minutes linear gradient to 37.5 % B, 15 
minute linear gradient to 45 % B, 5 minutes hold at 100 % B for a final time of 31 
minutes (Table 2.2). Elution was monitored with an excitation and an emission 
wavelength of 330 and 570 nm, respectively. Under these analytical conditions the 
retention time for the inhibitor was about 7.30 minutes. Concentrations of the TG 
inhibitors in the samples were determined by reference to a calibration curve prepared 
from dilutions of a stock solution of the inhibitor. 
 
Table 2.2 Parameters for the elution of the TG inhibitor from the RP-304 C4 column. Solvent A is 
1 % TFA in water and solvent B is ACN. Elution was monitored at a constant flow rate of 1 ml/min and 
excitation/emission 330/570 nm. 
 
Time (min.) % solvent A % solvent B 
0 
6 
7 
11 
21 
26 
31 
100 
100 
62.5 
62.5 
55 
55 
0 
0 
0 
37.5 
37.5 
45 
45 
100 
 
Afterwards, from a stock solution of the inhibitor in DMSO (0.1 µM), a different 
series of solutions in PBS between 0 and 200 µM were prepared (0, 25, 50, 100, 150 
and 200 µM). Subsequently, each sample was individually loaded into HPLC. The 
calibration curve was obtained by plotting the concentration of the inhibitor along the 
x-axis and the peak area along the y-axis.  
 
2.4.3 Inhibition of TG activity: ELSA (enzyme linked sorbent assay) 
The efficacy of the TG inhibitors as inhibitors of the enzyme TG was verified by 
studying the dose-dependency of their effect on the activity of human tissue 
transglutaminase (TG2) and human coagulation factor XIIIA (FXIIIA), using an 
enzyme-linked sorbent assay (ELSA) based on biotinylated cadaverine (BTC) 
incorporation into N, N’-dimethyl casein (DMC) as described previously (Slaughter et 
al., 1992). ELSA was performed as follows:  
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Initially, 96-well microtiter plates were coated with 100 µl of 10 mg/ml DMC as a 
substrate for the enzyme in 10 mM Tris pH 7.4 overnight at 4 °C. The following day, 
the plates were washed twice with Tris-buffered saline Tween (TBS-Tween) pH 7.4 
and once with Tris-buffered saline (TBS) pH 7.4. Then, a reaction mix was prepared 
that contained 5 mM calcium chloride (CaCl2), as a cofactor for activating the 
enzyme, 5 mM dichloro-diphenyl-trichloroethane (DTT) as a reducing agent and 
0.132 mM BTC as a substrate for the enzyme in 50 mM Tris pH 7.4. The TG 
inhibitors were initially prepared as 100 mM stock solution in DMSO and diluted to 
the appropriate final concentration in the same reaction solution. The mix was 
prepared so that the appropriate final concentrations would be achieved upon addition 
of 10 µl of 200 µg/ml TG to 990 µl of mix to start the reaction. Following addition of 
TG, 100 µl of the solution was pipetted into 8 replicate wells per sample, and the 
reaction was allowed to proceed for 1 hour at 37 °C. The reaction was terminated by 
removal of the solution and the addition of 100 µl of 10 mM 
ethylenediaminetetraacetic (EDTA) in PBS pH 7.4 to stop the activity of the enzyme. 
Plates were then again washed twice with TBS-Tween pH 7.4, once with TBS pH 7.4 
and blocked by incubation with 100 µl per wall of 3 % (w/v) bovine serum albumin 
(BSA) in PBS pH 7.4 for 1 hour at room temperature to occupy any remaining 
unbound sites. Incorporated BTC was detected by incubation with 100 µl per well of 
extravidine peroxidase (EXAP) solution diluted 1 in 5000 in blocking buffer for 1 
hour at 37 °C. Subsequently, the plates were washed as before and were pre incubated 
for 5 minutes in 0.05 M phosphate citrate buffer pH 5 containing 0.014 % (v/v) H2O2. 
Later, the solution was removed and replaced with 100 µl per well of distilled water 
containing o-phenylendiamine (OPD). The development reaction was terminated by 
the addition of 50 µl of 1 N H2SO4. Afterwards, the absorbance of the resulting colour 
which is directly proportional to TG activity was measured on a microtiter plate reader 
at 490 nm (Griffin et al., 2008). 
 
2.4.4 Half maximal inhibitory concentration (IC50)  
To measure and compare the potency of the TG inhibitors on the enzyme TG, the half 
maximal inhibitory concentration (IC50) of the inhibitors was measured. The IC50 was 
expressed as the inhibitor concentration at which 50 % inhibition of TG activity in 
vitro was observed (Griffin et al., 2008). 
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2.4.5 Cell culture studies 
Prior to any in vivo studies, preliminary in vitro investigations are required in order to 
determine the relative cytotoxicity and the rapid screening process of various 
formulations and compounds. To achieve this, external factors such as cell type, 
medium used and experimental protocol were kept constant throughout the study. 
Therefore, variation in cell viability and proliferation between formulations could be 
directly related to internal factors, such as substitution of the protecting group or 
warhead. 
 
2.4.5.1 Thawing cells from storage 
Vials of frozen cells were removed from liquid nitrogen and the cell suspension 
thawed quickly in a water bath at 37 °C. The cell suspension was carefully transferred 
to 15 ml tubes and 7 ml of serum supplemented growth medium was added drop-wise, 
mixing well after each addition. After that the cell suspension was centrifuged at 300 
x g for 5 minutes to discard the freezing agent DMSO. After centrifugation the 
supernatant was carefully removed and the pellet was resuspended in 5 ml complete 
medium. The diluted cell suspension was then transferred into a tissue culture flask 
and the cells were incubated for 24 hours before changing the medium. Cells were 
passaged once before use in an experiment. 
 
2.4.5.2 Passage of cells 
Cells were passaged at approximately 95 % confluency. The monolayer of adherent 
cells was first rinsed with PBS (pH 7.4), followed by the addition of 0.25 % (w/v) 
trypsin/5 mM EDTA solution in PBS. The trypsinised cells were incubated at 37 °C 
for 2 minutes. After detaching all the cells, the trypsin was diluted and inactivated by 
adding Dulbecco’s Modified Eagle’s Medium (DMEM). After that, the cell 
suspension was collected and added to a centrifuge tube and subsequently centrifuged 
at 300 x g for 5 minutes prior to reseeding. After centrifugation, under sterile 
conditions, the supernatant was carefully removed and the pellet was resuspended in a 
complete medium, then aliquots of cell suspension were seeded to an appropriate cell 
culture flask containing DMEM or on a 96-well plate and incubated at 37 °C in a 5 % 
(v/v) CO2 humidified atmosphere until cells reached confluence. In order to minimize 
the variation between formulations and obtain reproducible results, the adherent cells 
were evenly distributed between wells. If necessary, counting of cells was performed 
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using a haemocytometer and the required amount of cells seeded/used for the 
experiment. 
 
2.4.5.3 Incubation of cells with the TG inhibitors 
Adherent fibroblast cells were brought into suspension as previously described. 
Subsequently, the cells were seeded at a concentration of 5000 cells/well on a 96-well 
plate, flat bottom for XTT cell viability assay and incubated in a 5 % CO2 incubator at 
37 °C for 24 hours. All TG inhibitors were initially solubilized in DMSO. Then, a 
series of TG inhibitor solutions (0, 100, 200, 300, 400, 500 µM) were prepared in 
DMEM. Subsequently, the cell medium was removed and the adherent cells were 
treated with different concentrations of the TG inhibitors. Negative control was cells 
without treatment (cells and medium only). Positive control was inoculated cells with 
staurosporine (1 µM). Vehicle control was 0.5 % (v/v) DMSO. The treated cells were 
then incubated for 48 hours at 37 °C in a 5 % (v/v) CO2 humidified atmosphere. Later 
on, the cells were examined under an inverted microscope prior to any cytotoxicity 
assay. The final volume of tissue culture medium in each well was 0.1 ml. All 
treatments were carried out in three replicates.  
 
2.4.5.4 In vitro toxicological studies cytotoxicity studies 
Cell proliferation was evaluated by two methods, measurement of mitochondrial 
dehydrogenase activity (XTT assay) and direct cell counting (Trypan blue test). XTT 
assay (Cell proliferation assay kit II, Roche) using sodium 3′-[1-
(phenylaminocarbonyl)-3,4-tetrazolium]-bis (4-methoxy-6-nitro) benzene sulfonic 
acid hydrate (XTT) was performed according to the manufacturer's instructions. The 
XTT assay is based on the cleavage of the yellow tetrazolium salt XTT to form an 
orange formazan dye by metabolically active cells. Therefore, this conversion only 
occurs in viable cells. An increase in the number of living cells results in an increase 
in the overall activity of mitochondrial dehydrogenases in the sample, which directly 
correlates to the amount of orange formazn formed as monitored by the absorbance. 
To determine the number of dead cells, a Trypan Blue test was carried out. Trypan 
Blue is a vital dye. The reactivity of trypan blue is based on the fact that the 
chromophore is negatively charged and does not interact with the cell unless the 
membrane is damaged. Therefore, all the cells which exclude the dye are viable. 
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2.4.5.4.1 Cell proliferation assay with XTT reagent  
To each well of 96-well plate containing treated fibroblast cells, 15 µl of XTT 
labeling mixture (XTT labeling reagent and electron coupling reagent) was added. 
The plate was shaken gently to evenly distribute the dye in the wells and then 
incubated at 37 °C, in a 5 % humid CO2 atmosphere. After the incubation period, 
orange formazan solution was formed which can be spectrophotometrically 
quantified. In order to determine the optimal incubation period, the absorption was 
measured at different time points (1, 2, 3 and 4 hours) on a microplate reader at 490 
nm and 750 nm (as the reference absorbance for non-specific readings).  
 
2.4.5.4.2 Trypan blue cell viability test  
Initially fibroblast cells were seeded on a 12-well tissue culture plate at a density of 
100,000 cells/ well and incubated at 37 °C for 24 hours. After removing the medium, 
the cells were treated with 500 µM concentration of different types of the TG 
inhibitors. Positive control (1 µM staurosporine), negative control (cells and medium) 
and vehicle control (0.5 % DMSO) were also included. The plate was then incubated 
in a humid CO2 atmosphere. After 48 hour incubation, adherent fibroblast cells were 
brought into suspension as previously described and centrifuged for 5 minutes at 2000 
x g. The supernatant was discarded. Thereafter, 0.4 % Trypan Blue stain was added 
and gently mixed with the cell suspension (1:1 v/v). After standing for 3-5 minutes at 
room temperature, cell viability and cell counts were determined using a 
haemocytometer. To each side of the cover slip of the haemocytometer, 10 µl of the 
Trypan Blue cell suspension was added and viewed microscopically. The bright cells 
(viable cells) with intact cell membrane and stained blue cells (non viable cells) were 
counted. The average number of stained cells and unstained cells in each quadrant was 
calculated according to; 
 
Cells/ml =  
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and using a haemocytometer, with 0.1 mm chamber depth. The percentage of dead 
cells is the number of dead cells divided by the number of dead and viable cells (total 
cells), multiplied by 100 (Freshney, 1987).   
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2.5 Statistical analysis 
For all experiments, means and standard deviations were calculated and represent one 
of at least three separate experiments undertaken in triplicate, unless stated otherwise. 
To determine statistical significance in resultant data, a one-way analysis of variance 
(ANOVA) was performed. Differences described as significant or extremely 
significant in the text correspond to p < 0.05 or p < 0.001 respectively. Tukey’s post 
hoc test was conducted to determine which conditions differ significantly from each 
other.    
         
2.6 Results and discussions 
2.6.1 Determination of excitation/ emission spectra 
Using spectrofluorometry, the excitation and emission spectra of the TG inhibitors 
with a fluorescent pyrene group (AM1/99) were determined to be 340 and 456 nm 
respectively. While the TG inhibitors with a fluorescent dansyl group (AM1/107, 
AM2/97 and AM2/169) were determined to be 330 nm and 570 nm respectively.  
 
2.6.2 Construction of the calibration curve using spectrofluorometry 
To quantify concentrations of the TG inhibitors in buffer, initially solutions were 
analyzed via fluorescence, using direct measurement. 
 
 
Figure 2. 2 Graphic representation of the calibration record of AM1/99. A series of the inhibitor in 
PBS (0 - 250 µM) from a stock solution of the inhibitors in DMSO (0.1 µM) were prepared. The drug 
emission intensity was measured fluorometrically with excitation at 340 nm and emission at 456 nm by 
a spectrofluorometer. Results denote mean ± SD from 3 independently synthesized batches. 
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The results in Figure 2.2 indicate a non-linear, sigmoidal relationship between the 
inhibitor concentration and relative fluorescence unit, which may be due to the 
formation of fluorescence group-mediated dimers at higher concentrations of the 
inhibitor. To investigate this further, samples were measured at fixed excitation or 
fixed emission wavelengths (Figures 2.3 and 2.4). 
 
 
Figure 2.3 Scanning the emission wavelengths of different concentrations of AM1/99 (0-200 µM) 
in a fixed excitation wavelength (340 nm) using spectrofluorometry. 
 
 
         
 
Figure 2.4 Scanning the excitation wavelengths of different concentrations (0-200 µM) of AM1/99 
in a fixed emission wavelength (456 nm) using spectrofluorometry. 
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Figures 2.3 and 2.4 suggest that the fluorescence spectrum of the compound is 
composed of two bands, a structured band with peaks at 370 nm from uncomplexed 
excited pyrene (monomer) and an unsaturated band centered at 460 nm from an 
excited state pyrene dimmer (eximer). Consequently, the results prove that the 
formation of dimers occurs at higher concentrations of the inhibitor, as pyrene rings 
are known to dimerise in solution at certain concentrations causing a change in the 
fluorescence emission wavelength (Föster et al., 1955). 
 
 
Figure 2. 5 Graphic representation of the calibration record of AM1/107. A series of the inhibitor 
solution in PBS (0-100 µM) from a stock solution of the inhibitors in DMSO (0.1 µM) were prepared. 
The drug emission intensity was measured fluorometrically with an excitation at 330 nm and emission 
at 570 nm by a spectrofluorometer. Results denote mean ± SD from 3 independently synthesized 
batches.
 
Figure 2. 6 Graphic representation of the calibration record of AM2/97. A series of the inhibitor 
solution in PBS (0-100 µM) from a stock solution of the inhibitors in DMSO (0.1 µM) were prepared. 
The drug emission intensity was measured fluorometrically with an excitation at 330 nm and emission 
at 570 nm by a spectrofluorometer. Results denote mean ± SD from 3 independently synthesized 
batches. 
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Figure 2. 7 Graphic representation of the calibration record of AM2/169. A series of the inhibitor 
solution in PBS (0- 60 µM) from a stock solution of the inhibitors in DMSO (0.1 µM) were prepared. 
The drug emission intensity was measured fluorometrically with an excitation at 330 nm and emission 
at 570 nm by a spectrofluorometer. Results denote mean ± SD from 3 independently synthesized 
batches. 
 
Figures 2.5, 2.6 and 2.7 demonstrate calibration of AM1/107, AM2/97 and AM1/169 
concentration versus relative fluorescent unit (RFU). The linearity of a method is a 
measure of the range within which the observed detector response (y) are directly 
proportional to the analyte concentration (x) in samples within a given range 
(expressed as a linear regression equation: y = a + bx) (Cao et al., 2005). A straight 
line correlation was obtained between the inhibitor concentration and the RFU with a 
correlation coefficient (measuring the degree of correlation) of 0.99 in all cases. The 
fitting line of the calibration data for AM1/107, AM2/97 and AM1/169 was y = 
3.2945x - 1.8065, y = 12.242x + 39.948 and y = 4.3778x + 7.5222 respectively, which 
was further applied to measure the amount of drug in buffer.  
 
2.6.3 Construction of the calibration curve using HPLC 
To allow for the quantification of the TG inhibitor (AM1/169) in blood serum and 
tissues, HPLC analysis was also undertaken and the drug concentration plotted against 
AUC (Figure 2.8).  
 
Figure 2.8 indicates a linear relationship between the inhibitor concentration and the 
area under the curve (AUC) of the chromatogram peak with a correlation of 0.9984. 
The fitting line of the calibration data (y = 4.4177x + 7.906) was then further applied 
to measure the amount of drug in plasma and tissue 
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Figure 2. 8 Graphic representation of the calibration record of AM2/169. Reverse phase HPLC 
was used with a fluorescence detector on a RP-304 C4 column and a linear gradient of two solvents 
(0.1 % TFA in water and ACN) at a flow rate of 1 ml/minute. The elutes were monitored at an 
excitation and emission wavelengths of 330 and 570 nm respectively. Results denote mean ± SD from 
3 independently synthesized batches. 
 
2.6.4 Inhibition of TG activity 
To investigate the effectiveness of the TG inhibitors on the TG enzymes (FXIIIA and 
TG2), the activity of the enzyme inhibitor was determined by studying the dose-
dependency of its effect on the activity of human FXIIIA and human tissue 
transglutaminase using ELSA as described previously.  
 
Results in Figures 2.9-2.13 demonstrate the effect of the TG inhibitors on human 
FXIIIa and human tissue transglutaminase. Upon increasing the concentration of the 
inhibitor, the measured absorbance and consequently the activity of the enzyme TG 
decreases. Hence, the inhibitory action can be seen to be concentration dependent. The 
TG enzyme binds to the inhibitor via the formation of a covalent bond between the 
inhibitor and the active site cysteine, thus blocking irreversibly the action of this thiol 
dependent TG enzyme. Irreversible inhibition (inactivation) by covalent modification 
of the active site cysteine of TG is one of the approaches to enzyme inhibition. 
Several nonspecific thiol reactive reagents were established to inactivate TG2 and 
FXIIIa including iodoacetamide, α-halogenmethyl carbonyl compounds designed on a 
scaffold of amine pseudo-substrates were shown to inactivate FXIIIa in crude plasma 
fraction from bovine blood. Although their structure activity profile confirmed 
previously learned lessons about the enzyme active site architecture; however, high 
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intrinsic activity of these compounds towards thiol and thiol dependant enzymes is at 
the root of their toxicity and lack of potential therapeutic utility (Wodzinska, 2005). 
 
Therefore, it can be deduced that the tested TG inhibitors can act as an enzyme 
inhibitor for the TG enzyme (FXIIIa and TG2) in a concentration dependent manner. 
To compare the potency of the TG inhibitors tested; the half maximal inhibitory 
concentration (IC50) of the TG inhibitors was measured.  
  
Figure 2. 9 The inhibition of FXIIIa and TG2 by R281. The activity of the enzyme inhibitor was 
determined by studying the dose-dependency of its effect on the activity of human FXIIIa and human 
tissue transglutaminase using an enzyme linked sorbent assay (ELSA) based on biotinylated cadaverine 
(BTC) incorporation into N, N’-dimethyl casein (DMC). The results represent mean ± SD. n = 8.  
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Figure 2.10 The inhibition of FXIIIa and TG2 by AM1/99. The activity of the enzyme inhibitor was 
determined by studying the dose-dependency of its effect on the activity of human tissue 
transglutaminase (A) and human FXIIIa (B) using an enzyme linked sorbent assay (ELSA) based on 
biotinylated cadaverine (BTC) incorporation into N, N’-dimethyl casein (DMC). The results represent 
mean ± SD. n = 8. 
 
 
 
Figure 2.11 The inhibition of FXIIIa and TG2 by AM1/107. The activity of the enzyme inhibitor 
was determined by studying the dose-dependency of its effect on the activity of human tissue 
transglutaminase (A) and human FXIIIa (B) using an enzyme linked sorbent assay (ELSA) based on 
biotinylated cadaverine (BTC) incorporation into N, N’-dimethyl casein (DMC). The results represent 
mean ± SD. n = 8.  
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Figure 2.12 The inhibition of FXIIIa and TG2 by AM2/97. The activity of the enzyme inhibitor was 
determined by studying the dose-dependency of its effect on the activity of human FXIIIa and human 
tissue transglutaminase using an enzyme linked sorbent assay (ELSA) based on biotinylated cadaverine 
(BTC) incorporation into N, N’-dimethyl casein (DMC). The results represent mean ± SD. n = 8.  
 
 
  
Figure 2.13 The inhibition of FXIIIa and TG2 by AM2/169. The activity of the enzyme inhibitor 
was determined by studying the dose-dependency of its effect on the activity of human FXIIIa and 
human tissue transglutaminase using an enzyme linked sorbent assay (ELSA) based on biotinylated 
cadaverine (BTC) incorporation into N, N’-dimethyl casein (DMC). The results represent mean ± SD. n 
= 8. 
 
2.6.5 Determination of the half maximal inhibitory concentration (IC50) of the 
TG inhibitors 
The IC50 of the TG inhibitors for the two types of the enzyme TG (TG2 and FXIIIa) 
was calculated in order to measure and compare the potency of the inhibitors tested on 
the enzyme TG. IC50 is the required concentration of the inhibitor for 50 % inhibition 
of the TG enzyme.  
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Table 2.3 IC50 values of the TG inhibitors on the two types of the enzyme TG (TG2 and FXIIIa) 
 
Compound TG2 IC50 (µM) FXIIIa IC50 (µM) 
R281 10 ± 2 105 ± 20 
AM1/99 7 ± 3 40 ± 10 
AM1/107 85 ± 20 195 ± 25 
AM2/97 6 ± 3 2 ± 3 
AM2/169 8 ± 2 9 ± 3 
 
Table 2.3 indicates that R281 and its fluorescent versions (AM1/99, AM1/107, 
AM2/97 and AM2/169) can act as an enzyme inhibitor for the TG. In general, the 
lower the IC50, the greater the potency of the inhibitor, and the lower the concentration 
of the drug that is required to inhibit the enzyme. While, AM1/99, AM2/97 and 
AM2/169 demonstrate lower IC50 and consequently more inhibition activity for FXllla 
and TG2 compared with R281, AM1/107 shows a higher IC50 and less inhibitory 
activity for both TG enzymes. This suggests that that the addition of the dansyl group 
to replace the CBZ group (carbobenzyloxy) at the N-terminus of the peptide-based 
inhibitor reduces the activity of the inhibitor and increases the IC50 from ~ 10 µM to ~ 
85 µM for TG2 and from ~ 105 µM to ~ 195 µM for FXIIIa; conversely, the addition 
of the pyrene group (AM1/99) enhances the activity of the enzyme inhibitor by 
approximately 2 fold for both the enzymes and decreases the IC50  from ~ 10 µM to ~ 
7 µM for TG2 and from ~ 105 µM to ~ 40 µM for FXIIIa. Furthermore, the 
substitution of the CBZ group with the dansyl group, as well as the substitution of 
dimethylsulphonium warhead with tetramethylimidazolium warhead (AM2/97) 
dramatically decrease the IC50 value from ~ 105 µM to ~ 2 µM and therefore augment 
the activity of the enzyme inhibitor for FXIIIa by approximately 52.5 folds. However, 
upon the exchange of the CBZ group with the dansyl group and the exchange of 
dimethylsulphonium warhead with tetramethylimidazolium warhead (AM2/169), 
there was no a significant difference in the IC50 value for TG2 (from ~ 10 µM to ~ 8 
µM). In summary, AM2/97 and AM2/169 demonstrate a greater effectiveness in terms 
of inhibiting FXIIIa and TG2 respectively amongst all the TG inhibitors tested.  
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2.6.6 XTT cell proliferation assay  
To investigate the cytotoxicty of the novel group of TG inhibitors, the proliferation of 
fibroblast cells was assessed by XTT-based colorimetric cellular cytotoxicity assay. 
 
Figure 2.14 Effect of different concentrations of the TG inhibitors on fibroblast cell viability. The 
cytotoxicity of a wide range (100-500 µM) of the TG inhibitors (R281, AM1/99, AM1/107, AM2/97 
and AM2/169) was determined using XTT cell proliferation assay. The viability of the cells remained 
constant within the range of the concentration tested (100-500 µM) of R281, AM1/107, AM2/97 and 
AM2/169. Additionally, there was no a considerable variation in terms of cell viability amongst the 
four types of the TG inhibitors tested. On the contrary, the viability of the cells decreased considerably 
(~ 50 %) for very high concentrations (300 - 500 µM) of AM1/99. The results from three independent 
experiments denote mean ± SD absorbance at 490-750 nm, n=3.  
 
Figure 2.15 Cytotoxicity of various TG inhibitors to fibroblast cells. The in vitro toxicity of 500µM 
of the TG inhibitors (R281, AM1/99, AM1/107, AM2/97 and AM2/169) was assessed by XTT based 
colorimetric cellular cytotoxicity assay. Results are expressed as a percentage of negative control 
(without treatment: cells and medium only). Positive control includes cells incubated with 1 µM 
staurosporine. Vehicle control was 0.5 % (v/v) DMSO. Aside from AM1/99, there was no significant 
disparity in the percentage of the viability of R281, AM1/107, AM2/97 incubated cells when compared 
with negative control. The results from three independent experiments denote mean ± SD, n=3.  
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According to Figures 2.14 and 2.15, the viability of the fibroblast cells remained 
constant within the range of the concentration tested (100-500 µM) for R281, 
AM1/107, AM2/97 and AM2/169. Additionally, there was no significant variation 
(ANOVA, p > 0.05) in terms of cell viability amongst the four types of the TG 
inhibitors tested. Furthermore, there was no a significant disparity (ANOVA, p > 
0.05) in the percentage of the viability of R281, AM1/107, AM2/97 incubated cells 
when compared to negative control (~ 100 %). However, the viability of the cells 
decreased considerably (~ 50 %) for very high concentrations (300 - 500 µM) of 
AM1/99 (0.35 g/L) (ANOVA, p < 0.001). Across all the tested concentration, each 
inhibitor was shown to have a significant cellular viability when compared to positive 
control (ANOVA, p < 0.001). Using 0.5 % (v/v) DMSO as a vehicle control had no 
effect on the viability of the cells in the tested concentration range; however the 
toxicity of higher concentration of DMSO (1 % (v/v)) has been reported to decrease 
cell viability, increase cellular apoptosis, and up regulate Bax in human lens epithelial 
cells (Cao et al., 2007). 
 
These results suggest that while replacing the CBZ group at the N-terminus of R281 
with the fluorescent dansyl group does not interfere with the proliferation of the cells, 
replacing the CBZ group with the pyrene group could result a decrease in cell 
proliferation. Pyrene is a polycyclic aromatic hydrocarbon (PAH) consisting of four 
fused benzene rings. A large amount of literature exists for the toxicity and 
carcinogenicity of PAHs, but toxicity data for pyrene is very limited. As a result, the 
United States Environmental Protection Agency classified pyrene in Group D (not 
classifiable as to human carcinogenicity) as there was no human data and inadequate 
data from animal bioassays (U.S. EPA, 1993 a and b). 
 
The measured IC50 of AM1/99, AM1/107 and AM2/97 for FXIIIa was 40, 2 and 195 
µM respectively. Therefore, it can be concluded that AM1/107 and AM2/97 were not 
toxic to the cells up to 500 µM which is respectively ~ 3 and ~ 250 fold higher than 
their recorded efficacy. Regarding AM1/99, there was no significant difference in the 
viability of the cells at concentrations ~7 fold higher (up to 300 µM). However at 
concentrations of 500 µM the viability decreases by 50 % compared to negative 
control, R281 and the other dansyl compounds. Therefore, it can be concluded that in 
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contrast to AM1/99 (pyrene compound) neither R281 nor the dansyl compounds are 
toxic to the cells at the tested concentrations (100 - 500 µM). 
 
2.6.7 Trypan Blue test 
To investigate the cytotoxicty of the novel group of inhibitors of TG, the proliferation 
of fibroblast cells was assessed by direct cell counting using a trypan blue test. 
Figure 2.16 Effect of the TG inhibitors on fibroblast cell death. The Percentage of cell death after 
48 hour incubation with different types of TG inhibitors (R281, AM1/99, AM1/107, AM2/97 and 
AM2/169) was measured using a Trypan blue test. Trypan blue is a diazo dye which is unable to cross 
intact plasma membranes, and so only labels dead cells. Positive control includes cells incubated with 1 
µM staurosporine. Vehicle control was 0.5 % (v/v) DMSO. Results denote mean ± SD from three 
independent experiments, n=3.  
 
The percentage of dead cells for R281 (500 µM), AM1/107 (500 µM), AM2/97 (500 
µM), AM2/169 (500 µM), negative control, vehicle control (0.5 % DMSO) and 
positive control (1 µM staurosporine) was 2.3 %, 10 %, 6 %, 3.7 %, 5 %, 6 %, 5 % 
and 100 % respectively (Figure 2.16). The percentage difference could be attributed to 
the external factors rather than the formulation of inhibitors. Aside from AM1/99, cell 
viability remained above 95 % of control across all the inhibitors tested, indicating 
that all the inhibitors were non toxic to the cells at the studied concentration. 
However, treated cells with 500 µM of AM1/99 decreased dramatically (by about 50 
%) in viability and proliferation of the cells with 10 % of dead cells. These results are 
in clear agreement with the previous XTT cell proliferation study and confirm the 
potential cytotoxicity of the pyrene compound previously shown in Figures 2.14 and 
2.15 earlier. 
 
0
10
20
30
40
50
60
70
80
90
100
R281 AM1/99 AM1/107 AM2/97 AM2/169 Positive
Control
Vehicle
control
Negative
Control
Ce
ll 
De
at
h 
(%
)
Chapter 2 – Characterisation of fluorescent derivatives as potential probes for novel TG inhibitors 
47 
 
 
2.7 Conclusion 
All the tested TG inhibitors were found to be effective on the activity of the TG 
enzyme. With the exception of AM1/99, all the inhibitors deemed to have a linear 
relationship between the inhibitor concentration and either the area under the curve or 
relative fluorescence unit. Regarding the cytotoxicity test, high concentration (500 
µM) of AM1/99 (the fluorescent inhibitor with pyrene group) reduced cell viability 
and consequently increased cell toxicity and this needs to be taken into account by any 
further studies. On the other hand, the rest of the inhibitors tested (AM1/107, AM2/97 
and AM2/169) appeared to be suitable for future investigations as they have not 
indicated any sign of toxicity to the cells at the concentration ranges tested. AM2/97 
appeared to be more appropriate for inhibiting FXIIIa enzyme as it demonstrated the 
lowest IC50 and consequently more inhibition activity for FXllla amongst the TG 
inhibitors tested. Furthermore, the tetramethylimidazolium warhead makes the 
inhibitor more stable than the dimethylsulphonium warhead at the N-terminus of the 
peptide based inhibitor. Therefore, it was selected as the inhibitor of choice to coat or 
to be integrated into catheters or other implant devices, with the aim of reducing the 
incidence of catheter sheath formation, thrombotic occlusion and associated infection 
in central venous catheters (CVCs). AM2/169, with one of the lowest IC50 for TG2, is 
the favoured inhibitor for targeting the liver with the aim of treating liver fibrosis and 
its end stage disease liver cirrhosis. Moreover, the proline amino acid in the structure 
of AM2/169 results in a more stable compound than the other inhibitors investigated 
for bio-distribution studies.  
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3.1 Introduction  
Catheters are used widely for a variety of therapeutic purposes in modern medical 
practice. 
 
3.1.1 Catheter requirements  
The British standard states the specifications, to which all catheter devices and 
materials must conform (British Standard EN 30993, 1992). These requirements were 
listed below; 
 
3.1.1.1 Biocompatibility 
All biomaterials are required to possess suitable properties, in particular good 
biocompatibility. British Standards for catheter materials are outlined so as to ensure 
appropriate quality and diminish toxicity to tissues. The importance of such standards 
is emphasised by a research study (Salama, 1993), which found that four out of seven 
commercially existing urethral catheters demonstrated considerable cytotoxicity with 
severe urethral strictures in patients for urinary catheters. It was then concluded that 
the international standards for urethral catheter toxicity, in addition to quality controls 
for the devices were inadequate (British Standard EN 30993, Lawrence & Turner, 
2005), suggesting that further development of such systems are required. 
 
3.1.1.2 Physical and mechanical properties 
An appropriate combination of physical and mechanical properties is of great 
importance for a catheter to be efficacious in its application (Lawrence & Turner, 
2005). These properties include smooth surface finish, flexibility and strength.  
 
3.1.1.2.1 Smooth surface finish  
A catheter needs to have a smooth surface finish and a low coefficient of friction, 
once manufactured and ready for application. This is specified in the British standard 
EN 1616:1997 as, ‘shall appear free from extraneous matter’. This applies to the shaft, 
tip, balloon and eyes of the device, and examination is to be conducted using a 
magnification of 2.5 × (British Standard EN 1616, 1997). This yields to a minimum 
mechanical trauma and shear forces at the biomaterial–tissue interface, enhancing 
ease of insertion and removal, which also improves patient comfort (Denstedt et al., 
1998; Lawrence & Turner, 2005). 
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3.1.1.2.2 Flexibility  
The flexibility of the catheter material is also imperative. A smooth and pliable 
catheter tips reduce the occurrence of venous perforation during insertion (Lawrence 
& Turner, 2005).  
 
3.1.1.2.3 Strength and elastic recovery 
Strength is also essential in terms of device integrity. Whilst flexible, a catheter must 
also be strong enough to avoid kinking or collapse (Cox et al., 1987). Catheters can be 
exposed to considerable tensile force upon removal from the patient which must not 
lead to damage or dislodging of the shaft from the balloon as occurs with the Foley 
catheter, or in the separation of the device into two or more parts. Therefore, the 
elastic recovery of the constituent biomaterial is a necessary property that must be 
considered when manufacturing catheters (British Standard EN 1618, 1997; 
Lowthian, 1998; Lawrence & Turner, 2005). 
 
3.1.2 Types of polymeric coatings 
The choice of coating material depends on the device material, its application and 
other processing requirements. Table 3.1 outlines some of the key characteristics of 
the most commonly applied coatings for catheters such as silicone and hydrogel 
(Polymer coatings for powder-free medical gloves, 1999; Lawrence & Turner, 2005).  
 
A number of researchers suggested that polyurethane catheters might be a better 
alternative to silicone catheters for long term venous access and polyurethane 
catheters should have a lower thrombogenicity than silicone elastomer catheters 
(Pottecher et al., 1984; Curelaru et al., 1983; Wheeler et al., 1992). However in a 
comparative study of polyurethane and silicone cuffed-catheters in long-term home 
total parenteral nutrition patients (TPN), Beau and Matrat (1999) demonstrated that 
both silicone and polyurethane catheters enable safe, long-term venous access and 
usually prevent inadvertent catheter dislodgement. Therefore, there is little evidence 
to support the hypothesis that polyurethane catheters offer more security than silicone 
catheters in home TPN adult patients. 
 
In this chapter, hydrogel-coated polyurethane catheters will be discusses, whilst 
silicone catheters will be detailed in chapter 4.  
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Table 3.1 Comparison of properties of common coating substances (hydrogel and silicone) 
Property 
 
Hydrogel 
 
Silicone 
 
Tensile strength Low Low 
Adhesion to natural rubber Low Moderate 
Elongation Low Moderate 
Puncture resistance Low Low 
Abrasion resistance Low Moderate 
Oil resistance Moderate Low 
Swelling on exposure to water High Low 
Integrity after stretch Low Low 
Hydration/water swelling High Low 
Allergic reaction No 
 
No 
 
 
3.1.3 Hydrogels: General introduction and background 
Introduced to the medical device industry in the early 1960s (Wichterle & Lim, 1960), 
hydrogels are three-dimensional, hydrophilic, polymeric networks which are able to 
imbibe large quantities of biological fluids while remaining insoluble in aqueous 
solutions (Peppas et al., 2000). Since the establishment of the first synthetic hydrogels 
by Wichterle and Lim in 1954 (Wichterle & Lim, 1960), the growth of hydrogel 
technologies has advanced many fields ranging from food additives to 
pharmaceuticals to biomedical implants. Among these applications, hydrogel-based 
drug delivery devices represent a major area of research interest with several 
commercial products already developed (Lin & Metters, 2006). Hydrogels 
demonstrate many physicochemical attributes that make them beneficial for 
application as biomaterials; they are soft and pliable (Huang, 2003) and do not 
dissolve while holding a large quantity of water within their structure, on account of  
physical and chemical cross-linkage of hydrophilic polymer chains. This results in the 
formation of a thin water film on the contacting surface, thus improving its 
smoothness and lubricity (Lawrence and Turner, 2005). Hydrogels mirror natural 
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living tissue more than any other class of synthetic biomaterials, due to their high 
water content and soft consistency which is similar to natural tissue, which contributes 
to their biocompatibility (Peppas, 2000). As a result, hydrogels are particularly useful 
in biomedical and pharmaceutical applications.  
 
Hydrogels can be prepared from natural or synthetic polymers. Although hydrogels 
made from natural polymers may not offer adequate mechanical properties and may 
contain pathogens or engender immune responses, they do provide some advantages 
such as inherent biocompatibility, biodegradability, and biological recognised 
moieties that support several cellular activities. Synthetic polymers do not manifest 
these innate bioactive properties; however their well defined structures can be altered 
to yield tailorable degradability and functionality. Chitosan, alginate, fibrin, collagen, 
gelatin, hyaluronic acid and destran are the examples of natural hydrogels, while N-(2-
hydroxypropyl) methacrylate (HPMA), N-vinyl-2-pyrrolidone (NVP), N-isopropyl 
acrylamide (NIPAAm), vinyl acetate (VAc), acrylic acid (AA), methacrylic acid (MAA), 
polyethylene glycol, acrylate/methacrylate (PEGA/PEGMA), polyethylene glycol and 
diacrylate/dimethacrylate (PEGDA/PEGDMA) are examples of the synthetic ones (Lin 
& Metters, 2006).   
 
3.1.4 Hydrogel coating  
Hydrogel coatings are used on medical products such as catheters, angioplasty 
balloons, introducers, contact lenses and other indwelling medical devices, to enhance 
surface lubricity (Ikada & Uyama, 1993). This could be attributed to the nature of the 
soft and slippery surface of hydrogels upon hydration (Park et al., 2002). In spite of 
technological advances, studies and trials of hydrogel-coated catheters have been 
controversial. On the one hand, some researchers have indicated that there is 
promising potential for these catheters. Talja et al. (1990) claimed that a hydrogel-
coated catheter was less prone to encrustation compared to full silicone or siliconized 
catheters. A similar encrustation trend on various indwelling double-J stents was also 
observed by Cormio et al. (1995). On the other hand, others have raised doubts and 
concerns over their usage (Liedberg et al., 1990; Bologna et al., 1999; Ahearn and 
Grace, 2000). For instance, research has indicated that despite the fact that hydrogel 
catheters had been designed to resist bacterial contamination and subsequent 
encrustation, they were amongst some of the most rapid to block (Morris et al., 1997; 
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Lawrence and Turner, 2005). Other trials (Cox et al., 1988; 1989; Thibon et al., 2000) 
also demonstrated no statistical difference between the incidence of infection in 
patients treated with a hydrogel catheter and a standard all-silicone device. The 
possibility of higher encrustation on hydrogel surfaces than on other surfaces has also 
been suggested (Tunney et al., 1996; Desgrandchamps, 1997). Consequently, it was 
concluded that there was insufficient evidence to support or recommend the 
widespread use of such modified catheters (Lawrence and Turner, 2005). 
 
In terms of bacterial infection, once again, results have been varied. Some researchers 
have reported positive findings where bacterial adherence to hydrogel-coated 
catheters was notably lower than on standard devices. On the contrary, some other 
reports have stated that there was no significant difference between the rate and 
incidence of bacterial infection in hydrogel-coated and standard catheters and 
concluded that there was insufficient data to prove any clinical benefits from using 
these devices (Monson et al., 1974; Chene et al., 1990; Liedberg et al., 1990; 
Lawrence and Turner, 2005).  
 
3.2 Aim and objectives 
This present research is aimed at the incorporating of the fluorescent FXIIIa enzyme 
inhibitor (AM2/97) into the polymeric coatings of polyurethane (PU) central venous 
catheters (CVCs) and other medical implant devices. The sustained release of 
biologically active compound from the catheters could reduce the incidence of 
catheter sheath formation, thrombotic occlusion and associated infection in CVCs 
(Griffin et al., 2004; Lambert et al., 2007).  
 
The objectives of this work were:  
 
• Defining the key characteristics for an effective polymeric-coating such as 
drying time, flexibility, uniformity and consistency of finish and thickness of 
the coated PU strips. 
• Ascertaining the most suitable polymer for coating of the PU strips according 
to predefined key characteristics for an effective coating. 
• Determining the most appropriate solvent which is compatible with the 
enzyme inhibitor, the PU strips and the polymer of choice. 
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• Producing a polymeric coating on the PU strips for the incorporation of the 
enzyme inhibitor. 
• Quantifying the enzyme inhibitor release from the PU strips in vitro. 
 
3.3 Materials 
Phosphate buffered saline (PBS), polyethylene oxide (PEO) with molecular weight 
1000000 and 5000000; polyethylene glycol (PEG) with molecular weight 8000, 4600 
and 2000; polyvinylpolypyrrolidone (PVP) with the molecular weight 360000, 10000 
and 40000, poly(D,L-lactide-co-glycolide) (PLGA) with a lactide/glycolide ratio 
50:50 and 85:15  were supplied by Sigma-Aldrich (Dorset, England). Polyethylene 
oxide with molecular weight 300,000 was purchased from Fisher Scientific 
(Loughborough, UK). Poly(L-lactic acid) (PLA) with molecular weight 2000, 50000 
and 300000 were obtained from Polysciences, Inc. (Eppelheim, Germany). The 
polyurethane (PU) sheets with a hardness of 85 Ao, thickness of 1 mm and dimensions 
of 3 m x 700 mm were ordered from PPL Polyurethane Products Ltd (Reforfd, 
Nottinghamshire, UK). Unless stated otherwise PBS was used at 0.01 M, pH 7.4. 
Doubly distilled and filtered water was used in the preparation of all solutions. 
AM2/97 (fluorescent-labeled FXIIIa inhibitor) was prepared within the chemistry 
department of Aston University by Dr. Alexandre Mongeot and Dr. Dan Rathbone as 
previously described (Griffin et al., 2008). 
 
3.4 Methods 
3.4.1 Polyurethane sheet 
The intravascular guiding catheters are 
extensively used in clinics at the present time 
and polyurethanes (PU) are extensively selected 
as the matrix material (Wang et al., 2001). For 
preliminary studies, the polyurethane sheets 
(Figure 3.1) cut into equal strips to a size of 5 x 
1 cm2.                                                                                   
 
3.4.2 Cleaning 
As with any coating procedure, surface cleanliness is essential prior to dipping to 
ensure successful adhesion between the polymer and the substrate. Common 
Figure 3. 1 Polyurethane sheet 
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contaminants are finger oils, dust, and it is critical that these are removed prior to 
coating. Thus, a variety of cleaning methods have been successfully employed, 
including washing with alkaline detergent and soaking in solvents such as isopropanol 
(IPA) or ethanol (Reitman & McPeak, 2005). 
 
3.4.3 Key requirements for an effective polymer coating 
For an effective coating of the polyurethane strips, 4 key characteristics were defined 
and investigated. 
 
• Drying time 
• Flexibility  
• Smoothness and consistency of finish 
• Thickness 
 
3.4.3.1 Drying time  
The first feature examined was drying time 
of the PU strips subsequent to coating. The 
strips were dip-coated 1-5 times in a 
selection of polymer solutions at intervals. 
The drying process of the coated strips was 
conducted by hanging them from a stand in 
a vertical position at room temperature 
(Figure 3.2) and once dried the same 
procedure was repeated. The time of drying 
for each coated strip was measured by a 
stopwatch.  
 
3.4.3.2 Flexibility  
As discussed in 3.1.1.2.2, capability of being twisted devoid of breaking, cracks or 
delamination of the PU strips after the polymeric coating was qualitatively assessed.  
 
 
 
Figure 3. 2 The polymer-coated strips were 
hung from a stand in a vertical position and 
dried at room temperature subsequent to 
coating. 
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3.4.3.3 Smoothness and consistency of finish  
The smoothness and consistency of finish is detailed in 3.1.1.2.1 and visually 
analysed, following the polymeric-coating of the PU strips. 
 
3.4.3.4 Thickness of the PU strips 
3.4.3.4.1 Scanning electron microscopy (SEM) 
The thickness of the polymer-coated PU strips was determined using scanning 
electron microscopy (SEM). At the outset, specimens were thoroughly dried and gold 
coated by a gold sputter coater (Emscope SC500 Sputter coater, Ashford, Kent, Great 
Britain). The thickness of the strips was then measured by a scanning electron 
microscope (Cambridge Instruments, Stereoscan 90) at six points and the average was 
used. The experimental conditions involved the PU strips coated in 5 % (w/v) 
polymer in DCM, 1-5 times. 
 
3.4.3.4.2 Epifluorescent microscopy  
The thickness of the inhibitor-and polymer-coated strips was measured using 
epifluorescent microscopy by an Axiocam HRC camera mounted on a Zeiss Axioskop 
microscope with AxioVision version 3.1 software and a Achroplan 4x/ 0.10 objective. 
Layers were recorded using a Zeiss filter set giving excitation at 365 nm, and 
emission at 420 nm. The experimental conditions were the PU strips coated using a 
solution composed of 5 % (w/v) polymer and 0.25 % (w/v) AM2/97 in DCM, 2-4 
times. 
 
3.4.4 Choice of polymer 
As per the criteria defined above, and based on preliminary studies (appendix 1), 
polyvinylpyrrolidine (PVP) with 40 k molecular weight and poly (lactic-co-glycolic 
acid) (PLGA) with a lactide/glycolide ratio 85:15 appeared to fulfil the features 
mentioned for having an effective coating. 
 
3.4.5 Choice of solvent 
To investigate the most appropriate solvent which is compatible with the enzyme 
inhibitor, polyurethane and the polymer (PVP or PLGA), a different range of solvents 
such as PBS, acetone, methanol, ethanol, dimethyl sulfoxide (DMSO), chloroform 
and dichloromethane (DCM) were examined. DCM appeared to be the optimum 
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solvent; it evaporated fast and had no effect on the polyurethane strips. Furthermore, it 
was a good solvent for both the polymer and inhibitor. Acetone fades the colour of the 
PU strips, whilst methanol dissolves it. PBS and DMSO do not evaporate fast.  
 
3.4.6 Dip-coating method 
The polyurethane strips were coated using dip-coating method (Jones, 2000). Initially, 
the polymer was dissolved in the appropriate solvent at a desired concentration, in a 
suitable tank. To create a local drug delivery system, a requisite amount of the 
enzyme inhibitor was also added to the polymer solution. The coating solution was 
maintained on dry ice to avoid evaporation of the organic solvent and a consequent 
increase in the polymer concentration. The polyurethane strips were inserted vertically 
into the container containing the coating material and the inhibitor and then taken out 
and force dried. The strips were coated by a two, three and four times dip-coating 
procedure to achieve a dense and regular polymer coating. The coated polyurethane 
strips were dried at room temperature, allowing the solvent to evaporate completely. 
To obtain reproducible and consistent coatings, attempts were made to ensure that the 
strips were immersed in and removed from the coating solution at the same rate. The 
benefits of this technique include simplicity, low cost, ease of control, good coverage 
and consistency (Jones, 2000). The coating process was followed by measurement of 
weight alterations after each coating layer. The schematic of the dip coating process is 
illustrated in Figure 3.3.  
 
                                    
 
Figure 3. 3 The schematic of dip-coating of the polyurethane strips in the polymer solution 
containing the fluorescent inhibitor 
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Given that the fluorescent compounds are highly photosensitive, precaution was taken 
to protect them from light, using aluminium foil to cover the drug solution throughout 
the duration of the experiment. 
 
3.4.7 in vitro release study of FXIIIa inhibitor 
To study the drug release from the inhibitor and polymer coated polyurethane strips (2 
x 1 x 0.1 cm3), each of the strips was placed in a 50 ml universal tube containing 10 
ml of 0.01 M of phosphate buffer saline pH 7.4 (Figure 3.4). The universal tubes were 
then put in a shaking water bath set at 80 rpm and 37 °C. The release medium was 
sampled and replaced constantly (to promote sink condition). The amount of relative 
fluorescent unit (RFU) within the release media was measured using 200 µl aliquots 
taken at pre-determined time points and measured spectrofluorimeterically with an 
excitation maximum at 330 nm and emission peak at 570 nm (Spectra Max Gemini 
XPS, Molecular Probes), to quantify the amount of inhibitor release from the coated 
polyurethane strips. 
 
 
 
 
 
 
 
                                
 
Figure 3. 4 The inhibitor-and polymer-coated polyurethane strips placed in PBS 
 
Accordingly the concentration of the inhibitor released within the media was 
calculated using a drug calibration curve which was formerly prepared from a set of 
standard samples of known concentration. The results were then reported as 
cumulative drug release, which corresponds to accumulation of the drug within the 
release media from time zero up to the measured time point, expressed as percentage 
(%) of total drug added and concentration (µmole/ ml) of the inhibitor released. 
Estimation of the amount of the inhibitor entrapped within the coatings was calculated 
by measuring the density of the coating solution and weight changes of the solution 
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subsequent to each coating, which was followed by calculating the number of moles 
of the inhibitor incorporated per coating. 
 
3.5 Results and Discussion 
3.5.1 Drying time   
The PU strips were repeatedly dip-coated using the polymer solutions with various 
concentrations at room temperature. The coating formulation was incorporating 5 %, 
10 % and 20 % (w/v) PVP or PLGA in DCM.  
 
Regarding Figure 3.5, the drying time was lengthened correspondingly with the 
number of coatings from 1 to 5 times, and the concentration of the polymer from 5 % 
to 20 % (w/v). 
 
Figure 3. 5 Drying time (minute) of the PU strips at different concentrations of the polymeric-
coating solution. The coating formulation was incorporating 5 %, 10 % and 20 % (w/v) PVP or PLGA 
in DCM. The drying time was augmented correspondingly with the number of coatings and the 
concentration of polymers. Results denote mean ± SD from 3 independently synthesized batches.  
 
As the number of coatings and consequently the thickness of the strips was increased, 
the drying time was raised from ~ 2 minutes to ~ 15 minutes for 5 % (w/v) polymer 
solution, from ~ 7 minutes to ~ 17 minutes for 10 % (w/v) polymer solution and 
finally from ~ 15 minutes to ~ 25 minutes for 20 % (w/v) polymer solution. Drying is 
a complex procedure which involves simultaneous heat and mass transfer phenomena. 
The phenomena which must be considered in convective air drying of solids are the 
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moisture diffusion in the solid toward its external surface, the vaporization and 
convective transfer of the vapour into the air stream, the conductive heat transfer 
within the solid mass and the convective heat transfer from the air to the solid’s 
surface (Catalano, 2008).  
 
These results could be explained using Fick’s Law of diffusion, the equation 
describing the rate at which diffusion occurs (equation 3.1). Jx (the flux density) is the 
amount of species x crossing a certain area per unit time. The diffusion rate is directly 
proportional to the difference in concentration, dc, and the cross-sectional area, A, 
across which the molecules are diffusing and inversely proportional to the distance, 
dx, through which the molecules diffuse or in other words the thickness. The diffusion 
coefficient (D), has units of m2/s. The negative sign indicates that the direction of 
flow is from high to low concentration.  
 
                                             
 
According to Fick’s law, a longer time is required for the moisture diffusion in the 
solid towards its external surface in a thicker layer than in the thinner one. Therefore, 
a consequent increase of coating thickness results in an increase in drying time. 
 
Furthermore, an approximate dependence of the diffusion coefficient on temperature 
can often be found using the Stokes-Einstein equation, which predicts that: 
 
       (Equation 3.2)  
 
T1 and T2 denote temperatures 1 and 2, respectively, D is the diffusion coefficient 
(m²/s), T is the absolute temperature and µ is the dynamic viscosity of the solvent 
(Pa·s). 
 
In accordance with Stokes-Einstein equation, the diffusion rate is directly proportional 
to the temperature. Therefore, as temperature and consequently the diffusion rate 
increases, the drying time decreases. Thus, an attempt was made to conduct the 
experiment for all the specimens at the same temperature.   
(Equation 3.1) 
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3.5.2 Flexibility, Smoothness and consistency of finish  
It is essential that the polymer coating adheres well to the underlying substrate, 
providing integrity during performance. Hence, a number of techniques have been 
established to ensure this, such as treating the substrate with an acidic solution or a 
polymeric adhesion layer prior to application of the hydrogel (Allegiance Research & 
Technology, 1999). Nevertheless, due to a significant difference between the elastic 
modulus of hydrogels and that of substrate, the hydrogel coatings tend to crack 
throughout device manufacture and use. If the adhesion of the coating to the rubber is 
poor, the coating flakes off from the substrate. This can result in problems including 
particulate debris and the formation of adherence sites for bacteria. Furthermore, in 
terms of physical properties, tensile strength and puncture resistance are typically low 
in hydrogel coating (Young et al., 1998; Allegiance Research & Technology, 1999; 
Lawrence and Turner, 2005). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                       
                    Figure 3. 6 Complete delamination of the polymeric coating of the PU strips 
 
Cracking, partial or complete delaminating was observed subsequent to coating of a 
quantity of the PU strips with the various polymer solutions. Some others exhibited 
Figure 3. 7 The polymeric coating of the 
PU strips with partial delamination and 
cracks 
 
Figure 3. 6 Partial delamination of the 
polymeric coating of the PU strips 
Figure 3. 8 Complete delamination of the polymeric coating of the PU strips 
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irregular and inconsistent surface finish (Figures 3.6-3.8, additional details have been 
presented in appendix 1).  
 
PVP and PLGA demonstrated optimum coating amongst the entire range of polymers 
tested, in terms of flexibility and smooth surface finish (appendix 1). The coating had 
the ability to withstand the compressive and tensile strains imparted and was devoid 
of cracking or delamination during the expansion process. Moreover, the coatings 
were consistent, unvaried in texture and free from extraneous matter. 
 
3.5.3 Thickness 
3.5.3.1 Scanning electron microscopy  
To determine the thickness of the polymer-coated strip, scanning electron microscopy 
was performed. The coating formulation was incorporating 5 % (w/v) PVP or PLGA 
in DCM.  
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Figure 3. 7 The thickness of the polymer-coated polyurethane strips, using SEM. The coating 
formulation was incorporating 5 % (w/v) PVP or PLGA in DCM. The thickness was measured at six 
points and the average was used. There was a steady increase in the thickness of the PU strips with 
increasing the number of coatings. Results denote mean ± SD from 3 independently synthesized 
batches. 
 
As shown in Figure 3.9, there was a steady increase in the thickness of the PU strips 
from about 5 µm to around 25 µm, with increasing the number of coatings from 1 
layer to 5 layers. Insufficient information is available on the commercial application 
of the coatings; however they are commonly believed to be in the order of 50 µm in 
thickness (Lawrance and Turner, 2005). 
 
Figure 3. 9 The thickness of the polymer-coated polyurethane strips, using SEM. The coating 
formulation was incorporating 5 % (w/v) PVP or PLGA in DCM. The thickness was measured at six 
points and the average was used. There was a steady increase in the thickness of the PU strips with 
increasing the number of coatings. Results denote mean ± SD from 3 independently synthesized 
batches. 
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3.5.3.2 Epifluorescent microscopy 
To confirm the integration of the enzyme inhibitor throughout the coating of the PU 
strips and to certify the coating thickness of the inhibitor-and polymer-coated PU 
strips, epifluorescent microscopy was achieved. The coating formulation was 
incorporating 5 % (w/v) PVP or PLGA and 0.25 % AM2/97 in DCM.  
                                             
Figure 3. 8 A-C epifluorescent microscope images of the 2, 3 and 4 times inhibitor-and polymer-
coated polyurethane strips, using 4 x objectives. The coating formulation was incorporating 5 % 
(w/v) PVP or PLGA and 0.25 % AM2/97 in DCM. The thickness of the coatings augmented with the 
number of the coatings. Bar indicates 100 µm.  
 
The thickness of the coated PU strips was measured by an epifluorescent microscope. 
The epifluorescent microscope images form the strips confirmed the integration of the 
enzyme inhibitor throughout the coating of the strips. As was expected, the thickness 
of the coatings augmented with the number of the coatings. The PU strips coated 2, 3 
and 4 times, demonstrated an average thickness of about 5.5 µm, 8.5 µm and 15 µm 
respectively (Figures 3.10). These results were in agreement with the findings from 
SEM previously reported.  
 
The coatings of the strips were performed manually; this would result in different 
withdrawal velocity which could affect the thickness of coatings and consequently the 
quantity of the integrated polymer into the PU strips. The increase of withdrawal 
velocity results in the increase of film thickness at the moderately low withdrawal 
velocity regime. Nevertheless, it was noted that the layer thickness begins to decrease 
with increasing withdrawal velocity, at the relatively high withdrawal velocity regime 
of the dip-coating process (Fang, 2008). Consequently, attempts were made to ensure 
that the strips were immersed in and removed from the coating solution at the same 
rate.  
 
A B C 
Figure 3. 10 A-C epifluorescent microscope images of the 2, 3 and 4 times inhibitor-and 
polymer-coated polyurethane strips, using 4 x objectives. The coating formulation was 
incorporating 5 % (w/v) PVP or PLGA and 0.25 % AM2/97 in DCM. The thickness of the coatings 
augmented with the number of the coatings. Bar indicates 100 µm. 
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3.5.4 Rate-controlled release in drug delivery and targeting  
The mechanisms controlling the rate of drug release from a delivery system are; 
• Diffusion-controlled release mechanism 
• Dissolution-controlled release mechanism 
• Osmosis-controlled release mechanism  
• Mechanical-controlled release mechanism 
• Bio-responsive controlled release mechanism 
 
Diffusion-controlled release mechanism 
Diffusion-controlled release mechanism is briefly described here and is further 
detailed in chapter 4. In this case, the drug must diffuse either through the 
macromolecular mesh or the water-filled pores of the reservoir device or matrix 
system in order to be released. 
 
Dissolution-controlled release mechanism 
There are two major types of dissolution-controlled systems; reservoir device or 
matrix system. In dissolution-controlled release devices, drug release is controlled by 
dissolution rate of an employed polymer. Since the dissolution of polymeric material 
is the key to this mechanism, the polymer must be water-soluble or degradable in 
water (Hillery et al., 2001). The dissolution process includes two steps; initial 
dissolution and detachment of drug molecules from the surface of their solid structure 
to the adjacent liquid interface, followed by diffusion of the solvated molecules from 
the interface into the bulk liquid medium. It is generally believed that the first step is 
much faster than the second step. This procedure could be manipulated to create 
controlled release delivery systems with desired profiles and a favourite rate of release 
(Wang & Shmeis, 2005).  
 
The rate of dissolution, the amount of dissolved solid per unit time, can be calculated 
by the Noyes-Whitney equation which relates the rate of dissolution of solids to the 
properties of the solid and the dissolution medium and written as: 
 
 = A   (Cs – Cb)     (Equation 3.2) 
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Where M = mass, t = time, A = surface area of the solid, D = diffusion coefficient, h = 
thickness of diffusion layer, Cs = concentration of the solid in the diffusion layer 
surrounding the solid, Cb = concentration of the solid in bulk dissolution medium. 
 
Alteration of the thermal and spatial aspects of drug release using coatings involves 
applying a layer or layers of retardant material between the drug and the 
elution/dissolution medium. When a coated system is made of water-soluble 
constituents, the rate limiting step leading the release of drug from the system is the 
dissolution rate of polymer coating over time. Once the polymeric membrane has 
dissolved by gentle disentanglement of the polymer chain, the drug inside the 
membrane is instantaneously available for dissolution and absorption. At this stage, 
release is depending on the core properties (drug and excitements) including porosity, 
drug solubility and dissolution rate in the dissolution medium. Cores can be 
immediate release systems or controlled release matrix system (Wang & Shmeis, 
2005).  
 
3.5.4.1 Initial burst drug release from the PU strips 
Poly vinyl pyrrolidone (PVP) was the first polymer which was selected for coating of 
the PU strips and studying in vitro drug release. PVP is a water-soluble polymer made 
from the monomer N-vinylpyrrolidone (Haaf et al., 1985) and a typical example of 
hydrogel polymers that have been utilised in indwelling medical device surface 
modifications (Huang, 2003; Shintani, 2004). PVP is a hydrophilic hydrogel which 
adsorbs water on contact with the blood and produces an extremely smooth surface. 
As well as improved haemocompatibility, the hydrogel significantly reduces bacterial 
adhesion in in vitro assays (John, 1996). Therefore, the chosen PVP coating enables 
the possibility of covering medical implants with biodegradable and biocompatible 
surface coating. The release pattern of the enzyme inhibitor into the medium was 
represented by plotting the cumulative drug release (µmole/ml) and the cumulative 
percent (%) drug released against time. The coating formulation of the PU strips was 
incorporating 5 % (w/v) PVP and 0.25 % (w/v) AM2/97 in DCM (Figures 3.11 & 
3.12). 
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Figure 3. 9 Cumulative releases (µmole/ml) of the fluorescent FXIIIa inhibitor (AM2/97) into 10 
ml PBS from the individually coated polyurethane strips over 60 minutes under sink condition. 
The formulation was incorporating 5 % (w/v) PVP and 0.25 % (w/v) AM2/97 in DCM. Cumulative 
drug release corresponds to accumulation of the drug within the release media from time zero up to the 
measured time point, expressed as concentration (µmole/ ml) of the inhibitor released. Results denote 
mean  ±  SD from 3 independently synthesized batches  
 
 
Figure 3. 10 Cumulative percentage release of the fluorescent FXIIIa inhibitor (AM2/97) into 10 
ml PBS from the individually coated polyurethane strips over 60 minutes under sink condition. 
The formulation was incorporating 5 % (w/v) PVP and 0.25 % (w/v) AM2/97 in DCM. Cumulative 
drug release corresponds to accumulation of the drug within the release media from time zero up to the 
measured time point, expressed as percentage (%) of total drug added. Results denote mean  ±  SD 
from 3 independently synthesized batches. 
 
With regards to Figures 3.11 and 3.12, an initial burst release of the integrated 
inhibitor (0.09 - 0.17 µmole/ml) was obtained within the first minute for all the 
coatings tested (~ 50 %). The 2, 3 and 4 times PVP coatings, demonstrated 80 %, 75 
% and 60 % cumulative percent drug release and 0.011, 0.017 and 0.020 µmole/ml 
total cumulative drug release subsequent to 10 minutes respectively, thereafter the 
Figure 3. 11 Cumulative releases (µmole/ml) of the fluorescent FXIIIa inhibitor (AM2/97) into 
10 ml PBS from the individually coated polyurethane strips over 60 minutes under sink 
condition. The formulation was incorporating 5 % (w/v) PVP and 0.25 % (w/v) AM2/97 in DCM. 
Cumulative drug release corresponds to accumulation of the drug within the release media from time 
zero up to the measured time point, expressed as concentration (µmole/ ml) of the inhibitor released. 
Results denote mean  ±  SD from 3 independently synthesized batches. 
 
Figure 3. 12 Cumulative percentage release of the fluorescent FXIIIa inhibitor (AM2/97) into 10 
ml PBS from the individually coated polyurethane strips over 60 minutes under sink condition. 
The formulation was incorporating 5 % (w/v) PVP and 0.25 % (w/v) AM2/97 in DCM. Cumulative 
drug release corresponds to accumulation of the drug within the release media from time zero up to the 
measured time point, expressed as percentage (%) of total drug added. Results denote mean  ±  SD 
from 3 independently synthesized batches. 
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drug release was insignificant. In this case, the drug release was controlled by the 
dissolution rate of polymer coating over time. Upon contact of the polymer coating of 
the PU strips with PBS, a rapid release of the incorporated inhibitor from the surface 
on hydration and consequently dissolution of the biodegradable polymer was 
achieved. Increasing the number of coatings had no affect on the release time; 
however it affected the concentration of drug released into the media, due to the 
higher total concentrations within the coat. Unlike some diffusion-controlled release 
coated systems, release profile from dissolution-controlled release coated systems do 
not follow zero-order kinetic (Wang & Shmeis, 2005).  
 
To investigate the drug concentration-effect on release behaviour, the percentage of 
the integrated drug in the formulation was incorporated from 0.25 % to 0.5 % (w/v). 
The coating formulation of the PU strips incorporated 5 % (w/v) PLGA and 0.5 % 
(w/v) AM2/97 in DCM. 
 
 
Figure 3. 11 Cumulative releases (µmole/ ml) of the fluorescent FXIIIa inhibitor (AM2/97) into 10 
ml PBS from the individually coated polyurethane strips over 60 minutes under sink condition. 
The formulation was incorporating 5 % (w/v) PVP and 0.5 % (w/v) AM2/97 in DCM. Cumulative drug 
release corresponds to accumulation of the drug within the release media from day zero up to the 
measured time point, expressed as concentration (µmole/ ml) of the inhibitor released. Results denote 
mean  ±  SD from 3 independently synthesized batches. 
 
 
 
Figure 3. 3 Cumulative r leases (µmole/ ml) of the fluorescent FX IIa inhibitor (AM2/97) into 
10 ml PBS from the individu lly coated polyurethane strips over 60 minute  under sink 
condition. The formulation was incorporating 5 % (w/v) PVP and 0.5 % (w/v) AM2/97 in DCM. 
Cumulativ  drug release orresponds to accumulation of t  drug within the release media from day 
zero up to th  measured tim  point, expressed as concentration (µmole/ ml) of the inhibitor released. 
Results denote ean  ±  SD from 3 i dependently synthesized batches. 
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Figure 3. 12 Cumulative percentage release of the fluorescent FXIIIa inhibitor (AM2/97) into 10 
ml PBS from the individually coated polyurethane strips over 60 minutes under sink condition. 
The formulation was incorporating 5 % (w/v) PLGA and 0.5 % (w/v) AM2/97 in DCM. Cumulative 
drug release corresponds to accumulation of the drug within the release media from day zero up to the 
measured time point, expressed as percentage (%) of total drug added. Results denote mean  ±  SD 
from 3 independently synthesized batches.  
 
Upon doubling the amount of the incorporated inhibitor, the same trend was observed 
as in Figure 3.12, in terms of the total cumulative drug release. Nevertheless, the total 
amount of drug release augmented from ~ 0.011 to ~ 0.025 µmol/ml for 2 times 
coating, from ~ 0.017 to ~ 0.035 µmol/ml for 3 times coating and from ~ 0.020 to ~ 
0.050 µmol/ml for 4 times coating, at the end of 5 minutes (Figure 3.13). Afterwards 
the drug release was insignificant for all tested coatings. The cumulative percentage 
drug release was virtually the same for all the tested coatings with no significant 
difference, reaching a maximum of ~ 65 % after 5 minutes (Figure 3.14). A higher 
drug incorporation results in a greater amount of the drug being present on the surface 
or proximal to the surface which leads to a greater initial and ultimate drug release. 
Thus, it can be concluded that a twofold increase in the amount of the integrated 
inhibitor, approximately twice the total amount of drug release from the PU strips, 
however it does not influence the release time. 
 
3.5.4.2 Delayed drug release from the PU strips 
To improve the drug release profile, a hydrophobic co-polymer such as PLGA with a 
lactide/glycolide ratio 85:15 was selected as the polymer of choice for coating of the 
PU strips. The coating formulation was incorporating 5 % (w/v) PLGA and 0.25 % 
(w/v) AM2/97 in DCM (Figures 3.15 & 3.16).  
4  l s  f the fluorescent FXIIIa inhibitor (A 2/97) into 10 
i i i ll  t  oly ret a e strips over 60 minutes under sink condition. 
 ( / )  and 0.5  (w/v) A 2/97 in DCM. Cumulative 
 t  r  it in the release edia from day zero up to the 
t  ) f total drug added. Results denote mean ± SD 
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Figure 3. 13 Cumulative releases (µmole/ ml) of the fluorescent FXIIIa inhibitor (AM2/97) into 10 
ml PBS from the individually coated polyurethane strips over 7 days under sink condition. The 
formulation was incorporating 5 % (w/v) PLGA and 0.25 % (w/v) AM2/97 in DCM. Cumulative drug 
release corresponds to accumulation of the drug within the release media from day zero up to the 
measured time point, expressed as concentration (µmole/ ml) of the inhibitor released. Results denote 
mean  ±  SD from 3 independently synthesized batches.  
 
 
Figure 3. 14 Cumulative percentage release of the fluorescent FXIIIa inhibitor (AM2/97) into 10 
ml PBS from the individually coated polyurethane strips over 7 days under sink condition. The 
formulation was incorporating 5 % (w/v) PLGA and 0.25 % (w/v) AM2/97 in DCM. Cumulative drug 
release corresponds to accumulation of the drug within the release media from day zero up to the 
measured time point, expressed as percentage (%) of total drug added. Results denote mean  ±  SD 
from 3 independently synthesized batches. 
 
PLGA is a synthetic copolymer of lactic acid ( -hydroxy propanoic acid) and glycolic 
acid (hydroxy acetic acid) (Avgoustakis, 2005). Indeed, it has been established that 
PLGA has desirable characteristics such as good biocompatibility and biodegradation. 
It has been utilised extensively for a variety of applications, including the design and 
Figure 3. 15 u ulative releases (µ ole/ l) of the fluorescent FX Ia inhibitor (AM2/97) into 
10 ml PBS from the individually coated polyurethane strips over 7 days under sink condition. 
The formulation was incorporating 5 % (w/v) PLGA and 0.25 % (w/v) A 2/97 in DCM. 
Cumulative drug release corresponds to accum lation of the drug within the release media from day 
z ro p to the measur d time point, expressed as concentration (µmole/ ml) of th  inhibitor releas d. 
R sults denote ean  ±  SD from 3 independently synthesized batches. 
 
Figure 3. 16 Cumulative percentage release of the fluorescent FXIIIa inhibitor (AM2/97) into 
10 ml PBS from the individually coated polyurethane strips over 7 days under sink condition. 
The formulation was incorporating 5 % (w/v) PLGA and 0.25 % (w/v) AM2/97 in DCM. Cumulative 
drug release corresponds to accumulation of the drug within the release media from day zero up to 
the measured time point, expressed as percentage (%) of total drug added. Results denote mean  ±  
SD from 3 independently synthesized batches. 
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properties of the controlled-release systems for pharmaceutical agents. In recent years, 
PLGA has been broadly investigated for usage as implantable biodegradable carriers 
for controlled release of drugs. Using PLGA as drug carrier for medical implants 
coating could overcome the side effects of non biodegradable polymers (Gombotz & 
Pettit, 1995; Pan et al., 2007; Zheng et al., 2006). 
 
The Figures 3.15 and 3.16 demonstrate that the cumulative drug release for the 2 
times coating was ~ 0.009 µmole/ ml, which is significantly lower than the 
cumulative drug release for 3 and 4 times coating (~0.013 and ~ 0.14 µmole/ ml 
respectively), whereas the cumulative percent drug release for the same layers of 
coatings is approximately between 0.80 % and 1.20 %, at the end of 7 days. These 
values are extremely low when compared to the other polymer used former in this 
study. This could be attributed to the poor solubility of the drug, as will be detailed in 
chapter 4. Briefly, lipophilic drugs are solubilised in matrix system, diffuse, and are 
released. Water-soluble drugs neither dissolve nor diffuse in a matrix system. Initially, 
water-soluble drugs existing on the surface, and subsequently the ones near the 
surface dissolve into water. Repetition of these procedures results in channel 
formation, allowing water-soluble drugs to be released in bulk. However water-
insoluble drugs neither dissolve nor diffuse in a matrix system; they are not released 
since channels are not formed because of their insolubility in water. Hence, the release 
of the insoluble drugs from matrix system has long been considered challenging 
(Kajihara, 2003). 
3.5.4.3 Sustained drug release from the PU strips 
To provide a sustained release profile over a longer time for the enzyme inhibitor, a 
polymer blend of PVP (hydrophilic) and PLGA (hydrophobic) was utilised in order to 
release the active drug continuously at a moderate rate to grant a long-term 
therapeutic effect. The coating formulation integrated 2.5 % (w/v) PVP, 5 % (w/v) 
PLGA and 0.25 % (w/v) AM2/97 in DCM (Figures 3.17 & 3.18). 
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Figure 3. 15 Cumulative releases (µmole/ ml) of the fluorescent FXIIIa inhibitor (AM2/97) into 10 
ml PBS, from the individually coated polyurethane strips over 7 days under sink condition. The 
formulation was incorporating 2.5 % (w/v) PVP, 5 % (w/v) PLGA and 0.25 % (w/v) AM2/97 in DCM. 
Cumulative drug release corresponds to accumulation of the drug within the release media from day 
zero up to the measured time point, expressed as concentration (µmole/ ml) of the inhibitor released. 
Results denote mean  ±  SD from 3 independently synthesized batches. 
 
  
Figure 3. 16 Cumulative percentage release of the fluorescent FXIIIa inhibitor (AM2/97) into 10 
ml PBS from the individually coated polyurethane strips over 7 days under sink condition. The 
formulation was incorporating 2.5 % (w/v) PVP, 5 % (w/v) PLGA and 0.25 % (w/v) AM2/97 in DCM. 
Cumulative drug release corresponds to accumulation of the drug within the release media from day 
zero up to the measured time point, expressed as percentage (%) of total drug added. Results denote 
mean  ±  SD from 3 independently synthesized batches.  
 
The cumulative percent drug release was in the proximity of 0.015, 0.025 and 0.037 
µmole/ml for 2, 3 and 4 times coating respectively (Figure 3.17), whilst the 
cumulative percentage of drug release for all the three coatings was approximately 
between 11 % and 14 % at the end of 7 days with no significant difference (Figure 
3.18). It was deemed that utilization of the polymer blend for coating of the PU strips 
Figure 3. 17 Cumulative releases (µmole/ ml) of the fluorescent FXIIIa inhibitor (AM2/97) into 
10 ml PBS, from the individually coated polyurethane strips over 7 days under sink condition. 
The formulation was incorporating 2.5 % (w/v) PVP, 5 % (w/v) PLGA and 0.25 % (w/v) AM2/97 in 
DCM. Cumulative drug release corresponds to accumulation of the drug within the release media 
from day zero up to the measured time point, expressed as concentration (µmole/ ml) of the 
inhibitor released. Results denote mean  ±  SD from 3 independently synthesized batches. 
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increased the amount of drug release significantly. PVP, being a hydrophilic polymer 
undergoes dissolution and dissolves instantly. This process leads to the formation of 
channels in the PLGA-coating layers and eventually leads to drug release, which was 
not initially possible due to PLGA’s hydrophobic nature (Kajihara, 2003).  
                                                         
To investigate the release profiles in a more potentially relevant media, fetal bovine 
serum (FBS) and PBS 50:50 (v/v) was utilised as the release medium in replacement 
of PBS, where the formulation of coating was amalgamating 2.5 % (w/v) PVP, 5 % 
(w/v) PLGA and 0.25 % (w/v) AM2/97 in DCM (Figures 3.19 & 3.20). 
 
According to Figures 3.19 & 3.20 the cumulative percentage of drug release was 
measured from 11 – 14 % to 35 – 50 % for 2.5 % (w/v) PVP, 5 % (w/v) PLGA and 
0.25 % (w/v) AM2/97 coated PU strips. The cumulative drug release was measured at 
around 0.05, 0.08 and 0.13 µmole/ml for the PU strips coated 2, 3 and 4 times, by the 
end of 14 days. It was found that upon the substitution of the release medium, there 
was a substantial increase in the amount and duration of drug release.  
 
 
Figure 3. 19 Cumulative releases (µmole/ ml) of the fluorescent FXIIIa inhibitor (AM2/97) into 
PBS: FBS 50:50 (v/v) from the individually coated polyurethane strips over 14 days under sink 
condition. The formulation was incorporating 2.5 % (w/v) PVP, 5 % (w/v) PLGA and 0.25 % (w/v) 
AM2/97 in DCM. Cumulative drug release corresponds to accumulation of the drug within the release 
media from day zero up to the measured time point, expressed as concentration (µmole/ ml) of the 
inhibitor released. Results denote mean  ±  SD from 3 independently synthesized batches. 
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Figure 3. 20 Cumulative percentage release of the fluorescent FXIIIa inhibitor (AM2/97) into 10 
ml PBS: FBS 50:50 (v/v) from the individually coated polyurethane strips over 14 days under 
sink condition. The formulation was incorporating 2.5 % (w/v) PVP, 5 % (w/v) PLGA and 0.25 % 
(w/v) AM2/97 in DCM. Cumulative drug release corresponds to accumulation of the drug within the 
release media from day zero up to the measured time point, expressed as percentage (%) of total drug 
added. Results denote mean  ±  SD from 3 independently synthesized batches. 
 
In an attempt to further enhance the total amount and duration of the enzyme inhibitor 
release, the percentage of incorporated PVP in the formulation was increased from 2.5 
% to 5 % (w/v). The coating formulation was incorporating 5 % (w/v) PVP, 5 % (w/v) 
PLGA and 0.25 % (w/v) AM2/97 in DCM (Figures 3.21 and 3.22). 
  
Figure 3. 17 Cumulative releases (µmole/ ml) of the fluorescent FXIIIa inhibitor (AM2/97) into 
PBS: FBS 50:50 (v/v) from the individually coated polyurethane strips over 14 days under sink 
condition. The formulation was incorporating 5 % (w/v) PVP, 5 % (w/v) PLGA and 0.25 % (w/v) 
AM2/97 in DCM. Cumulative drug release corresponds to accumulation of the drug within the release 
media from day zero up to the measured time point, expressed as concentration (µmole/ ml) of the 
inhibitor released. Results denote mean  ±  SD from 3 independently synthesized batches.  
Figure 3. 20 Cumulative percentage release of the fluorescent FXIIIa inhibitor (AM2/97) into 
10 ml PBS: FBS 50:50 (v/v) from the individually coated polyurethane strips over 14 days 
under sink condition. The formulation was incorporating 2.5 % (w/v) PVP, 5 % (w/v) PLGA and 
0.25 % (w/v) AM2/97 in DCM. Cumulative drug release corresponds to accumulation of the drug 
within the release media from day zero up to the measured time point, expressed as percentage (%) 
of total drug added. Results denote mean  ±  SD from 3 independently synthesized batches. 
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Figure 3. 18 Cumulative percentage release of the fluorescent FXIIIa inhibitor (AM2/97) into 
PBS: FBS 50:50 (v/v) from the individually coated polyurethane strips over 14 days under sink 
condition. The formulation was incorporating 5 % (w/v) PVP, 5 % (w/v) PLGA and 0.25 % (w/v) 
AM2/97 in DCM. Cumulative drug release corresponds to accumulation of the drug within the release 
media from day zero up to the measured time point, expressed as percentage (%) of total drug added. 
Results denote mean  ±  SD from 3 independently synthesized batches.  
 
Subsequent to increasing the quantity of incorporated PVP in the formulation, there 
was a significant increase in the cumulative percentage of drug release from 35 – 50 
% to 50 – 70 %, and in the total cumulative drug release from ~ 0.05 - 0.13 µmole/ml 
to ~ 0.07 – 0.15 µmole/ml for 2, 3 and 4 times coating by the end of 14 days (Figures 
3.21 & 3.22). This could be due to the formation of more channels in the coating of 
the PU strips upon the increasing of the percentage of incorporated PVP which 
eventually leads to sustained release of the larger amount of the enzyme inhibitor. The 
greater total cumulative drug release for 4 times coating in all the cases could be 
attributed to the higher amount of drug loading. 
 
3.6 Conclusion 
Within this study, various polymers according to the predefined test criteria were 
investigated; PVP & PLGA were selected as the most suitable polymers for dip-
coating of the PU strips and further in vitro studies. The epifluorescent microscope 
images form the inhibitor-and polymer-coated PU strips confirmed the integration of 
the enzyme inhibitor throughout the coating of the strips. Upon incubation of the 
inhibitor-and polymer-coated strips in PBS, the PVP-coating was dissolved instantly, 
generating fast and significant drug release, whilst the PLGA-coating did not dissolve, 
yielding a slow and an insufficient amount of drug release. Nevertheless, the drug 
Figure 3. 22 Cumulative percentage release of the fluorescent FXIIIa inhibitor (AM2/97) into 
PBS: FBS 50:50 (v/v) from the individually coated polyurethane strips over 14 days under sink 
condition. The formulation was incorporating 5 % (w/v) PVP, 5 % (w/v) PLGA and 0.25 % (w/v) 
AM2/97 in DCM. Cumulative drug release corresponds to accumulation of the drug within the 
release media from day zero up to the measured time point, expressed as percentage (%) of total drug 
added. Results denote mean  ±  SD from 3 independently synthesized batches. 
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release profile was enhanced upon employing a blend solution of PVP and PLGA for 
the coating.  
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POLYMER PERCENT 
SOLUTION 
(w/v) 
The solubility and coating quality of the polymer within a range of solvents 
  Methanol comments Ethanol comments Acetone comments Chloroform comments DCM comments 
Polythylene-glycol 
H(OCH2CH2)nOH 
MW:8000 
 
 S C  
Poor 
quality 
coating 
was 
observed 
S C  S C  S C  S C  
2% √ X X -  
Polymer 
aggregates 
in ethanol 
X -  
Polymer 
aggregates 
in acetone 
√ X Poor 
quality 
coating  
X - Polymer 
aggregates 
in DMC 
5% √ X X - X - X - Insoluble 
solution 
X - 
10% √ X X - X - X - X - 
Polythylene-glycol 
H(OCH2CH2)nOH 
MW:4600 
 
2% √ X  
Same as 
above 
X -  
Same as 
above 
X -  
Same as 
above 
X -  
A thick 
white 
precipitate 
was 
observed 
√ X Poor quality 
coating was 
observed 
5% √ X X - X - X - X -  
Insoluble 
solution 
10% √ X X - X - X - X - 
Polythylene-glycol 
H(OCH2CH2)nOH 
MW:2000 
 
2% √ X  
Same as 
above 
√ X  
Poor quality 
coating was 
observed. 
√ X  
Poor quality 
coating was 
observed. 
√ X  
yPoor 
quality 
coating 
was 
observed. 
√ X  
Poor quality 
coating was 
observed 
5% √ X √ X √ X √ X √ X 
10% √ X √ X √ X √ X √ X 
Table 1 The solubility and coating quality of polyethylene-glycol of various molecular weights within a range of solvents.  S = the solubility of the polymer in the solvent, C = the 
coating of the PU strips, √ = good, √√ = very good and X= analysis not applicable. 
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POLYMER PERCENT 
SOLUTION 
(w/v) 
The solubility and coating quality of the polymer within a range of solvents 
  Methanol comments Ethanol comments Acetone comments Chlorofor
m 
comments DCM comments 
Polyethylene oxide 
-(CH2-CH2-O-)n 
MW:1000,000 
 
 S C  S C  S C  S C  S C  
          2% X -  X -  X -  X -  X -  
          5% X -  X -  X -  X -  X -  
         10% X -  X -  X -  X -  X -  
Polyethylene oxide 
-(CH2-CH2-O-)n 
MW:300,000 
 
          2% X -  X -  X -  X -  √ √ A fragile 
coating was 
observed. 
          5% X -  X -  X -  X -  √ √ 
         10% X -  X -  X -  X -  X -  
Polyethylene oxide 
-(CH2-CH2-O-)n 
MW:5000,000 
 
          2% X -  X -  X -  X -  X X  
           5% X -  X -  X -  X -  X -  
           10% X -  X -  X -  X -  X -  
Table 2 The solubility and coating quality of polyethylene oxide of various molecular weights within a range of solvents.  S = the solubility of the polymer in the solvent, C = the 
coating of the PU strips, √ = good, √√ = very good and X= analysis not applicable. 
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Table 3 The solubility and coating quality of polyvinylpolypyrrolidone of various molecular weights within a range of solvents.  S = the solubility of the polymer in the solvent, C = 
the coating of the PU strips, √ = good, √√ = very good and X= analysis not applicable 
 
 
 
 
 
POLYMER PERCENT 
SOLUTION 
(w/v) 
The solubility and coating quality of the polymer within a range of solvents  
  Methanol comments Ethanol comments Acetone comments Chloroform comments DCM comments 
Polyvinylpolypyrrolidone 
 
MW:360,000 
 
 S C  
 
 
A flimsy 
coat was 
observed 
S C  S C  S C  S C  
2% √ X √ X Not good 
coating 
X -  
 
Insoluble 
solution  
X - A milky 
white 
aggregate 
of the 
polymer 
was 
observed 
√ X Poor quality 
coating was 
observed 
5% √ X √ √ The coat 
splintered on 
drying. 
X - X - X -  
Insoluble 
solution was 
observed 10% √ X √ √ coat 
dissolved in 
PBS 
X - X - X - 
Polyvinylpolypyrrolidone 
 
MW:10,000 
 
2% √ X  
Same as 
above 
√ X  
Same as 
above 
X -  
Same as 
above 
√ √ The coat 
uncoupled 
when dried 
√ X Poor quality 
coating was 
observed 5% √ X √ √ X - √ √ √ X 
10% √ X √ √ X - X - Insoluble √ √ Coat dissol -
ved in PBS 
Polyvinylpolypyrrolidone 
 
MW:40,000 
 
2% √ X  
Same as 
above 
√ X Poor quality 
coating  was 
observed 
X -  
 
Same as 
above 
√ √  
A good 
quality 
coating was 
obtained 
√ X Poor quality 
coating was 
observed 
5% √ X √   
The coat 
splintered on 
drying. 
X - √ √ √ √ A good 
quality 
coating was 
obtained. 10% √ X √ √ X - √ √ √ √ 
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POLYMER PERCENT 
SOLUTION 
(w/v) 
The solubility and coating quality of the polymer within a range of solvents 
  Methanol comments Ethanol comments Acetone comments Chloroform comments DCM comments 
Poly(L-lactic acid) 
 
MW:300,000 
 
 S C  S C  S C  S C  S C  
2% X -  
Insoluble 
solution  
X -  
Insoluble 
solution 
X -  
Insoluble 
solution 
√ X Poor quality 
coating was 
observed 
√ X Poor quality 
coating was 
observed 5% X - X - X - √ X √ X 
10% X - X - X - X - Highly 
viscous 
solution 
X - Highly 
viscous 
solution 
Poly(L-lactic acid) 
 
MW:50,000 
 
2% X -  
Same as 
above 
X -  
Same as 
above 
X -  
Same as 
above 
√ X Poor quality 
coating was 
observed 
√ X Poor quality 
coating was 
observed 
5% X - X - X - √ √√  √ √√  
10% X - X - X - √ √√ √ √√ 
Poly(L-lactic acid) 
 
MW:2000 
 
2% X -  
Same as 
above 
X -  
Same as 
above 
X -  
Same as  
above 
√ √ Coat dissol 
-ves in PBS 
X √ Coat dissol- 
ves in PBS 
5% X - X - X - √ X Poor quality 
coating was 
observed 
X X Poor quality 
coat 
10% X - X  X - √ X X X 
 Table 4 The solubility and coating quality of poly(L-lactic acid) of various molecular weights within a range of solvents.  S = the solubility of the polymer in the solvent, C = the 
coating of the PU strips, √ = good, √√ = very good and X= analysis not applicable. 
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Table 5 The solubility and coating quality of poly(D, L-lactic-co-glycoside) of various molecular weights within a range of solvents.  S = the solubility of the polymer in the solvent, C 
= the coating of the PU strips, √ = good, √√ = very good and X= analysis not applicable 
 
POLYMER PERCENT 
SOLUTION 
(w/v) 
The solubility and coating quality of the polymer within a range of solvents 
  Methanol comments Ethanol comments Acetone comments Chloroform comments DCM comments 
Poly(D,L-lactide-co-
glycolide) 
50:50 
 
 S C  S C  S C  S C  S C  
2% X -  
Insoluble 
solution  
X -  
Insoluble 
solution 
X -  
Insoluble 
solution 
√ √  
Good 
coating 
√ X Coat 
dissolved in 
PBS 
Insoluble 
solution 
5% X - X - X - √ √ X X 
10% X - X - X - √ √ X - 
Poly(D,L-lactide-co-
glycolide) 
85:15 
 
2% X -  
Same as 
above 
X -  
Same as 
above 
√ √ Good 
coating but 
the coat 
dissolved 
in PLA 
√ √ A very good 
quality 
coating  was 
observed   
√ √ A very good 
quality 
coating  was 
observed   5% X - X - √ √ √ √√ √ √√ 
10% X - X - √ √ √ √√ √ √√ 
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Chapter 4: 
Controlled release of FXIIIa inhibitor from silicone 
elasotomers 
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Figure 4. 1 The 3-D polymer structure of silicone 
elastomer. Silicone elastomers are cross linked linear 
silicone fluids or gums with a three-dimensional 
structure (web image 12). 
 
4.1 Introduction 
Silicones [R2SiO]n are a large family of organic silicon polymer products which consist 
of a main chain of alternating silicon and oxygen atoms (…-Si-O-Si-O-Si-O-…) with 
four-coordinate organic side groups attached to the silicon atoms. The basic repeating 
unit is known as silicone and typically each silicon in the chain carries two organic 
groups mainly methyl groups (CH3).  
The most common silicone is called 
poly (dimethylsiloxane) abbreviated 
to PDMS (Bondurant et al, 2000). 
This is the basic characteristic of 
compounds with the name silicones, 
assigned by Kipping (Kipping, 1904) 
based on their similarity with 
ketones, since there is on average 
one silicon atom for one oxygen and two methyl groups in most cases. Silicone polymers 
can be simply transformed into a three-dimensional network a cross linking reaction, 
which allows the arrangement of chemical bonds between adjacent chains that form 
silicone elastomers (Figure 4.1).  
 
Silicone is one of the most common forms of polymeric biomaterials and has been 
employed in the manufacture of catheters, stents, cardiac leads, respiratory aids and 
similar medical devices (Malcolm et al., 2004). Although, numerous recent studies have 
focused on biodegradable implantable materials (Commandeur et al., 2006), certain 
advantages are acquired from non-degradable biomaterials, including their ready removal 
due to adverse effects which arise from the drug (Brooke et al., 2008). The silicone-based 
devices have been reported to possess several desirable features, such as biostability, non-
irritancy, non-toxicicity, non-carcinogenicity, non-allergic, good moisture resistance, 
biocompatibility, thermal stability, mechanical flexibility, excellent UV resistance, good 
chemical resistance, moderate adherence and non-biodegradability during an optimal 
treatment period (Huie et al., 1985; Lee et al., 1997; Kajihar et al., 2003; Maeda et al., 
2003; Lawrence and Turner, 2005; Mashak, 2008). Moreover, all-silicone apparatus can 
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be produced with a relatively thin wall which creates a large drainage lumen in relation to 
external diameter, causing a longer time to encrust and block. This is an important factor 
to consider when conducting any comparative tests with other catheter types (Lawrence 
and Turner, 2005). Additionally, some cases, such as children with high risk 
malignancies receive silicone CVCs at the initiation of chemotherapy, leaving their 
peripheral veins in good condition (Haire et al., 1990), while insertion of non-tunneled 
polyurethane CVCs which are often used for continuous blood flow in adults (Johansson 
et al., 1999), may cause local vessel damage because of the stiffness of the material, with 
subsequent local thrombosis and infectious complications (Madero et al., 1997; Hahn et 
al., 1995).  
 
Even though silicone elastomers are one of the widespread biomaterials utlised in 
medical device production, they have a relatively high coefficient of friction and the 
resulting lack of inherent lubricity leads to pain and tissue damage on device insertion 
and removal (Woolfson et al., 2003; Malcolm et al., 2004). Furthermore as with all 
biomaterials, silicone is also prone to surface formation of a drug-resistant microbial 
biofilm (Tunney et al., 1996; Marion-Ferey et al., 2003), leading to device-related 
infections and device blockage (Gorman and Tunney 1997; Haire et al., 1990; Malcolm 
et al., 2004). To reduce the risk of occlusion, different anticoagulation regimens including 
oral acetylsalicylic acid, minocycline, rifampin and heparin flushing or continuous 
heparin infusion have been described as detailed in chapter 1 (Stephens et al., 1993; 
Lawrence and Turner, 2005). Moreover, to overcome the problem of microbial biofilm 
formation in vivo, a variety of antomicrobial agents have been employed. 
 
In spite of this, there are no definitive studies to support the claims by manufacturers that 
their products showed improvements over the standard catheters. A number of 
researchers have reported that silicone coated and all-silicone devices, as well as all other 
currently available devices, are unable of resisting biofilm growth or encrustation and so 
far no single material has been established to be significantly superior in decreasing 
catheter-associated complications (Lawrence and Turner, 2005). 
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4.2 Aim and objectives                                                                           
The present study was to incorporate the novel group of the inhibitors of the enzyme 
Factor XIII (FXIII) into a lubricious silicone elastomer and subsequent polymeric coating 
of the produced elastomer in order to generate an optimized drug delivery system 
whereby a secondary sustained drug release profile occurs following an initial burst 
release for catheters and other medical devices.  
 
It was proposed that impregnation of the FXIIIa inhibitors into the lubricious silicone 
elastomer would produce an optimized drug delivery system in preventing both catheter 
associated staphylococcal infection and a lower incidence of thrombotic occlusion. 
Furthermore, the new technique could be used as a local delivery system for extended 
release with an immediate onset of action for other poorly soluble compounds.  
 
The objectives of this work were; 
 
• Preparation of the silicone elastomer strips.  
• Incorporation of the FXIIIa inhibitor into the silicone elastomer strips for 
sustained drug release. 
• Quantification of the amount of the FXIIIa inhibitor release from the silicone 
elastomer strips in vitro. 
• Determination of the biological activity of the released inhibitor from the silicone 
elastomer strips. 
• Production of a smart polymeric coating on the silicone strips for initial 
immediate drug release. 
• Morphological analysis of the silicone strips such as scanning electron 
microscopy, digital images and optical microscopy. 
• Investigation of the mechanical properties of the silicone elastomer strips such as 
tensile strength and Young’s modulus. 
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4.3 Materials and methods 
4.3.1 Materials 
MED5-6382 medical grade silicone elastomer (three component silicone: Base, cross-
linker and catalyst) was obtained from Nusil Technology (Carpinteria, USA). Sodium 
bicarbonate and phosphate buffered saline were acquired from Sigma-Aldrich (Dorset, 
England). Citric acid was purchased from VWR international Ltd. Spacer palates were 
procured from Bio-Rad Laboratories, Inc. Unless stated otherwise PBS was used at 0.01 
M, pH 7.4. Doubly distilled and filtered water was used in the preparation of all 
solutions. The silicone elastomers used in this study were manufactured by linear, 
hydroxy-terminated poly(dimethylsiloxane) macromolecules crosslinked with a low 
molecular weight tetraalkoxysilane crosslinking agent (TPOS), derived from propanol, in 
the presence of stannous octoate as a catalyst, via a condensation cure mechanism. 
AM2/97 (fluorescent-labeled FXIIIa inhibitor) was prepared within the chemistry 
department of Aston University by Dr. Alexandre Mongeot and Dr. Dan Rathbone as 
previously described (Griffin et al., 2008).  
 
4.3.2 Preparation of silicone elastomer strips integrated the FXIIIa inhibitor: 
sustained drug release 
As described in Figure 4.2, medical grade condensation cure silicone elastomers are 
conventionally manufactured by the cross linking of , -hydroxyl functionalised 
poly(dimethylsiloxane) with a tetra-functional tetraalkoxysilane (tetrapropoxysilane) 
(tetrapropyl orthosilicate) (tetrapropyl silicate) (TPOS). TPOS is renowned as the 
standard crosslinking agent in the commercial manufacturing of medical grade silicone 
elastomers (Etienne et al., 1990; Qusseaume et al., 1994; Woolfson et al., 2003). TPOS-
cured silicone elastomers generate propan-1-ol as a by-product of the crosslinking 
reaction that forms the elastomer. The evaporation of a volatile substance such as propan-
1-ol from a homogeneous polymeric material includes dissolution of the permeant in the 
matrix, its diffusion through the matrix, and subsequent evaporation from the surface of 
the polymer (Watson and Payne, 1990). Hence, propan-1-ol is lost from the surface of the 
elastomer rapidly (Woolfson et al., 2003). Such elastomers are nowadays regularly 
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utilised in drug delivery applications from silicone devices (Woolfson et al., 1999; 2003; 
Malcolm et al., 2003). 
 
 
 
Hydoxy-terminated poly (dimethylsiloxane)          Tetrapropoxysilane (TPOS)    
 
 
 
 
                                   Silicone elastomer crosslinking site                  Propran-1-ol 
 
Figure 4. 2 Cross-linking chemistry between hydroxy-terminated poly(dimethylsiloxane) and 
tetrapropoxysilane (TPOS) in the production of condensation cured silicone elastomer (-drawn using 
Chemskatch software). 
 
The conventional silicone elastomer mix was prepared by thoroughly mixing 2.5 parts by 
weight of TPOS as cross-linker, 97 parts of MED5-6382 silicone elastomer as base and 
0.5 parts of stannous octate as catalyst for two minutes. Different percentages of citric 
acid (CA) and sodium bicarbonate (SB) (0 % (blank), 5 %, 15 %, 30 % and 40 % w/w) in 
Stannous octate  
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a ratio of 1:3 as additives, together with the FXIIIa inhibitor (AM2/97) (0.5 % and 1 % 
w/w) were incorporated into the mixture. The formulations prepared are listed in Table 
4.1. 
 
Table 4.1 Composition of silicone elastomer formulations 
                     Drug Powder  Formulation 
         Drug                             Content (%)                           Additives (%) 
AM2/97                           0.5 % w/w  CA:SB = 1:3,  0 % w/w 
AM2/97                           0.5 % w/w  CA:SB = 1:3,  5 % w/w 
AM2/97                           0.5 % w/w   CA:SB = 1:3, 15 % w/w 
AM2/97                           0.5 % w/w   CA:SB = 1:3, 30 % w/w 
AM2/97                           0.5 % w/w   CA:SB = 1:3, 40 % w/w 
        AM2/97                              1 % w/w   CA:SB = 1:3, 30 % w/w 
      
 
The silicone elastomer mixture was then placed between one spacer plate with 1.0 mm 
integrated spacers, with a size of 10.1 x 7.3 cm, and a short plate, with a size of 10.1 x 7.3 
cm. The glass plates were left overnight at room temperature to de-aerate. The glass 
plates used were initially treated with an anti-static foam cleanser and a supergliss spray 
as a lubricant to avoid adherence of silicone mixture. The elastomeric silicone sheets thus 
produced were cut into strips of dimensions 10 × 30 mm using a scalpel and subsequently 
weighed (mean weight = 0.42 ± 0.08 g, mean surface area = 3.00 cm2). 
 
4.3.3 Production of a smart polymeric coating on the silicone strips: initial 
immediate drug release  
In order to obtain an immediate onset of action of drug, the silicone elastomer strips were 
then dip-coated with Poly-vinyl-pyrrolidone (PVP) as described in chapter 3. In brief, the 
polymer was dissolved in chloroform at a concentration of 5 % (w/w). Afterwards, 0.25 
% (w/w) of the enzyme inhibitor was added to the polymer solution. The coating solution 
was kept on dry ice to prevent evaporation of the organic solvent and a subsequent 
increase in the polymer concentration. Subsequently, the silicone strips were vertically 
dip-coated in the polymer solution containing the inhibitor and withdrawn three times. 
The strips were coated using a two, three and four times dip-coating procedure to achieve 
a dense and regular polymer coating. The invariableness of the lifting velocity and 
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coating times was confirmed to yield approximately the same coating thickness. The 
coated silicone strips were dried at room temperature to allow the solvent to evaporate 
completely. 
 
4.3.4 FXIIIa inhibitor release from the silicone elastomer strips In vitro 
Each of the silicone strips was placed in a 50 ml universal tube containing 10 ml of 0.01 
M of phosphate buffer saline (PBS, pH 7.4). The universal tubes were then put in a 
shaking water bath set at 80 rpm and 37 °C. The release medium was sampled and 
replaced every 24 hour (to promote sink condition) over a period of 30 or 40 days. The 
amount of relative fluorescent unit (RFU) within the release media was quantified using 
200 µl aliquots taken every 24 hours and measured spectrofluorimeterically with an 
excitation maximum at 330 nm and emission peak at 570 nm (Spectra Max Gemini XPS, 
Molecular Probes). Accordingly the concentration of the inhibitor released within the 
media was calculated using a drug calibration curve which was previously prepared from 
a set of standard samples of known concentration. The results were then reported as 
cumulative drug release, which corresponds to accumulation of the drug within the 
release media from time zero up to the measured time point, expressed as percentage (%) 
of total drug added and concentration (µmole/ ml) of the inhibitor released. Estimation of 
the amount of the inhibitor entrapped within the coatings through dip-coating method was 
calculated by measuring the density of the coating solution and weight changes of the 
solution subsequent to each coating, which was followed by calculating the number of 
moles of the inhibitor incorporated per coating. 
 
4.3.5 Biological activity of the released FXIIIa inhibitor  
The biological activity of the released inhibitor from the silicone strips as inhibition of 
human FXIII was verified by applying ELSA as previously described, using aliquots of 
200 µl which were collected from the release medium at preset incubation time points 
(one day, and one, two, three and four weeks). The results were then expressed as a 
percentage of FXIII activity compared to negative control (without the inhibitor).  
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4.3.6 Morphological analysis 
4.3.6.1 Scanning electron microscopy (SEM)  
The specimens were thoroughly dried and gold coated by a gold sputter coater (Emscope 
SC500 Sputter coater, Ashford, Kent, Great Britain) prior to SEM. Cross-sectional SEM 
images from silicone elastomer formulations were captured by a scanning electron 
microscope (Cambridge Instruments, Stereoscan 90) at 29 x, 49 x and 103 x 
magnification. The experimental conditions involved 0 %, 5 %, 15 % and 30 % (w/w) 
CA/ SB incorporated formulations, and before and subsequent to incubation (1 day, 1 
week and 1 month time points) in PBS. 
 
4.3.6.2 Digital images 
The appearance of the silicone strips was examined by a JVC KY-F1030 digital camera 
fitted with a zoom lens (18-108 / 2.5, Japan, NO-5019055) for 0 %, 5 %, 15 % and 30 % 
(w/w) CA/ SB integrated formulations, prior to and after one month incubation in PBS. 
 
4.3.6.3 Optical microscopy  
Optical images were obtained from the surface of the silicone elastomer specimen, using 
a Reichert-Jung Polyvar MET optical microscope with a JVC KY-F75 digital camera, at 
25 x and 50 x magnification. This was conducted in set conditions previously mentioned 
in section 4.3.6.1. 
 
4.3.7 Swelling studies 
The weight dimensions (width, length and thickness) and volume of silicone elastomer 
strips prior to and subsequent to incubation (1 day, 1 week and 1 month time points) in 
PBS (pH 7.4, 37 °C) were measured by a digital caliper. Accordingly, the swelling 
(alteration in the volume) of each strip after the preset time points was calculated. The 
results were then reported as percent change in the volume. 
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Figure 4. 3 Hounsfield H10KS  
Universal Testing Machine 
 
4.3.8 Mechanical properties  
4.3.8.1 Tensile strength  
Tensile properties were measured by a Hounsfield 
Universal Tester S Series H10KS-0393 (Figure 4.3). 
The Hounsfield S Series was supplied by Tinius Olsen 
Ltd (Surrey, UK) with Q-Mat 2.18 software including 
Test Generator, Testzone and File examination. The 
crosshead was able to move at jog speeds of 0.001 to 
1000 mm/min, with an extension accuracy of ± 0.01 
mm and a speed accuracy of ± 0.05 % of the set speed. 
The experimental set up is presented in Table 4.2.  
 
Stretching apparatus: 
The tensile strength (MPa) of the silicone strips was 
measured to investigate the greatest lengthwise stress 
the strips could withstand without breaking. While the 
Hounsfield universal tester (Figure 4.3) loads the strip, 
it measures the applied force and the elongation of the 
specimen over some distance. The amount of applied force and consequently stress on the 
strip is continuously increased until the rupture of the specimen (Figure 4.4). The level of 
exerted force required to pull the strip to the point where it breaks is directly proportional 
to the amount of tensile strength. The amount of force exerted on the specimen (Newton) 
(N) divided by the cross-sectional area (A) (m2) (mm2) of the strip, yields the stress 
experienced by the sample and the stress needed to break the strip is the tensile strength 
of the sample which is expressed as Pa or MPa. 
TS = Force (N)/cross-sectional area (Equation 4.1) 
In the SI system, the unit of measurement of tensile strength is the Newton per square 
meter (N/m2), also known as the Pascal (Pa), where 1MPa = 1 N/mm2 
 
Chapter 4 - Controlled release of FXIIIa inhibitor from silicone elastomers 
 
86 
Table 4.2 Experimental setup of Hounsfield Universal Tester for measuring the tensile strength of the 
silicone strips.   
 
 Setup Range available 
Load Range (N) 5000 [50-5000] 
Extension Range (mm) 2000 [0.1-2000] 
Speed (mm/min) 50 [0.01-1000] 
Gauge Length (mm) 20 [1-1000] 
         Approach Speed (mm/min) 50 [0.0005-1000] 
Preload (N) 0 [ 0-500] 
 
4.3.8.2 Force-extension curve 
  The Force-extension curves are a graphical representation of the relationship between 
force and extension. The curves were obtained by plotting the force which was derived 
from measuring the load on a silicone strip along the x-axis and extension which was 
derived from measuring the elongation of the strip before the break along the y-axis. 
 
4.3.8.3 Young’s modulus (modulus of elasticity) (elastic modulus) (Tensile modulus)               
Young’s modulus (E) was measured by plotting the amount of applied stress on the 
silicone strip versus elongation which were previously obtained during tensile tests 
conducted on silicone strips. The height of the curve when the strip breaks is the tensile 
strength and the Young’s modulus is the slope of this plot. Therefore, the modulus of 
elasticity was calculated easily by dividing the tensile strength at break by the strain at 
break (Woolfson et al., 2003).  
E = Stress/Strain = (F/A)/ (Li/Lo) = (F*Lo)/ (A*Li) (Equation 4.2) 
Where E is Young’s modulus, F is the force applied, A is the cross sectional area of the 
object, Lo is the original length, and Li is the alteration in length. The Young's modulus 
is expressed in units such as the Pascal, Newton per square meter or MPa. 
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4.3.9 Statistical analysis 
For all experiments, means and standard deviations were calculated and represent one of 
at least three separate experiments undertaken in triplicate, unless stated otherwise. To 
determine statistical significance in resultant data, a one-way analysis of variance 
(ANOVA) was performed. Differences described as significant or extremely significant 
in the text correspond to p < 0.05 or p < 0.001 respectively. Tukey’s post hoc test was 
conducted to determine which conditions differ significantly from each other.        
     
4.4 Results and discussions 
4.4.1 Drug release mechanism 
Diffusion can be defined ‘as a process by which molecules transfer spontaneously from 
one region to another in such a way as to equalise chemical potential or thermodynamic 
activity’ (Liu, 2001). Diffusion-controlled release is one of the few mechanisms by which 
drug release rate is controlled. Generally, in diffusion-controlled release mechanisms, the 
drug must diffuse through either a polymeric membrane or a polymeric or lipid matrix in 
order to be released. The rate of diffusion of drug molecule through the membrane can be 
described by classical Fick’s law of diffusion (Kim, 2000; Fan and Singh, 1989) and is 
Figure 4. 4 Measuring the tensile strength and Young’s modulus of the silicone strips by a Hounsfield 
Universal Tester. The silicone strip was held between upper and lower clamps and then the crosshead 
moved upwards. Subsequently, the amount of applied force continued to increase till the strip was broken. 
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thus dependant on the partition and diffusion coefficient of the drug in the membrane, the 
available surface area, the membrane thickness and the drug concentration gradient 
(Figure 4.5). 
          Drug                          Water  
    
                                                                    
                    Silicone membrane  
     
Figure 4. 5 Fick’s law of diffusion in diffusion controlled devices. Fick’s law of diffusion describes the 
rate at which diffusion occurs, where Jx (the flux density) is the amount of species x crossing a certain area 
per unit time and is typically expressed in units such as moles of particles per m2 per second. D is the 
diffusion coefficient of species x. The term dc/dx represents the concentration gradient of species x and is 
the driving force that leads to molecular movement. The negative sign indicates that the direction of flow is 
from high to low concentration. 
 
During preliminary studies, no drug release was observed from the silicone elastomer 
preparations after incubation in PBS. To overcome this problem, different alternatives 
were applied such as; 
1. Changing the release media (PBS, distilled H2O) 
2. Reducing the particle size of the inhibitor by milling and using different mesh 
sizes (100-300 µm) 
3. Reducing the percentage of cross linker in the formulations (from 2.5 % down to 
1.25 %) 
In spite of these approaches, the percentage of drug release from silicone carriers did not 
alter substantially. This could be due to poor solubility of the enzyme inhibitor. The 
release characteristics of drugs from diffusion-controlled polymeric delivery systems are 
largely determined by the solubility and diffusivity of the drug within the cross-linked 
polymer network (Chien et al., 1992). Therefore, the drug release mechanism from a 
silicone carrier differs depending on the physiochemical properties of the drugs (Figure 
4.6); lipophilic drugs are solubilized in silicone, diffuse, and are released (Figure 4.6a). 
Fick’s law of diffusion (Equation 4.3) 
 
                     
 
Jx = the flux density 
A = surface area 
D = diffusion coefficient 
dx = diffusion path length 
dc = concentration gradient 
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Water-soluble drugs neither dissolve nor diffuse in silicone (Figure 4.6b). At the outset, 
water-soluble drugs existing on the surface, and subsequently the ones in the near-surface 
area dissolve into water. Recurrence of these processes leads to channel formation, 
allowing water-soluble drugs in the bulk to be released. Conversely water insoluble drugs 
neither dissolve nor diffuse in silicone (Figure 4.6c), they are not released since channels 
are not formed because of insolubility in water. Therefore, their release from silicone has 
long been considered challenging (Kajihara, 2003). 
(a) Lipophilic drug 
                     
 
Lipophilic drug 
 
(b) Water-soluble drug 
                        
 
Water-soluble drug                                                                                                      channels 
 
(c) Insoluble drugs 
              
  
Insoluble drugs 
 
Figure 4. 6 Release mechanisms of drugs with different physiochemical properties from a silicone 
carrier. Lipophilic drugs are solubilized in silicone, diffuse, and eventually are released (Figure 4.6a). 
Water soluble drugs neither dissolve nor diffuse in silicone (Figure 4.6b). Water-soluble drugs exist on the 
surface area, and then, those existing in the near-surface area dissolve into water. Recurrence of these 
sequences lead to channel formation, allowing water-soluble drugs in the bulk to be released. On the 
contrary, insoluble drugs neither dissolve nor diffuse in silicone (Figure 4.6c), they are not released as 
channels are not formed due to insolubility in water (Kajihara, 2003). 
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4.4.2 Influence of additives on release behaviour 
4.4.2.1 Sustained drug release from the silicone elastomer strips 
Given the poor release of the FXIIIa inhibitors outlined already, a second approach was 
adopted. The release of insoluble or poorly soluble drugs from silicone carriers can be 
enhanced by employing additives. Accordingly, sodium bicarbonate (SB) and citric acid 
(CA) were added as additives to the silicone formulations. The fluorescent FXIIIa 
inhibitor as a poorly soluble drug was not released from the silicone carrier when it was 
dispersed in the silicone devoid of additives (0 % (w/w) CA and SB). However, the 
release of the enzyme inhibitor increased correspondingly with incorporation of CA and 
SB in the silicone strips (Figures 4.7 and 4.8).  
 
The results in Figures 4.7 and 4.8 indicate that the silicone preparations released the 
inhibitor in the rate depending on the concentrations of CA and SB (0 %, 5 %, 15 % and 
30 % (w/w)). The amount (and percentage) of the inhibitor release from all the 
preparations tested was enhanced by increasing CA and SB content. The amount (and 
percentage) of released inhibitor from the formulations containing 30 % (w/w) CA and 
SB powders was greater than the amount (and percentage) released from the preparations 
containing 15 % and 5 % (w/w) CA and SB powders, respectively. Similarly, the level 
and percentage of release from formulations containing 15 % (w/w) CA and SB powders 
was more than that of 5 % (w/w) formulation (P < 0.05, ANOVA). For example after 1 
day, 0.007 and 0.012 µmol/ ml of drug was released from silicone formulations 
containing 5 % and 15 % (w/w) of CA and SB respectively, whilst significantly higher 
amounts (0.032 µmol/ ml) were released from silicone preparations containing 30% of 
the additives. By day 7, the release rates from the silicone preparations were leveling out 
at approximately 0.098 µmole/ ml, which was about 5-fold higher than the amount 
released by preparations containing 5 % and about 3-fold higher than those containing 15 
% of the additives.  For each of the four preparations (0 %, 5 %, 15 % and 30 % (w/w) 
CA and SB) the maximum released after 30 days was 0, 0.043, 0.087 and 0.147 µmole/ 
ml respectively. These data as a percentage of initial amounts loaded are illustrated in 
Figure 4.8. Water-soluble CA and SB forms channels and pores in and on the specimen 
and react upon mixing to generate carbon dioxide in the channels. The gaseous carbon 
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dioxide as a driving force accelerates the release of the inhibitor (Figure 4.9). A faster 
release was attained by altering the quantity of carbonate and acid in the formulations 
from 0 % to 30 %, thus generating a larger amount of carbon dioxide (Kajihara, 2003). 
 
Figure 4. 7 Cumulative releases (µmole/ ml) of the fluorescent FXIIIa inhibitor (AM2/97) into 10 ml 
PBS from the silicone elastomer strips over 30 days under sink condition. The formulations 
incorporated 0 %, 5 %, 15 %, 30 % (w/w) CA: SB, and 0.5 % (w/w) AM2/97. Cumulative drug release 
corresponds to accumulation of the drug within the release media from day zero up to the measured time 
point, expressed as concentration (µmole/ ml) of the inhibitor released. No release was observed from the 
silicone carriers when it was dispersed inside the silicone devoid of additives (0 % CA: SB). The amount of 
drug release increased significantly when the percentage of acid and carbonate was raised. Results denote 
mean  ±  SD from 3 independently synthesized batches. 
 
 
 
Figure 4. 8 Cumulative percentage release of the fluorescent FXIIIa inhibitor (AM2/97) into 10 ml 
PBS from the silicone elastomer strips over 30 days under sink condition. The formulations 
incorporated 0 %, 5 %, 15 %, 30 % (w/w) CA: SB, and 0.5 % (w/w) AM2/97. Cumulative drug release 
corresponds to accumulation of the drug within the release media from day zero up to the measured time 
point, expressed as percentage (%) of total drug added. No release was observed from the silicone carriers 
devoid of additives (0 % CA: SB). The amount of drug release increased significantly when the percentage 
of acid and carbonate was raised. Results denote mean  ±  SD from 3 independently synthesized batches. 
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(a) Insoluble drugs        
                  
 
Insoluble drugs   SB CA                                 CO2 
 
Figure 4. 9 Diagrams demonstrating the process of drug release from a silicone carrier. Insoluble 
drugs can be released from the strips by gas generation using sodium bicarbonate and citric acid as 
additives (Kajihara, 2003). 
 
Nevertheless further increase in the content of sodium bicarbonate and citric acid was not 
achieved as silicone elastomers could not be formed with the formulation incorporating 
40 % (w/w) CA and SB, as a result of the high powder content in the specimen. This 
prevented the process whereby polymers become interlinked to form a solid, three-
dimensional matrix.  
 
Additionally, increasing the amount of drug loaded in the preparation (from 0.5 % to 1 
%) at 30 % (w/w) CA and SB improved significantly the duration of release from 30 days 
to 40 days and also total amount of release from 0.173 to 0.286 µmol/ ml, but caused a 
decline in the percentage of drug release from 26.27 % to 21.75 %, after 40 days (Figures 
4.10 & 4.11). This could be due to the low solubility of the inhibitor.  
 
Furthermore with regard to Figures 4.7 – 4.11, the rate of drug release decreased 
regularly for the first 14 days. Afterwards, a slow and constant drug release could be 
observed for the rest of the time points for all formulations incorporating acid and 
carbonate powders. If the drug concentration gradient remains constant, for instance 
where solid drug particles are present and constant dissolution maintains the 
concentrations of the drug in solution, the rate of drug release does not vary with time 
and zero-order controlled release is attained.  However, in the present study, regardless of 
the drug’s physical state in the polymeric matrix, this device does not provide zero-order 
drug release properties. This is because as the drug molecules at the surface of the device 
are released, those in the center of the device have to migrate a longer distance to be 
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released. This increased diffusion time results in a decrease in the release rate from the 
device with time (Hillery, 2001). 
 
Figure 4. 10 Cumulative releases (µmole/ ml) of the fluorescent FXIIIa inhibitor (AM2/97) into 10 ml 
PBS from the silicone elastomer strips over 40 days under sink condition. The formulations were 
incorporating 30 % (w/w) CA: SB, 0.5 % and 1 % (w/w) AM2/97. Cumulative drug release corresponds to 
accumulation of the drug within the release media from day zero up to the measured time point, expressed 
as concentration (µmole/ ml) of the inhibitor released. Augmenting the amount of inhibitor in formulations 
is increasing the amount of cumulative release. Results denote mean  ±  SD from 3 independently 
synthesized batches. 
 
 
Figure 4. 11 Cumulative percentage release of the fluorescent FXIIIa inhibitor (AM2/97) into 10 ml 
PBS from the silicone elastomer strips over 40 days under sink condition. The formulations were 
incorporating 30 % (w/w) CA: SB, 0.5 % and 1 % (w/w) AM2/97. Cumulative drug release corresponds to 
accumulation of the drug within the release media from day zero up to the measured time point, expressed 
as percentage (%) of total drug added. Augmenting the amount of inhibitor in formulations is decreasing 
the percentage of release. Results denote mean  ±  SD from 3 independently synthesized batches. 
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4.4.2.2 Initial immediate drug release 
In some cases an initial burst release of drug followed by a secondary sustained drug 
release is favoured. To investigate the potential of this, after manufacturing, the silicone 
elastomer strips was dip-coated with a hydrophilic polymer such as PVP by a solvent 
casting technique as described previously in chapter 3. 
 
The incorporated inhibitor demonstrated an immediate drug release within the first 5 
minutes of much of the loaded drug (Figure 4.12 & 4.13). For those systems coated twice 
with the PVP coating, 100 % release was achieved within 30 minutes, whilst maximum 
amounts of released drug were around 80 % and 70 %, respectively, for 3 x and 4 x PVP 
coating. Initially, the drug release may be controlled by the dissolution rate of polymer 
coating over time. Upon contact of the polymer coating of the silicone strips with PBS, a 
rapid release of the incorporated inhibitor from the surface on hydration and consequently 
dissolution of the biodegradable polymer was achieved. Furthermore, it can be concluded 
that increasing the number of coatings does not affect the release time but affects the 
concentration of drug released into the media, due to the higher total concentrations 
within the coat.  
 
Figure 4. 12 Cumulative release (µmole/ ml) of the fluorescent FXIIIa inhibitor (AM2/97) into 10 ml 
PBS from the silicone elastomer strips with 2, 3 and 4x PVP coatings over 60 minute under sink 
condition. The formulations contained 5 % (w/w) PVP and 2.5 % (w/w) AM2/97. Cumulative drug release 
corresponds to accumulation of the drug within the release media from day zero up to the measured time 
point, expressed as concentration (µmole/ ml) of the inhibitor released. The incorporated inhibitors showed 
an immediate release within the first 5 minutes of much of the loaded drug. Results denote mean  ±  SD 
from 3 independently synthesized batches. 
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Figure 4. 13 Cumulative percentage release of the fluorescent FXIIIa inhibitor (AM2/97) into 10 ml 
PBS from the silicone strips with 2, 3 and 4x PVP coatings over 60 minutes under sink condition. The 
formulations contained 5 % (w/w) PVP and 2.5 % (w/w) AM2/97. Cumulative drug release corresponds to 
accumulation of the drug within the release media from day zero up to the measured time point, expressed 
as percentage (%) of total drug added. The incorporated inhibitors showed an immediate release within the 
first 5 minutes of much of the loaded drug. Results denote mean  ±  SD from 3 independently synthesized 
batches. 
 
4.4.3 Biological activity of the released inhibitors 
The biological activity of the released inhibitor from the silicone elastomer strips in 
inhibition of human FXIIIa for a period of one month was then invested by applying 
ELSA. 
Table 4.3 Measurement of biological activity of the released inhibitors, using an enzyme linked 
sorbent assay. The results were expressed as a percentage activity of TG compared to positive control 
(without the inhibitor). Results denote mean  ±  SD from 3 independently synthesized batches. 
       
  
% activity of TG  
% reduction in activity of 
TG 
Inhibitor (w/w)   1 % 0.5 %   1 % 0.5 % 
time    
          
          1 Day 
 9.12 16.06  90.88 83.94 
1 week 
 6.55 12.06  93.45 87.94 
2 week 
 54.34 57.90  45.66 42.10 
3 week 
 46.16 50.23  53.84 49.77 
4 week 
  78.30 82.20   21.70 17.80 
 
      
Results in Table 4.3 indicates that biological activity of the released inhibitor was 
gradually reduced and consequently the activity of TG was increased as the amount of 
inhibitor released from the silicone strips decreased over a one month period. Therefore, 
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it can be concluded that the inhibitor is still biologically active after the release from the 
silicone elastomer strips; however the inhibitory activity decreases as the amount of 
released inhibitor decreases.  
 
4.4.4 Scanning electron microscopy 
To investigate the morphology of the silicone strips before and subsequent to immersion 
in PBS, SEM analysis of the strips was performed. Cross sectional SEM images (Figures  
4.14 - 4.17) captured from the silicone elastomer strips containing 5 %, 10 % and 30 % 
(w/w) CA/ SB prior to and after to incubation in PBS (37 °C, pH 7.4) confirmed the 
formation of channels and cracks inside the specimens. As the percentage of incorporated 
CA/ SB was raised, the number and size of pores and channels generated as a result of 
generating a larger amount of carbon dioxide was increased. The amount of channels and 
pores at 30 % (w/w) CA/ SB integrated preparations was considerably higher than that of 
formulations containing 0 %, 5 % and 15 % (w/w) CA/ SB. In contrast, in 0 % 
incorporated CA/ SB (blank), no channels or pores were observed. As previously stated, 
SB and CA might create channels and pores upon mixing and the high pressure caused by 
the consequent production of carbon dioxide eventually leads to sustained release of the 
inhibitor.  
 
Similarly, the production of pores and channels in specimens was found to be directly 
proportional to the length of incubation time. As a consequence, there is a greater amount 
of pores and channels in the one-month incubated strips as opposed to the one-day and 
one-week incubated specimens, for all the formulations tested. This could be attributed to 
the creation of more and larger channels and cracks over time (Figures 4.14 to Figures 
4.17). 
 
 
 
Chapter 4 - Controlled release of FXIIIa inhibitor from silicone elastomers 
 
97 
         
Figure 4. 14 Cross sectional SEM images from the silicone elastomer strips containing 0% to 30% 
(w/w) CA: SB (a to d), prior to incubation in PBS at 29 x, 49 x and 10 3x magnification respectively. 
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Figure 4. 15 Cross sectional SEM images from the silicone elastomer strips containing 0 % to 30 % 
(w/w) CA: SB (a to d), subsequent to 1 day incubation in PBS at 29 x, 49 x and 103 x magnification 
respectively. 
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Figure 4. 16 Cross sectional SEM images from the silicone elastomer strips containing 0 % to 30 % 
(w/w) CA: SB (a to d), subsequent to 1 week incubation in PBS at 29 x, 49 x and 103 x magnification 
respectively. 
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Figure 4. 17  Cross sectional SEM images from the silicone elastomer strips containing 0 % to 30 % 
(w/w) CA: SB (a to d), subsequent to 1 month incubation in PBS at 29 x, 49 x and 103 x magnification 
respectively. 
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4.4.5 Macroscopic morphology 
Macroscopic photographs of the silicone elastomer strips containing 0 %, 5 %, 10 % and 
30 % (w/w) CA/ SB were obtained prior to and after one month incubation in PBS (37 
°C, pH 7.4). Across all the formulations tested (Figure 4.18; a, b, c and d), there was no 
major difference in the macroscopic appearance of the strips prior to the incubation. 
However, after one-month immersion in PBS, the CA/ SB incorporated strips (Figure 
4.18; b´, c´ and d´) gently swelled, while retaining the initial shape. As the amount of 
amalgamated CA/ SB in the silicone matrix was increased from 5 % to 30 %, the strips 
were more swollen and expanded. The significant expansion of strips incorporating 30 % 
(w/w) CA/ SB compared to the other formulations and blank (0 % CA/ SB) was also 
visible to the naked eye. These results confirm the absorption of water by the strips 
integrating CA/ SB as a consequence of the creation of channels and pores during CO2 
production. In spite of this, the appearance of the silicone elastomer strips containing 0 % 
(w/w) CA/ SB (Figure 4.18; a´) after one month immersion in PBS, portrayed no 
noticeable alteration or swelling, indicating that channels and cracks were not created 
under these conditions.  
 
           
  
          
 
Figure 4. 18 Macroscopic photographs of the silicone elastomer strips before and after one-month 
incubation in PBS. a, b, c and d images represent silicone strips incorporating 0 %, 5 %, 15 % and 30 % 
(w/w) CA/ SB respectively, before incubation. a´, b´, c´ and d´ represent the same strips after one-month 
immersion in PBS (pH 7.4). Across all the formulations tested (a, b, c and d), there was no major difference 
in the appearance of the strips before the incubation. However, after one-month immersion in PBS, the CA/ 
SB incorporated strips (b´, c´ and d´) gently swelled, while retaining the initial shape. In spite of this, the 
appearance of the silicone elastomer strips containing 0 % CA/ SB (a´) after one month immersion in PBS, 
portrayed no noticeable alteration or swelling. All bars = 1cm. 
 
 
 (c)  (d)    (a)   (b) 
   (a´) (b´)   (c´)      (d´) 
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4.4.6 Optical microscopy 
To study the topography of the silicone elastomer strips’ surface, optical images of each 
of the strips prior to and after incubation were captured. Silicone prepared without the 
addition of CA and SB (0 % (w/w) CA and SB) had a smooth topography (Figure 4.19a), 
however as the quantities of CA and SB increased within the preparations from 5 % to 30 
% (Figure 4.19 b to d respectively), the exterior of silicone strips became less smooth and 
more ‘pitted’.  
 
For all the formulations tested, the surface of the silicone strips became irregular in 
nature with small apertures following one-day incubation in PBS (Figure 4.20 a to d). 
Subsequent to one-week incubation in PBS (Figure 4.21 a to d), the number and size of 
the apertures and pores increased. The surface of the strips subsequent to one-month 
incubation demonstrated more apertures and minute openings when compared to strips 
which had been incubated for one week (Figure 4.22 a to d). Particularly where CA and 
SB were present in the silicone mixes, pores and channels were visible with the porous 
nature increasing with the increased percentage of CA and SB contained within the 
preparations from 5 % to 30 %.  
 
Overall it can be seen that the quantity of channels and pores increased both with the 
amount of integrated CA and SB in the tested preparations and with longer incubation 
periods, confirming the formation of openings and pores on the surface and within the 
silicone strips structure with incorporated additives over incubation time.  
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(A) (B) 
(B) (A) (B) (A) 
(B) (A) 
Figure 4. 19 a-d Optical images from the surface of the silicone elastomer strips containing 0 % (1), 5 
% (2), 15 % (3) and 30 % (4) (w/w) CA: SB, prior to incubation in PBS at 25x (A) and 50x (B) 
magnifications respectively, using a Reichert-Jung Polyvar microscope. Silicone prepared without the 
addition of CA and SB (0 % CA: SB) had a smooth topography (Figure 4.19a), however as the quantities of 
CA and SB increased within the preparations from 5 % to 30 % (Figure 4.19 b to d respectively), the 
exterior of silicone strips became less smooth and more ‘pitted’. 
 
 
(1) (2) 
(4) (3) 
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(A) 
(B) (A) (A) (B) 
(B) (B) (A) 
Figure 4. 20 a-d Optical images from the surface of the silicone elastomer strips containing 0 % (1), 5 
% (2), 15 % (3) and 30 % (4) (w/w) CA: SB, after 1 day incubation in PBS (37 °C) at 25x (A) and 50x 
(B) magnifications respectively, using a Reichert-Jung Polyvar microscope. For all the formulations 
tested, the surface of the silicone strips became irregular in nature with small apertures following 1 day’s 
incubation in PBS. Particularly where CA and SB were present in the silicone mixes, pores and channels 
were visible with the porous nature increasing with the increased percentage of CA and SB contained within 
the preparations from 5 % to 30 %.  
 
 
(1) (2) 
(4) (3) 
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(A) (B) 
(A) (B) (A) 
(B) (A) 
(B) 
Figure 4. 21 a-d Optical images from the surface of the silicone elastomer strips containing 0 % (1), 5 
% (2), 15 % (3) and 30 % (4) (w/w) CA: SB, after 1 week incubation in PBS (37 °C) at 25x (A) and 50x 
(B) magnifications respectively, using a Reichert-Jung Polyvar microscope. Subsequent to one week’s 
incubation in PBS (Figure 4.21 a to d), the number and size of the apertures and pores increased, for all the 
formulations tested. Particularly where CA and SB were present in the silicone mixes, pores and channels 
were visible with the porous nature increasing with the increased percentage of CA and SB contained within 
the preparations from 5 % to 30 %.  
 
 
(1) (2) 
(4) (3) 
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Figure 4. 22 a-d Optical images from the surface of the silicone elastomer strips containing 0 % (1), 5 
% (2), 15 % (3) and 30 % (4) (w/w) CA: SB, after 1 month incubation in PBS (37 °C) at 25x (A) and 
50x (B) magnifications respectively, using a Reichert-Jung Polyvar microscope. For all the 
formulations tested, the surface of the strips after one month incubation demonstrated more apertures and 
minute openings when compared to strips which had been incubated for one week (Figure 4.22 a to d). 
Particularly where CA and SB were present in the silicone mixes, pores and channels were visible with the 
porous nature increasing with the increased percentage of CA and SB contained within the preparations 
from 5 % to 30 %.  
 
(B) 
(A) (B) 
(A) 
(B) (A) 
(B) (A) 
(1) (2) 
(4) (3) 
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4.4.7 Swelling studies 
To study the swelling properties of the silicone elastomer strips in buffer solution upon 
addition of CA and SB, the weight, dimensions (width, length and thickness) and 
corresponding volume of strips prior to and subsequent to incubation (1 day, 1 week and 
1 month time points) in PBS (pH 7.4, 37 °C) were measured. Swelling of the strips was 
investigated by monitoring the percent change in the volume of each strip for the pre-set 
time points.  
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Figure 4. 23 Percent change in volume (%) of the silicone elastomer strips integrating 0 %, 5 %, 15 
% and 30 % CA: SB after incubation (1 day, 1 week and 1 month) in PBS (pH 7.4, 37 °C). For all the 
formulations integrating CA and SB, the alteration in volume of the strips was found to increase with the 
incubation period. The maximum volume for all preparations was seen after one month of incubation in 
PBS. Furthermore, as the amount of integrated CA and SB in preparations rose, the volume change 
increased. Results denote mean  ±  SD from 3 independently synthesized batches. 
 
 
As shown in Figure 4.23, alterations in the volume of the strips across all of the measured 
time points for strips containing 0 % (w/w) CA and SB were minimal (< 5 %) amongst 
all the preparations tested. For the formulations integrating CA and SB, the alteration in 
volume of the strips was found to increase with the incubation period and the amount of 
integrated CA and SB in the preparations. The maximum volume for all the preparations 
tested was seen following one month of incubation in PBS with the modification in 
volume at 30 % (w/w) CA and SB being the highest for all the tested formulations (45 
fold). For the same time point, the formulations containing 5 % (w/w) CA and SB 
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demonstrated a 15-fold increase in volume, whereas those containing 15 % demonstrated 
a 35 fold increase. As previously discussed inclusion of more CA and SB in formulations, 
increases the creation of pores and channels, which results in absorbing more PBS over 
time, and eventually swelling and expanding of the strips. This is in line with the systems 
initially proposed by Kajihara (2003), demonstrating again the presence of CA and SB 
was able to suitably modify the morphology of the silicone strips, thereby supporting the 
proposed mechanism of drug release. 
 
4.4.8 Mechanical properties of silicone strips 
Mechanical characteristics of the silicone strips were measured to reveal the reaction of 
the silicone elastomer strips to an applied external force, thereby indicating their 
suitability for mechanical applications such as Young’ modulus and tensile strength.  
 
4.4.8.1 Tensile strength  
As mentioned earlier in chapter 1, catheters can be exposed to significant tensile force 
upon removal from the patient which might result in destruction or detachment of the 
shaft from the balloon in the case of Foley catheters or in the separation of the catheter 
into two or more parts. Consequently, the elastic recovery of the constituent biomaterial 
is a necessary property that must be considered when manufacturing catheters (British 
Standard EN 30993, 1992; Lowthian, 1998; Lawrence and Turner, 2005). Tensile 
strength (MPa) is the resistance of a material to longitudinal stress, measured by the 
minimum amount of longitudinal stress required to rupture the material. It is expressed as 
the minimum tensile stress (force per unit area) needed to split the material apart. The 
tensile strength of each strip prepared in these studies was measured after initial 
preparation in PBS at 37 °C (Figure 4.24) to investigate the greatest lengthwise stress that 
the silicone strips could withstand without breaking. 
 
According to Figure 4.24, there was no a considerable variation (ANOVA, P > 0.05) in 
terms of tensile strength amongst the blank formulations (0 % (w/w) CA/ SB) within the 
range of time points measured (approximately 5 MPa). For the rest of the formulations 
tested, a common trend apparent is that with an increase in percentage of incorporated 
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CA/ SB, the maximum force required to break the strips and hence the tensile strength 
was reduced. Across all the time points, the specimens incorporating 30 % (w/w) CA/ SB 
demonstrated the lowest tensile strength, whereas the ones with 0 % represented the 
highest. From these findings it could be suggested that incorporation of more acid and 
carbonate powders in the formulations results in the weakening of intermolecular, 
secondary forces (Van der Waals' forces) in the polymer structure due to the presence of 
the pockets of CA/ SB which subsequently form channel and pores in the silicone strips.  
 
Moreover, all the silicone elastomer strips illustrated a greater tensile strength prior to 
incubation than after incubation in PBS. As the incubation period for the formulations 
amalgamated with CA/ SB increased from one day to one month period the tensile 
strength decreased. For the preparations incorporating 5 % and 15 % (w/w) CA/ SB, there 
was a downward trend in the tensile strength from 4.75 to 2.45 MPa and from 3.88 to 
1.76 MPa respectively over the entire incubation period. The greatest reduction in the 
amount of tensile strength at 30 % (w/w) CA/ SB was on the first day (from 3.33 to 1.32 
MPa), after which it remained constant. Again this would be consistent as a consequence 
of the formation of holes and pores, as a result of gas generation upon the mixing of 
carbonate and acid powders. Hence, the longer the period of time that the specimens were 
maintained in PBS, the greater number of pores and channels were formed. Commonly, 
silicone has a tensile strength of 2.4 - 7 MPa and an elongation of 350-600 % (Lawrence 
and Turner, 2005). These results are in conjunction with the results obtained in this study 
(Figure 4.24). 
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Figure 4. 24 The true tensile strength of the silicone elastomer strips incorporating 0 %, 5 %, 15 % 
and 30 % CA: SB previous to and after incubation (1 day, 1 week and 1 month) in PBS (pH 7.4, 37 
°C). It was apparent that with a rise in the percentage of incorporated CA and SB and incubation period, the 
maximum force required to break the strips and consequently the tensile strength was decreased. In all of 
the formulations, the specimen containing 30 % CA/ SB showed the lowest tensile strength, whereas, the 
ones with 0 % CA/ SB demonstrated the highest. Furthermore, all the silicone elastomer strips exhibited a 
greater tensile strength prior to incubation than after incubation in PBS. As the incubation period for 
formulation amalgamated with CA/ SB increased from one day to one month period, the tensile strength 
decreased. Results denote mean  ±  SD from 3 independently synthesized batches. 
 
4.4.8.2 Force-extension curve 
The major product of a tensile test is a load versus elongation curve. Force-extension 
graphs were plotted in order to display the silicone strips deformation under a load. As 
the force was applied to the strips, the specimen began to stretch or extend. The force was 
applied at a constant rate and readings of force and extension were recorded until the 
specimen broke. These readings could be plotted on a graph to display the overall 
performance of the specimen. The shape of the graph is imperative in predicting how the 
material would react under different loading conditions. In the elastic region, the graph is 
a straight line; this means that the material stretches under the load in proportion to 
applied stress, however when the load is removed, it returns to its original length. The 
graph becomes non-linear beyond the elastic region, as Hooke's Law is not obeyed and 
force is not proportional to extension. The line in the linear region of the curve obeys the 
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relationship defined as Hooke's Law where the ratio of force to elongation is a constant. 
The elongation of the strip is directly proportional to the tensile force and the length of 
the strip and inversely proportional to the cross-sectional area and the modulus of 
elasticity. 
 
Hooke's experimental law; 
            
        P ℓ 
δ = ──── (Equation 4.4) 
        AE   
                                                                                                                                                                                                                              
δ = Tensile strength 
P = Force producing extension of bar (lbf) 
ℓ = Length of bar (in) 
A = Cross-sectional area of bar (in2) 
d = Total elongation of bar (in) 
E = Elastic constant of the material, called the Modulus of Elasticity, or Young’s           
Modulus (lbf/in2)    
 
Figures 4.25 - 4.28 below illustrate the force-extension curves of a silicone elastomer 
strip containing 0 %, 5 %, 15 % and 30 % (w/w) CA/ SB, prior to and subsequent to 
incubation in buffer (1 day, 1 week and 1 month). As can be seen, the amount of exerted 
force increases proportionally to the amount of extension of the strips. A sheer and short 
slope indicates that more fore is required for deformation of polymer strips. On the other 
hand, a slight and long slope implies the conversely. Similarly, if the slope is steep, the 
sample has a high tensile modulus, which means it resists deformation. On the contrary, 
if the slope is gentle, then the sample has a low tensile modulus, which means it is easily 
deformed. Accordingly, CA/ SB integrated specimen curves have a gentler slope than the 
ones devoid of CA/ SB powders. By augmenting the amount of incorporated CA/ SB in 
the formulations from 5 % to 30 %, a gradual diminishing effect of the slope of the 
curves could be observed, suggesting that less strength is mandatory to break the strips. 
Correspondingly, a decrease in the slope of the curves is directly associated with an 
increase in incubation time. The one-month incubated strips appear to break more 
effortlessly than their one-day and one-week counterparts. This could be due to the 
formation of more holes and pores throughout the incubation period. 
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Figure 4. 25 a-d Force-extension curve of the silicone elastomer strip containing 0 % (w/w) CA: SB, 
prior to incubation in PBS (1) and after 1 day (2) 1 week (3) and 1 month (4) incubation in PBS (pH 
7.4, 37 °C). The curve is a graphical representation of the relationship between force, derived from 
measuring the load applied on the silicone strip and extension derived from measuring the elongation of the 
strip before the break. 
(a) 
(b) 
(c) 
(d) 
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Figure 4. 26 a-d Force-extension curve of the silicone elastomer strip containing 5 % (w/w) CA: SB, 
prior to incubation in PBS (1) and after 1 day (2) 1 week (3) and 1 month (4) incubation in PBS (pH 
7.4, 37 °C). The curve is a graphical representation of the relationship between force, derived from 
measuring the load applied on the silicone strip and extension derived from measuring the elongation of the 
strip before the break. 
(a) 
(b) 
(c) 
(d) 
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Figure 4. 27 a-d Force-extension curve of the silicone elastomer strip containing 15 % (w/w) CA: SB, 
prior to incubation in PBS (1) and after 1 day (2) 1 week (3) and 1 month (4) incubation in PBS (pH 
7.4, 37 °C). The curve is a graphical representation of the relationship between force, derived from 
measuring the load applied on the silicone strip and extension derived from measuring the elongation of the 
strip before the break.  
(a) 
(b) 
(c) 
(d) 
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Figure 4. 28 a-d Force-extension curve of the silicone elastomer strip containing 30 % (w/w) CA: SB, 
prior to incubation in PBS (1) and after 1 day (2) 1 week (3) and 1 month (4) incubation in PBS (pH 
7.4, 37 °C). The curve is a graphical representation of the relationship between force, derived from 
measuring the load applied on the silicone strip and extension derived from measuring the elongation of the 
strip before the break.  
 
 
(a) 
(b) 
(c) 
(d) 
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4.4.8.3 Young’s modulus (modulus of elasticity) (elastic modulus) (Tensile modulus) 
To quantify the elasticity or stiffness of the silicone elastomers, the Young’s modulus (E) 
of each silicone strips was measured (Figure 4.29). 
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Figure 4. 29 Young’s modulus of the silicone elastomer strips incorporating 0 %, 5 %, 15 % and 30 
% CA: SB previous to and after incubation (1 day, 1 week and 1 month) in PBS (pH 7.4, 37 °C). A 
common trend apparent is that with an increase in the percentage of incorporated CA and SB and the 
incubation period Young’s Modulus and consequently the elasticity of silicone elastomer strips decreased. 
Results denote mean  ±  SD from 3 independently synthesized batches. 
 
As illustrated in Figure 4.29, Young’s modulus and consequently the elasticity of the 
silicone elastomer strips declined steadily, with an increase in the amount of incorporated 
CA/ SB in the formulations from 0 % to 30 %. The highest modulus, ~ 0.110 MPa, was 
measured in the preparations incorporating 0 % (w/w) CA/ SB which were the most 
elastic and the least stiff of all the specimens. Conversely, the smallest modulus, 0.06 -
0.08 MPa, was measured in 30 % (w/w) CA/ SB integrated formulations, indicating the 
lowest elasticity and highest stiffness among the formulations. 
 
There was no considerable disparity (ANOVA, P > 0.05) in the Young’s modulus 
measured in all the preparations devoid of CA/ SB (0 %), prior to and subsequent to 
incubation in PBS (~ 0.110 MPa). For the rest of the formulations (5 %, 15 % and 30 % 
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(w/w) CA/ SB), the amount of applied force and stress which was required to break the 
strips, in addition to Young’s modulus, declined slowly with increased incubation time 
from one day to one month. Particularly at 30 % CA/ SB (w/w), where the Young’s 
modulus measured declined gradually from 0.085 MPa to 0.063 MPa. However, when 
comparing the time point prior to release with that after one-day release, the alteration in 
the Young’s modulus was insignificant (ANOVA, P > 0.05), for both 5 % and 15 % 
(w/w) CA/ SB incorporated formulations. Similar results were also observed when 
comparing the time point after one-week release with that after one-month release. The 
creation of channels and pores in the CA/ SB amalgamated preparations during the 
suspension of strips in PBS weakens the intermolecular forces that act between molecules 
or between functional groups of macromolecules, in turn lessening the elastic properties 
of the strips and enhancing stiffness.  
 
In a similar study conducted by Wolfson et al. (2003), the tensile strength of the silicone 
strips measured from 1.46 – 3.37 MPa and the Young’s modulus measured from 0.68 – 
2.26 MPa. The resultant tensile strength was in accordance with the experimental results 
obtained from Figure 4.23, while the elastic modulus was greater than the comparative 
study conducted in this chapter (Figure 4.29). This could be attributed to the 
incorporation of CA/ SB in the formulations as earlier discussed. 
 
4.4.9 Summary 
Characteristics of different strips are summarised in the four tables below (Table 4.4 to 
4.7); these high-light the differences in material characteristics in terms of increasing the 
CA/SB content,  resulting in reduced tensile strength and Young’s modulus. 
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Table 4.4 The data obtained from measuring tensile strength of the silicone elastomer strips by a 
Hounsfield Universal Tester. The experimental conditions involved; 0 %, 5 %, 15 % and 30 % CA/ SB 
incorporated formulations, and prior to incubation in PBS. 
 
 
Blank  5 % (w/w) 15 % (w/w) 30 % (w/w) 
Tensile (MPa) 2.45 ± 0.33 2.31 ± 0.44 1.96 ± 0.34 1.76 ± 0.21 
Max Force (N) 24.58 ± 3.31 23.16 ± 4.41 19.63 ± 3.4 17.65 ± 2.12 
Elong at Max % 103.24 ± 10.51 105.85 ± 12.45 108.13 ± 19.92 105.25.± 4.59 
Break (Mpa) 0.08 ± 0.17 0.01 ± 0 0.34 ± 0.4 0.12 ± 0.12 
Break (N) 0.88 ± 1.7 0.15 ± 0 3.45 ± 4.02 1.25 ± 1.27 
Elongation% 375.9 ± 537.35 124.5 ± 11.73 116 ± 24.07 112.5 ± 2.82 
 
Table 4.5 The data obtained from measuring tensile strength of the silicone elastomer strips by a 
Hounsfield Universal Tester. The experimental conditions involved; 0 %, 5 %, 15 % and 30 % CA/ SB 
incorporated formulations, and after one day incubation in PBS.  
 
 
Blank  5 % (w/w) 15 % (w/w) 30 % (w/w) 
Tensile (MPa) 2.51 ± 0.52 2.01 ± 0.39 1.87 ± 0.41 0.93 ± 0.19 
Max Force (N) 25.15 ± 5.23 20.16 ± 3.94 18.72 ± 4.14 9.33 ± 1.95 
Elong at Max % 115.56 ± 17.52 92.83 ± 19.34 95.84 ± 18.86 64.59 ± 17.57 
Break (Mpa) 0.28 ± 0.61 0.05 ± 0.04 0.04 ± 0.06 0.04 ± 0.05 
Break (N) 2.8 ± 6.13 0.5 ± 0.44 0.41 ± 0.65 0.44 ± 0.52 
Elongation% 147.14.± 35.27 123.46 ± 38.83 182.5 ± 183.33 78.75 ± 14.13 
 
Table 4.6 The data obtained from measuring tensile strength of the silicone elastomer strips by a 
Hounsfield Universal Tester. The experimental conditions involved; 0 %, 5 %, 15 % and 30 % CA/ SB 
incorporated formulations, and after one week incubation in PBS.  
 
 
Blank  5 % (w/w) 15 % (w/w) 30 % (w/w) 
Tensile (MPa) 2.64 ± 0.3 1.78 ± 0.13 1.24 ± 0.21 0.92 ± 0.31 
Max Force (N) 26.49 ± 3.02 17.83 ± 1.31 12.42 ± 2.13 9.26 ± 3.16 
Elong at Max % 130.9 ± 16.86 79.33 ± 11.47 63.11 ± 4.36 57.78 ± 13.59 
Break (Mpa) 0.02 ± 0.01 0.02 ± 0.01 0.1 ± 0.14 0.12 ± 0.15 
Break (N) 0.2 ± 0.1 0.28 ± 0.11 1 ± 1.43 1.28 ± 1.57 
Elongation % 149.35 ± 12.55 112.03 ± 26.13 76.51 ± 9.33 67.87 ± 15.12 
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Table 4.7 The data obtained from measuring tensile strength of the silicone elastomer strips by a 
Hounsfield Universal Tester. The experimental conditions involved; 0 %, 5 %, 15 % and 30 % CA/ SB 
incorporated formulations, and after one month incubation in PBS.  
 
 
Blank  5 % (w/w) 15 % (w/w) 30 % (w/w) 
Tensile (MPa) 2.42 ± 0.47 1.41 ± 0.25 1.14 ± 0.24 0.92 ± 0.21 
Max Force (N) 24.26 ± 4.76 14.1 ± 2.58 11.46 ± 2.45 9.23 ± 2.13 
Elong at Max % 121.92 ± 16.76 70.91 ± 12.24 67.77 ± 13.99 68.92 ± 12.97 
Break (Mpa) 0.22 ± 0.48 0.06 ± 0.11 0.14 ± 0.22 0.17 ± 0.22 
Break (N) 2.21 ± 4.85 0.64 ± 1.19 1.4 ± 2.24 1.76 ± 2.28 
Elongation % 141.03 ± 18.03 138.64 ±122.64 85.83 ± 25.6 82.95 ± 22.66 
 
4.4.10 Conclusion 
The results presented within this chapter demonstrate that the incorporated FXIIIa 
inhibitor as a poorly soluble drug was not released from the silicone carrier when it was 
dispersed devoid of additives; however its release profile was improved by using CA and 
SB as additives. CA and SB as water-soluble compounds form channels and pores upon 
dissolution and generate gaseous carbon dioxide as a driving force to accelerate the 
release of the inhibitor. The drug release rate could be controlled by the amount of CA 
and SB incorporated in the silicone matrix. A common trend apparent was that with an 
increase in the percentage of incorporated CA and SB, the consequent drug release also 
increased. Thus, the amount of the inhibitor released at 30 % CA and SB is the most 
amongst the formulations and approximately 30 folds higher when compared to the 
blank. Morphological analysis confirmed the formation of channels and cracks inside the 
specimens upon the addition of CA and SB. Furthermore, it was found that the inhibitor 
was still biologically active subsequent to being released from the silicone elastomer 
strips. However, the tensile strength, in addition to Young’s modulus of silicone 
elastomer strips, decreased constantly with an increasing amount of amalgamated CA/ SB 
in the formulations. According to these studies, FXIIIa inhibitor incorporating catheters 
and other medical devices could offer new perspectives on preventing bio-material 
associated infections and thrombosis.  
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5.1 Introduction 
As detailed in chapter 1, liver fibrosis and its end stage disease cirrhosis are a major 
cause of mortality and morbidity around the world. There is no effective 
pharmaceutical intervention for liver fibrosis at present. Liver fibrosis is characterized 
by increased synthesis and decreased degradation of the extracellular matrix (ECM). 
Increase in TG2 activity has been linked to an increase in the deposition of 
extracellular matrix proteins in fibrotic conditions. It can therefore be predicted that 
TG2 inhibitors could be used for the cure of fibrotic diseases characterised by 
increased ECM deposition and cross linking. 
 
5.2 Aim 
In the development of new drugs, pharmacokinetic data is essential. In contrast to in 
vitro studies, animal models allow the estimation of many variables, such as 
absorption, distribution, clearance, drug interactions and toxicity by reproducing the 
host immune defects and systemic infections. The aim of this study was to examine in 
vivo pharmacokinetics and tissue biodistribution of the TG2 inhibitor (AM2/169) 
subsequent to intraperitoneal (IP) administration in rats. The inhibitor concentrations 
in major organs and plasma were quantitatively analysed using a high performance 
liquid chromatography-fluorescence assay. Pharmacokinetic parameters were 
calculated based on plasma concentration-time profiles of AM2/169.  
 
5.3 Animals 
All animal experimentation strictly adhered to the 1986 Scientific Procedures Act and 
to the Guidance on the Operation of Animals (Scientific Procedures) Act, as outlined 
by the Home Office in the UK and adopted by the ethics committee on animal 
experimentation within the research establishment. All protocols were subject to 
stringent ethical review and were carried out in a designated establishment. All 
animals were kept in a typical laboratory environment: four or five per cage with an 
air filter cover under light (12 hour light/ 12 hour dark cycles) and temperature-
control (19 ± 23 °C), a relative humidity of 55 ± 15 %, and were observed daily for 
any signs of distress. 
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5.4 Study design, drug administration and sample collection 
The study design in this chapter was initially based on the work of previous 
researchers specific to this field of research (Choi et al 2005; Strnad et al, 2006). Bio-
distribution studies were carried out in Wistar rats at different time intervals after 
parenteral administration of the fluorescent drug (n = 5 rats per time point). Initially, a 
total of twenty male Wistar rats, with an average bodyweight of 95 gram were 
injected with 50 mg/kg of 10 mg/ml AM2/169 in 50 % DMSO/PBS intraperitoneally 
(IP). At each time point (0.083, 0.33, 0.5, 1, 2, 4, 12 and 24 hours) five rats were 
anesthetized with isoflurane (4-5 %). Subsequently, the blood samples were collected 
at various time intervals using different techniques. At 0.083 and 0.33 hours, blood 
samples were collected by cannulation of the jugular vein, by cardiac puncture at 0.5, 
1, 4 and 24 hours time points and from tail vein at 0.5, 2 and 12 hours time points. 
After predetermined time intervals (0.33, 1, 4 and 24 hours time points) the rats were 
terminated and organs such as the liver, lungs, kidneys, brain and spleen were 
removed and kept in autoclaved PBS for further analysis.  
 
Blood plasma was collected after centrifugation of whole blood at 10000 g for 10 
minutes at room temperature on a table-top centrifuge. The plasma was then separated 
and transferred to micro centrifuge tubes. The amount of inhibitor in the plasma was 
determined fluorometrically using HPLC as described in chapter 2. 
 
Extraction of the TG2 inhibitor from the organs was performed on 250 mg of each 
organ. To each weighted organ 0.5 ml of methanol (40 % v/v) was added and 
homogenized for several minutes using a tissue homogenizer, which was carefully 
cleaned and disinfected with 70 % ethanol after each homogenization. The 
homogenate was centrifuged at 10000 g for 10 minutes, after which the supernatant 
was collected and read by fluorimetric estimation using HPLC. All harvested samples 
were stored at −80 °C and analyzed within one month.  
 
5.5 Results and discussions 
5.5.1 Biodistribution and pharmacokinetic of the TG2 inhibitor  
To investigate the biodistribution and pharmacokinetic of the TG2 inhibitor, the plasma 
concentration of AM2/169 following IP administration in rats was measured at various 
time points (Figures 5.1a, 5.1b and 5.1c). Figure 5.1a represents a linear plot of the 
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decline in the mean plasma concentration of AM2/169 following an IP dose of 50 mg/kg 
to a group of male Wistar rats. The time scale is from a 0.083 hour time point (the time 
the drug has reached the blood stream) to a 2 hour time point (the time the drug has 
completely cleared from the blood stream). Figure 5.1b demonstrates a semi logarithmic 
plot of the data shown in Figure 5.1a. The time scale is the same as in Figure 5.1a (0.083 
to 2 hours time points), although the ordinate (concentration) scale is logarithmic. Figure 
5.1c shows the same data as Figure 5.1b, but with a time scale from a 0.33 hour time 
point (the time the drug has reached the maximum blood concentration) to a 2 hour time 
point (the time the drug has completely cleared from the blood stream). 
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Figure 5. 1a A linear plot of the decline in the mean plasma concentration of AM2/169 following 
an IP dose of 50 mg/kg to a group of male Wistar rats. The time scale is from a 0.083 hour time 
point (the time the drug has reached the blood stream) to a 2 hour time point (the time the drug has 
completely cleared from the blood stream). The area under the curve (AUC) represents total systemic 
exposure to the drug. Values denote mean ± SD (n=3). 
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Figure 5. 1b A semi logarithmic plot of the decline in the mean plasma concentration of AM2/169 
following an IP dose of 50 mg/kg to a group of male Wistar rats. The time scale is the same as 
Figure 5.1a (0.083 to 2 hours time points), however the ordinate (concentration) scale is logarithmic. 
Values denote mean ± SD (n=3). 
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Figure 5. 1c A semi logarithmic plot of the decline in the mean plasma concentration of AM2/169 
following an IP dose of 50 mg/kg to a group of male Wistar rats. The time scale is from a 0.33 hour 
time point (the time the drug has reached the maximum blood concentration) to a 2 hour time point (the 
time the drug has completely cleared from the blood stream). Values denote mean ± SD (n=3). 
 
Based on the time-points measured, the inhibitor reached the blood circulation after 5 
minutes subsequent to intraperitoneal injection (absorption phase). The maximum 
plasma concentration (Cmax) of the drug was measured after 20 minutes (tmax) at 35.74 
µg/ml with rapid clearance thereafter. Two hours after the injection, the inhibitor had 
been eliminated from the systematic circulation and entered the body tissues 
(elimination phase). Thus, the area under the curve (AUC) represents total systemic 
exposure to the drug. The area under the curve up to the time of the peak 
concentration is a measure of early exposure to the drug. The concentration profile 
before the peak is a function of how quickly the drug enters the systemic circulation 
(Figure 5.1a). 
 
Accordingly, based on Figures 5.1b and 5.1c, the elimination half-life (t½), volume of 
distribution (Vd) and clearance (CL) of the inhibitor were calculated.  
 
Commonly, the kinetics of a drug is characterised by its half-life (t½). The elimination 
half life is the time taken for the plasma concentration of the drug to fall by one half. 
ek
693.0
t½ =  
ke is the elimination rate constant and presented by the slope of the line of the 
logarithmic plasma concentration versus time. Ke was calculated to be equal to 0.0233 
min-1. Thus; 
t½ was calculated to be 29.74 minutes. 
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For drugs that are hydrophobic (as in this case), comparatively little of the dose 
remains in the circulation to be measured; hence, plasma concentration is low and 
volume of distribution is high (Tozer & Rowland, 2006). 
 
In order to quantify the distribution of the drug between the plasma and the rest of the 
body after parenteral dosing, the volume of distribution (apparent volume of 
distribution) and blood volume (BV) was measured. When the logarithm of drug 
concentration was plotted against time a straight line resulted (Figure 5.1c). If this is 
extrapolated back to time zero it gives the blood drug concentration before any drug is 
eliminated, i.e. when the whole dose (4.75 mg, t = 0) is still in the body. In this case, 
the extrapolated concentration at time zero is 36.22 mg/L and the Vd is 0.131 L. 
 
ml 131L 131.0
mg/L 36.22
mg 4.75
ionconcentrat drug Plasma
body in the drug ofAmount Vd ====  
 
Blood volume was calculated by (Lee, 1985): 
BV (ml) = 0.06 x BW (body weight) + 0.77 (r = 0.99, n = 70, p < 0.00)  
which was equal to 6.47 ml. 
 
As expected, the volume of distribution for the inhibitor is significantly high. This 
could be attributed to the hydrophobicity of the drug. Lipid-soluble drugs would 
usually be absorbed via transcellular passive diffusion through the lipid membrane 
barrier. Therefore, they concentrate more in peripheral tissues or organs rather than 
plasma itself. Furthermore, one of the major determinants that quantify the 
distribution of the drug between the plasma and the rest of the body after parenteral 
administration is the relative avidity of the drug for tissue components as compared 
with blood. If a drug is very tightly bound by tissues and not by blood, most of the 
drug in the body will be held in the tissues and very little in the plasma, so that the 
drug will appear to be dissolved in a large volume and Vd will be large (in this case). 
Conversely, if the drug is tightly bound to plasma proteins and not to tissues, Vd can 
be very close to blood volume. 
 
Clearance or rate of elimination is the single most important factor determining drug 
concentrations within the body and is influenced by dose, blood flow and intrinsic 
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function of the liver or kidneys. However, plasma protein binding may lead to false 
interpretation of drug clearance. In the data shown in the above graphs (Figure 5.1b 
and 5.1c), it can be seen that the drug is eliminated over a period of time as expected, 
as the rate of drug elimination is directly proportional to the concentrations of drug in 
the blood. To measure the rate at which the active drug is removed from the body, the 
rate of elimination (CL) was calculated as follows;  
 
1
d
e min ml 3131.00233.0
V
kCL −=×==
 
 
Furthermore, as there is a straight line on the logarithmic concentration plot (Figure 
5.1c), it can be concluded that the reaction is first order and the rate of reaction is 
directly proportional to the concentration of the drug. In fact, first order kinetics 
reactions follow a natural logarithmic degradation. When absorption occurs through a 
first-order process, the rate of absorption is proportional to the amount of drug 
remaining to be absorbed. Therefore, as the drug is absorbed, its rate of absorption 
decreases and its rate of elimination increases. Consequently, the difference between 
the two rates diminishes. As long as the rate of absorption exceeds that of elimination 
the concentration in the blood continues to rise. Eventually, a time, tmax, is reached 
when the rate of elimination exceeds the rate of absorption (20 minutes, in this case); 
the concentration is then at a maximum, Cmax (35.74 µg/ml). Subsequently, the rate of 
elimination exceeds the rate of absorption and the concentration declines (Figure 
5.1a). 
 
When a drug enters the systemic circulation, the drug molecules are distributed via the 
blood flow to the body’s tissues. The drug is carried not only to the site of action, but 
also carried to other tissues including: skin, fat, muscle and eliminating organs (liver 
and kidney). The pattern of drug distribution in body tissues is determined by a 
number of factors such as the physicochemical properties of the drug (lipid solubility, 
molecular size and the degree of ionisation), the rate of blood flow to tissues (tissues 
with the highest blood flow receive the drug in a greater proportion), tissue mass, 
protein binding (lipophilic drugs are usually largely protein bound) and properties of 
the membrane. In order for a drug to be distributed to the site of action it must cross 
one or usually more membranes. Since for the majority of drug molecules, crossing of 
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the membrane occurs by simple diffusion, and given the largely lipophilic nature of 
the membrane, the prime determinant of the rate of absorption is the lipophilicity of 
drug molecules. As a result, lipophilic drugs penetrate cellular barriers and enter most 
tissues of the body.  
 
Figurer 5.2 demonstrates the concentration (µM) of the inhibitor in 1 mg of lung, 
kidney, liver and spleen at the indicated time points (0.33, 1 and 24 hours) following 
IP injection.    
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Figure 5. 2 Bio-distribution of AM2/169 in Wistar rats. The values represent the concentration 
(µM) of the inhibitor in 1 mg of each organ at the indicated time point. On a per organ basis, the 
distribution of the inhibitor is higher in the kidney and liver compared with other organs at all 
measured time points. Values denote mean ± SD (n=3). 
 
The distribution of AM2/169 in tissues was rapid and substantial. The distribution of 
drug into tissues primarily determines the early rapid decline in plasma concentration. 
As a result, the distribution of the enzyme inhibitor in tissues was significantly higher 
than the corresponding levels in serum.  
 
On a per organ basis, the distribution of the inhibitor is higher in the kidney and liver 
compared with other organs at all measured time points. Initially, the drug 
concentration in the kidney and the liver was about 0.30 and 0.25 µM per mg of each 
organ at 0.33 hours. The concentration of the enzyme inhibitor reduced significantly 
at a 1 hour time point (~ 0.08 µM per mg of each organ) in both organs. No drug was 
detected in the kidney at a 24 hour time point, nevertheless for the same time point a 
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substantial amount of the drug was found in the liver; the level was roughly the same 
as that at the 1 hour time point. 
 
The liver and kidneys are the two principal organs of elimination; kidneys are the 
primary organs for excretion of the chemically unaltered or unchanged drug, while the 
liver is the main organ for drug metabolism. Therefore, the distribution of the 
inhibitor in the kidney and liver is higher than the other organs. Furthermore, the drug 
stayed for a longer period in the liver (24 hours), suggesting that the preferred site of 
drug accumulation is the liver. This can be affected by the intrinsic lipophilicity of the 
drug. The initial concentration of the drug in the spleen was quite substantial and 
about 0.13 µM per mg of the organ; however no drug was detected after 0.33 hours in 
the spleen. There was also a small amount of drug distribution in the lungs at the 
primarily measured time points (~ 0.03 µM per mg of each lung); nonetheless 
subsequent to 24 hours, the drug was cleared from the lungs. The fastest drug 
clearance was in the spleen (after 0.33 hours). It can also be concluded that this drug 
has a very short journey within the body and after 24 hours time it has been 
eliminated entirely. 
 
5.6 Conclusion 
The novel inhibitor investigated has a rapid clearance and short half life in rats (20 
minutes). Therefore an appropriate carrier system is required to enhance targeting of 
the inhibitor into the liver. Liposomes have been previously shown to be effective 
drug delivery systems for site specific delivery to the liver and could be similarly 
employed for the targeting of the novel group of inhibitors of enzyme 
transglutaminase into the liver. Integrating TG2 inhibitors into liposomes as a 
potential carrier system and subsequently targeting liposomes into the liver could 
reduce the large drug distribution, increase half life and eliminate the potential side 
effects of the drug.  
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6.1 Targeted delivery of the TG2 inhibitors into the liver  
There has been tremendous activity in the field of drug development and testing for 
hepatic fibrosis. Nevertheless as previously stated, thus far no drugs have been approved 
as antifibrotic agents in humans. A successful approach for the cure of hepatic disease 
should be based on the application of nontoxic drugs with a high therapeutic index and 
safety profile along with selective targeting. To accomplish these goals, several biological 
and synthetic carriers with a wide range of chemical and physical properties have been 
formulated (Di Campli et al., 1999).  
 
As detailed in chapter 1 & 5, the application of transglutaminase inhibitors (TG2) in the 
treatment of tissue fibrosis shows great promise as a therapeutic strategy where increased 
ECM deposition and accumulation is involved. However, without effective delivery 
systems to the target organ, these novel peptide-based inhibitors are prone to rapid 
degradation or widespread biodistribution which may lead to adverse side effects.  
Therefore an appropriate carrier system is required to improve delivery and targeting of 
the inhibitor to the required side of action, in this case the liver. The open and relatively 
large fenestrations of the endothelial lining of the sinusoids makes the liver an ideal 
candidate for particulate targeting and uptake, this allows the greater possibility of 
particle extravasation, compared to the capillary bed of most other organ systems 
(Longmuir et al., 2006). Liposomes can be used as an efficient drug delivery system for 
site specific delivery of these site-directed inhibitors of transglutaminase into the liver.  
 
Liposomes have been extensively evaluated as a potential drug delivery system for 
therapeutic applications due to their ability to alter the pharmacokinetics and diminish the 
toxicity of their associated drugs (Hwang, 1987; Allen and Hansen, 1991), relative ease 
of preparation, ability to protect effector molecules from degradation, and specific 
targetability. More significantly, liposomal drugs have established their efficacy and 
safety in humans with products such as Caelyx® and AmBiosome® which have already 
been clinically used (Allen and Cullis, 2004; Perrie, & Rades, 2009). Liposomes, 
depending on their formulation can be prepared to be nontoxic, non-immunogenic, bio-
degradable and can have a high loading capacity for a variety of drugs. Furthermore, 
fluorescent markers or radiolabels could be simply integrated into the liposomes; this 
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incorporation of marker molecules can provide precious information about the site and 
distribution of the injected agent (Yao et al., 1995). Despite many of these valuable 
properties, liposome application for the delivery of drugs by injection into the blood 
stream has been restricted by the rapid removal of liposomes subsequent to injection by 
the mononuclear phagocyte system (MRS), also called the reticuloendothelial system 
(RES), of which the liver and spleen are the main organs (Jones, 1995). Nevertheless, 
while the inherent affinity of liposomes for the liver has been the primary weakness and 
flaw in liposomal therapy for other researchers, it would prove to be an advantage for 
drug targeting to the liver with the aim of curing liver diseases (Yao et al., 1995). 
Therefore, liposomes can be selected as a potential vehicle for delivery of the TG2 
inhibitors into the liver.  
 
6.2 Liposomes 
6.2.1 General background and application 
In the early 1960s, Alec Bangham and his collaborators at Cambridge University 
observed under an electron microscope that 
purified phospholipids dispersed in water 
spontaneously formed multilayered vesicles 
(Bangham and Horne, 1964) which their 
colleague Gerald Weissman named liposomes 
(Bangham, 1992). They demonstrated that each 
layer was a bimolecular lipid membrane, and 
that the layers enclosed internal aqueous 
compartments. Liposomes as drug delivery 
vehicles were initially proposed by Gregoriadis 
and Ryman in 1971 as a carrier of enzymes in 
the treatment of lysosomal storage disease 
(Gregoriadis et al., 1971). Since then, the application of liposomes has been extended to a 
variety of drugs such as antineoplastic agents, antimicrobial compounds, 
immunomodulators, chelating agents, steroids, vaccines and genetic material (Gregoriadis 
and Florance, 1993).  
Figure 6. 1 Diagrammatic representation of 
a liposome and its bi-layer forming lipid 
molecule in an aqueous medium 
(web image 13). 
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6.2.2 Liposomes (micro-particulate vesicular carrier) 
Liposomes are micro-particulate or colloidal carriers which form spontaneously upon 
hydration of certain lipids in aqueous media (Bangham and Horne, 1964) (Figure 6.1). 
They range from 50 nm to 10 µm diameter (Crommelin et al., 2002) and consists of an 
aqueous volume entrapped by one or more bi-layers of natural and/or synthetic lipids 
(phospho and sphingo-lipids), and may also contains cholesterol or other hydrophilic 
polymer conjugate lipids.  
 
6.2.3 Why liposomes are formed? 
Lipids could form liposomes or other colloidal structures display a dual chemical nature; 
the head groups are hydrophilic (water loving) and the fatty acyl chains are hydrophobic 
(water hating) (Weiner et al., 1989). When the lipid molecules are dispersed within an 
aqueous medium, such as water, the polar part of the phospholipid interacts with the water 
and the non-polar part of the molecule avoids the water. In order to accomplish this, the 
phospholipids align themselves side-by-side with their non-polar portions orienting 
themselves towards each other as shown in cross-section in the middle Figure 6.2. This 
structure is known as a phospholipid bi-layer. This bi-layer extends itself in water to form 
sheets which then curls into liposomes (Figure 6.2). The large free energy change between 
water and a hydrophobic environment (15.3 Kcal/mole for 
dipalmitoylphosphatidylcholine and 13.0 Kcal/mole for dimyristoylphosphatidylcholine) 
illustrates the natural preference of typical lipids for assembly in bi-layer structures 
excluding water as much as possible from the structure to reach the lowest free energy 
level and thus the maximum stability for the aggregate structure. It is also evident from 
these thermodynamic considerations that bi-layer structures do not form as such in the 
absence of water, since it is water that acts as the driving force for lipid molecules to 
assume a bi-layer arrangement (Weiner et al., 1989). 
 
Drugs with extensively varying lipophilicities could be encapsulated, in the phospholipid 
bi-layer (lipophilic drugs), in the entrapped aqueous volume (hydrophilic drugs) or at the 
bi-layer interface (interface-associated drug) in liposomes (Sharma and Sharma, 1997). 
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Figure 6. 2 Diagrammatic illustration of a phospholipid molecule with a polar (water soluble) and a 
non polar group (oil like), a phospholipid bi-layer and a self-assembled liposome. When the lipid 
molecules dispersed within an aqueous medium, such as water, the polar part of the phospholipid interacts 
with the water and the non-polar part of the molecule avoids the water. In order to accomplish this, the 
phospholipids align themselves side-by-side with their non-polar portions orienting themselves towards 
each other as shown in cross-section in the middle figure above. This structure is known as a phospholipid 
bi-layer. This bi-layer extends itself in water to form a sheet which then curls into a liposome (web image 
14).   
 
6.2.4 Advantages of liposomes for drug delivery  
Liposomes can be formulated in various sizes, compositions, surface charges. Thus, they 
could be formulated to present the most appropriate properties for the drug and the target 
site (Goyal et al., 2005). Upon injection into the systemic circulation, drugs incorporated 
within liposomes will remain with the carrier systems and have their pharmacokinetic 
distribution dictated by the liposomal carrier rather than the properties of the drug. 
Entrapped drugs are also physically separated from the environment, and are, therefore, 
protected against degradative enzymes (Chaize et al., 2004). These factors combined with 
their innate ability to passively target the MPS, sites of inflammation and tumor sites 
result in their capacity to enhance the drug therapeutic profile, by increasing the quantity 
of drug reaching the site of action whilst reducing general drug distribution and associated 
toxicity issues (Storm & Crommelin, 1998).   
 
6.2.5 Manufacturing problems and limitations   
As described above, liposomes have a great potential in the area of drug delivery. 
However, the number of liposome based therapies remains limited (Table 6.1).  
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The limitations to their application have been to find a way to manufacture a discrete 
liposomal formulation using a fully reproducible method, in large quantities and to 
guarantee a long shelf-life. To accomplish this, problems regarding stability, sterility, 
scale up and shelf life of the liposomes/liposomal preparations must be overcome. To 
solve each of these problems extensive work is needed to find appropriate conditions, 
firstly for stable liposomal systems. Secondly, the whole manufacturing process should be 
performed in a sterile condition. In terms of large scale preparations, a number of 
techniques exist, such as high pressure homogenization, injection method and detergent 
dialysis. Finally, freeze-drying of the liposomal formulation subsequent to preparation 
and storage of the liposome preparations at low temperature are two ways to slow down 
the diffusion process during shelf life (Massing and Fuxius, 2000). 
 
6.2.6 Classification of liposomes  
At a New York Academy of Sciences meeting in 1978 (Papahadjopoulos, 1978) 
liposomes were classified using several three letter acronyms as follows:  
 
6.2.6.1 Multilamellar vesicles (MLV) 
Multilamellar vesicles (MLV) are widely studied and are 
characterized by the presence of multiple lamellae with a 
volume diameter, ranging from as little as 100 nm to 10 
microns in size (Ahl et al, 1994) (Figure 6.3). MLV can be 
prepared using a thin-film hydration method or hydration of 
lipids in the presence of an organic solvent Vemuri and 
Rhodes, 1995. 
 
6.2.6.2 Unilamellar vesicles of small size (SUV) 
MLV can be sonicated or extruded through polycarbonate filters to produce a small and 
more uniformly sized population (Saunders et al., 1962). Small unilamellar vesicles 
(SUV) (Figure 6.4) have a volume diameter equal and are under approximately 0.1 µm in 
diameter (Gregoriadis, 1990). 
 
Figure 6. 3 Multilamellar vesicle 
(MLV) 
(web image 15). 
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6.2.6.3 Large unilamellar vesicles (LUV) 
Large unilamellar vesicles (LUV) (Figure 6.5) are characterized by diameters in excess of 
100 nm and are comprised of a solitary bilayer of lipids. LUV encapsulate a larger 
quantity of drug for a given concentration of lipid and thus have higher encapsulation 
efficiency compared with SUV (Liu et al., 2001). Nonetheless, the absence of multiple 
lamellae renders the vesicle more fragile compared with MLV (Kirby and Gregoriadis, 
1999). 
                                                              
 
6.2.6.4 Reverse phase evaporation vesicles (REV) 
Reverse phase evaporation vesicles (REV) are unilamellar vesicles and have a size range 
of 150-450 nm and are produced from an aqueous-organic emulsion by evaporation of the 
organic phase (Szoka and Papahadjopoulos, 1978). 
 
6.2.6.5 Vesicles produced using the extrusion technique (VET) 
VET are unilamellar with a size range from 50 to 180 nm and are produced by extruding 
MLV through controlled pore filters under high pressure (Mayer et al., 1986). 
 
6.2.6.6 Dehydration-rehydration vesicles (DRV) 
Dehydration-rehydration method was developed by Kirby and Gregoriadis (1984) to 
enhance the efficacy of drug incorporation within the liposomes. Dehydration-
rehydration vesicles (DRV) are produced from dehydrated dispersions using a 
rehydration technique which enables relatively large quantities of materials to be 
entrapped. 
 
Figure 6. 4 Small unilamellar vesicles (SUV) 
                              (web image 16). 
 
Figure 6. 5 Large unilamellar vesicles (LUV) 
                               (web image 17). 
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6.2.7 Parameters which influence in vivo behavior of liposomes 
Liposomal formulations of various drugs can be optimized in terms of drug content, 
stability, desirable bio-distribution patterns, and cellular affinity and in terms of the organ 
disposition of liposomes by altering their physicochemical parameters. These parameters 
include fluidity of the bi-layer membrane, surface charge density, surface hydration, 
particle size and method of preparation (Juliano and Stamp, 1975; Sharma and Sharma, 
1997; Fraley et al., 1981; Gabizon and Papahadjopoulos, 1988; Liu et al., 1992; 
Straubinger et al., 1993; Yu and Lin, 1997). The effects of some of these parameters on 
the physical and biological properties of liposomes are detailed below. 
 
6.2.7.1 Bi-layer fluidity  
Lipids have a characteristic phase transition temperature (Tc). They exist in a rigid well-
ordered arrangement below the Tc, and a liquid crystalline phase above the Tc (Weiner et 
al., 1989). The physical state of the bi-layer affects the permeability, leakage and overall 
stability of the liposomes. Accordingly, phospholipid liposomes must be produced at 
temperatures above the chain-melting temperature of the phospholipid, in order that the 
bi-layers be in the liquid-crystalline state. The chain-melting temperature of a 
phospholipid is verified by the head group type, the alkyl chain length and nature 
(saturated and non-saturated) of the fatty acid chain (Jones et al., 1995; Sharma and 
Sharma, 1997). Using phospholipids with a phase transition temperature higher than body 
temperature (e.g. distearoyl phosphatidylcholine (DSPC) with a Tc of above 55 ˚C) 
makes the liposome bi-layer membrane less fluid, consequently less leaky and more 
stable at physiological fluid; it could also diminish the extent of MPS uptake (Gabizon 
and Papahadjopoulos, 1988) and overcome the problem of liposome destabilization 
induced by plasma high-density lipoproteins (HDL) (Gregoriadis, 1995; Yu and Lin, 
1997).  
 
6.2.7.2 Surface charge 
Surface charge is one of the main parameters which influence vesicle stability, the 
mechanism and extent of liposome-cell interaction and the in vivo fate of liposomes. 
Neutral liposomes show more aggregation and less stability compared to charged 
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liposomes (Weiner et al., 1989).  The surface charge of liposomes has also a crucial role 
in cellular uptake and blood distribution of liposomes and it can be controlled by the type 
of lipid used. Neutral liposomes have less interaction with cells than charged liposomes. 
However, negatively charged liposomes are mainly taken up by cells through coated-pit 
endocytosis due to the high electrostatic surface charge which could promote the extent 
of liposome-cell interaction (Sharma and Sharma, 1997; Gabizon et al., 1990). Therefore, 
the inclusion of negatively charged lipids in liposome formulations accelerates the 
process of opsonization and subsequently the rate of hepatic uptake, resulting in rapid 
elimination of the liposomes from blood circulation following systematic administrations 
(Kamps et al., 1999, Huong et al., 2001; Massing and Fuxius 2000). Apparently, the 
exposure of negatively charged lipid serves as a signal for the removal of the liposomes 
(Liu et al., 1995). Some studies have even reported that the phosphatidyl serine-
negatively charged liposomes were taken up by the liver to a 10-fold higher extent than 
the neutral ones (Rothkopt et al., 2005). As a consequence, negatively charged liposomes 
may be more appropriate than neutral or positively charged liposomes as an 
intrahepatocyte delivery vehicle since the cellular uptake of negatively charged liposomes 
is higher than positively charged or neutral liposomes (Yu and Lin, 1997). Furthermore, 
previous investigations revealed that the presence of negatively charged lipids, 
phosphatidyl serine (PS), phosphatidyl inositol (PI), or phosphatidyl glycerol (PG) or 
positively charged detergents such as stearylamine in liposome formulations reduces the 
likelihood of aggregation subsequent to the formation of vesicles. Furthermore, it leads to 
a greater overall entrapped volume; due to increase of the intercellular distance between 
successive bi-layers in the MLV structure (Weiner et al. 1989).  
 
6.2.7.3 Liposome size  
The average size of liposomes and size distribution are also main factors which verify the 
fraction cleared by MPS (Harashima et al., 1994) with the rate of liposome clearance 
increasing with greater vesicle size. Large liposomes (≥ 0.1 µm) are more prone to 
opsinization, thus clear more quickly and to a higher extent by the MPS when compared 
to small liposomes of the same composition (≤ 0.1 µm) (Sharma and Sharma 1997; 
Huong et al., 2001). Therefore, the size of liposomes is one of the physical properties 
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which can influence liposome targetability to the liver. Indeed it has been stated that an 
efficient liposome size for liver targeting is approximately 100 nm. At this size, the vast 
majority of liposomes deliver their contents to Kupffer cells as evidenced by fluorescence 
and EM studies (Yao et al., 1995).  
 
6.2.8 Optimization of liposome composition 
It has been shown that the membrane composition of liposomes is essential for its 
targeting and function. Liposome membranes consisting of glycerophospholipids with 
long hydrogenated fatty acid esters (e.g. synthetic phospholipids such as 
distearoylphosphatidylcholine (DSPC) are more rigid than membranes consisting of 
glycerophospholipids composed of fatty acids of different length and saturation (e.g. egg 
lecithin, soya lecithin) (Patel, 1992; Devine et al., 1994). Thus, these liposome 
membranes are more stable against lipid exchange by serum proteins (e.g. high density 
lipoprotein (HDL)). Furthermore, increasing the hydrocarbon chain length of the fatty 
acid part of the phospholipid, results in a tighter film packing. A rigid membrane 
decreases the efflux of drugs from liposomes and stabilizes the liposomes themselves. In 
contrast, increasing the degree of unsaturation of the hydrocarbon chain of the 
phospholipid chain, the branching of the hydrocarbon chain of the phospholipid, or 
increasing the temperature of the system, yields to a looser film packaging (Massing and 
Fuxius, 2000).  
 
Cholesterol also improves the fluidity of the bi-layer membrane, decreases the 
permeability of water soluble molecules through the membrane, and enhances the 
stability of the bi-layer membrane in the presence of biological fluids such as 
blood/plasma. Liposomes devoid of cholesterol have a propensity to react with the blood 
proteins such as albumin, m-transferrin, and macroglobulin which have a susceptibility to 
destabilize the liposomes and diminish the utility of liposomes as drug delivery systems 
(Kirby et al., 1980; Damen et al., 1981; Vemuri and Rhodes, 1995).  
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6.3 Aim and objectives 
The work in this chapter focuses on the development of a liposome-based drug delivery 
system for site specific delivery of a novel group of inhibitors of the enzyme TG2 into 
the liver. The ultimate aim of the work is to develop a drug delivery system which can be 
applied in the delivery of site directed irreversible transglutaminase inhibitors to the liver 
which can then be further studied for the treatment of  liver fibrosis in animal models. 
Integrating of the TG2 inhibitors into liposomes as a potential carrier system and 
subsequent passive targeting of vesicles into the liver could focus drug distribution, 
increase half life and eliminate the potential side effects of the drug.  
 
The objectives of this work were,  
 
• Preparation of multilamellar vesicle incorporating the TG2 inhibitor 
• Preparation of small unilamellar vesicles incorporating the TG2 inhibitor 
• Separation of non-incorporated drug from liposome suspension 
• Characterising the TG2 incorporated liposomes in terms of liposome size, 
polydispersity, zeta potential and drug entrapment efficiency 
• Investigating the effect of salt on the physico-chemical properties of the TG2 
incorporated liposomes 
• Stability studies in buffer and serum, in terms of drug retention, particle size and 
zeta potential. 
• Bio-distribution study of the TG2 incorporated liposomes in mice 
 
6.4 Materials  
Egg phosphatidylcholine, distearoyl phosphatidylcholine and phosphatidylserin lipids 
were purchased from Avanti Polar Lipids, Inc. (Alabaster, AL, USA) and were used 
devoid of any further purification. Phosphate buffered saline (PBS) and cholesterol were 
acquired from Sigma-Aldrich (Dorset, England). Cholesterol, [1,2-3H(N)]-, 1mCi (37 
MBq) and Ultima GoldTM scintillation fluid were obtained from PerkinElmer (Waltham, 
MA, USA). Fetal bovine serum was purchased from Biosera (East Sussex, England). 
AM2/169 (TG2 inhibitor) was prepared within the chemistry department of Aston 
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University by Dr. Alexandre Mongeot and Dr. Dan Rathbone as previously described 
(Griffin et al., 2008). Male Outbred mice were obtained from Charles River UK Ltd 
(Kent, England). Unless stated otherwise PBS was used at 0.01 M, pH 7.4. Doubly 
distilled and filtered water was used in the preparation of all solutions.  
 
6.5 Methods 
6.5.1 Liposome production 
6.5.1.1 Production of multilamellar vesicle incorporating the TG2 inhibitor 
Multilamellar vesicles (MLV) were prepared using a technique based on the established 
film method, the assembly of phospholipids into closed lipid bilayers within excess water 
as described by Bangham (1965). Initially, phosphatidylcholine (PC), 1,2-distearoyl- -3-
glyceryl-phosphatidylcholine (DSPC), phosphatidylserin (PS) and cholesterol (Chol) 
were dissolved in a solvent mixture of chloroform and methanol (9:1 v/v) and 
subsequently mixed at the required composition and molar ratios, with(out) a requisite 
amount of the enzyme inhibitor. Phospholipids were dissolved in organic solvents in 
order to avoid oxidation of lipids during storage, assist uniform distribution of lipids in 
the lipid bi-layer and attain molecular mixture of various lipids amongst themselves 
(Vemuri and Rhodes, 1995). The required lipid solutions, at the desired concentrations, 
were then placed in a round-bottom spherical Quick-fit® flask. Thereafter, the solvents 
were evaporated on a rotary evaporator (Buchi Rotavapor-R) at about 37 °C to yield a 
dry lipid film on the inner wall of the flask. The thin lipid film on the wall of the flask 
was flushed with oxygen-free nitrogen in order to ensure complete removal of all solvent 
traces, since the residual quantity of solvents left in the final preparation could pose 
health hazards to the end user (Vemuri and Rhodes, 1995). The dry lipid film was 
hydrated through addition of an aqueous medium (PBS or distilled H2O) and vortexed 
until the thin lipid film was transformed into a milky suspension. The hydration of the 
thin lipid film was maintained above the gel-liquid crystal transition temperature (Tc) of 
the phospholipids (>Tc). PC has a Tc of 0 °C and DSPC has a Tc above 55 °C, thus the 
aqueous medium added to hydrate DSPC was pre-warmed to a temperature above 55 °C. 
The preparations were left to stand above the Tc for 30 minutes during which time the 
vesicles formed and stabilized (Figure 6.6).   
Chapter 6 – Transglutaminase inhibitor loaded liposomes: a new approach to the treatment of liver fibrosis 
 
 
142 
6.5.1.2 Production of small unilamellar vesicles incorporating the TG2 inhibitor 
Sonication is one of the common methods of producing homogenous liposomes of 
specific sizes. To generate small unilamellar vesicles (SUV), the MLV suspension 
(prepared as detailed in section 6.5.1.1) was sonicated above Tc using a probe sonicator 
(Soniprep 150, MSE, England) with a titanium probe (exponential micro-probe and 
diameter 3 mm) and frequent intervals of rest (to prevent overheating), The tip of the 
sonicator was slightly immersed in the suspension for a few minutes at an amplitude of 5 
microns to yield a clear suspension of small unilamellar vesicles (Figure 6.7). The 
amount of time required for sonication, varies depending on the lipid composition 
(approximately 2-5 minutes). Subsequent to sonication, the preparations were left to 
stand above the Tc for 30 minutes. 
 
Figure 6. 6 Schematic representation of the preparation of MLV by ‘hand-shaking’ method. Lipids 
and drugs were dissolved in the organic solvents (A) and then evaporated (B); thereafter, dried lipid film 
was hydrated in the aqueous medium (PBS or d.H2O) (C) and finally left to stand for 30 minutes to yield 
vesicles (D). 
 
Figure 6. 7 Preperation of small unilamellar vesicles by sonication of MLV suspension. To generate 
SUV, MLV entrapped with the drug were sonicated at above Tc with frequent intervals of rest using an 
ultrasound probe sonicator. Sonication is one of the common methods of producing homogenous liposomes 
of specific sizes.  
 
6.5.2 Separation of non-incorporated drug from liposome suspension 
In order to utilize liposomes as a controlled release or pharmaceutical dosage form, the 
complete removal of the non-incorporated drug is essential. Various approaches have 
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Figure 6. 8 Schematic representation of 
size-exclusion chromatography. As the 
liposome suspension flows down the 
column, vesicles incorporating fluorescent 
enzyme inhibitor (red balls), are not capable 
to penetrate the gel pores due to the large 
size and are therefore entirely excluded and 
eluted foremost. The free drug (green balls), 
which is smaller in size, is held back as an 
outcome of permeating the particle pores 
and elutes in reverse order of size. 
been taken to remove the non-incorporated drug molecule in a laboratory setting. 
Centrifugation and size exclusion chromatography were applied to separate vesicles from 
the freely floating drug and to quantify the entrapped enzyme inhibitor of liposomes. 
 
6.5.2.1 Size-exclusion chromatography                                                        
Size-exclusion chromatography is a chromatographic method that separates 
liposomes from the free drug molecules due to differences in the molecular 
weight and shapes of drug molecules and vesicles. Size-exclusion 
chromatography was performed on the AKTA Purifier (Amersham 
Biosciences) FPLC system, with a fluorescent detector (Cecil Instruments 
Limited, CE 4500 fluorescence detector) on a Superdex™ 200 10/300 GL 
column from GE Healthcare. PBS was used as the buffer and elution was 
monitored at excitation and emission wavelength 330 and 570 nm. Initially, the 
column was equilibrated with a buffer of the same osmolarity as the medium in 
which the liposomes were prepared and an aliquot of the liposomes was applied 
to the column. The column was eluted with the same buffer and fractions were 
collected (Weiner et al., 1989). The pores of support were of such a range as to 
allow only some of the molecules to enter. As shown in Figure 6.8, while the 
liposome preparation flows down the column, vesicles incorporating 
fluorescent enzyme inhibitor (red balls), are unable 
to enter any of the pores of the gel due to the large 
size and are therefore totally excluded and eluted 
first. The free drug (green balls), which is smaller 
in size, is held back as a consequence of 
permeating the particle pores and elutes in reverse 
order of size (Vemuri and Rhodes, 1995).  
 
Injection of MLV into the chromatographer was not possible due to the large size of the 
liposomes; therefore another approach was applied to effect the separation of the non-
incorporated drug from the liposome mixture.  
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6.5.2.2 Centrifugation 
Centrifugation technique applies centrifugal force to separate the liposome mixture. 
Liposomes sediment when subjected to a centrifugal force at a rate that is dependent on 
their density. More-dense components of the mixture (liposomes) fade away from the 
axis of the centrifuge and precipitate, whilst less-dense components of the mixture (free 
drug) move towards the axis. Large liposomes composed of neutral lipids such as PC can 
be simply pelleted at fairly low g forces in a conventional centrifuge (Weiner et al., 
1989). 
 
Accordingly, subsequent to the preparation of MLV incorporating enzyme inhibitor, each 
sample was examined by retaining small unwashed aliquot and washing the non-
incorporated drug from the liposome suspension by two times centrifugation at 14000 
rpm in a Beckman model J2-21 centrifuge (JA-20 rotor), for 30 minutes at 4 °C 
following centrifugation, the supernatants (containing the free drug) were carefully 
removed and the pellets (containing entrapped or associated drug) were suspended to the 
required volume within the aqueous medium. The same cycle was repeated once more to 
ensure maximum separation of non-incorporated drug from liposome suspension. 
Liposomes were then ruptured by adding isopropranolol (1:1 v/v) to the pellets and mixed 
through vigorous shaking. The mixture incubated for 2-5 minutes at room temperature. 
The drug content in the liposome and supernatant was then analyzed by 
spectrofluorimetry at the corresponding wavelengths (excitation/emission 330/570 nm) as 
previously described. 
 
6.5.3 Characterisation of liposomes 
Methods of characterisation of liposomes instantaneously following production and upon 
storage are required for sufficient quality control of the product. The methods have to be 
reproducible, precise, and rapid in their application in an industrial setting (Vemuri and 
Rhodes, 1995). 
 
6.5.3.1 Determination of the liposome size and polydispersity 
The volume mean diameter (VMD) for all MLV formulations and preparations was 
determined by light scattering based on laser diffraction spectroscopy using Sympatec 
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Helos Compact laser diffraction analyzer (GmbH, Clausthal-Zellerfeld, Germany). An 
appropriate dilution of the sample was made in double-distilled water. Particle size 
distribution (PSD) is presented as X10, X50 and X90-values derived from the cumulative 
volume distribution curves as a function of the particle diameter. These diameters 
correspond to 10 %, 50 % and 90 % of total volume from cumulative percentage 
undersize curves. All measurements were performed at ambient temperature. 
 
The z-average diameter and polydispersity for all SUV formulations and preparations, was 
determined by photon correlation spectroscopy on a ZetaPlus (Brookhaven Instrument 
Corporation, USA) at 25 °C and for the viscosity and refractive index the value of pure 
water was used (0.89 Cp and 1.0, respectively). Liposome samples (50 µl) were diluted to 
2 ml with 0.001M PBS to maintain optimal vesicle count rate and concentration. The 
reported measurements were the average of ten readings. 
 
6.5.3.2 Measuring zeta potential 
Zeta potential which is an indirect measurement of vesicle surface charge (Perrie et al., 
2004) for all liposome formulations and preparations was measured on a ZetaPlus 
(Brookhaven Instrument Corporation, USA) at 25 °C. The technique used was 
microelectrophoresis, where the measured velocity of a particle is said to be proportional 
to the applied electric field. Liposome samples (50 µl) were diluted to 2 ml with 0.001M 
PBS. The zeta potential results were mean averages taken from ten readings made for each 
formulation in triplicate. Control and transfer standard readings were regularly taken and 
logged for particle size (499 ± 5 nm, Brookhaven) and zeta potential (-68 mV ± 6.8, 
Malvern) for the ZetaPlus Brookhaven Instrument.  
 
6.5.3.3 Drug encapsulation studies 
Percent encapsulation is typically defined as the total amount of encapsulant 
encapsulated vesicles versus the total initial input of encapsulant (Edwards and 
Baeumner 2006; Terzano et al., 2005). The extent of drug entrapped in vesicles can be 
determined using the column chromatography technique or other methods such as 
centrifugation. As mentioned previously, the liposome preparations are a mixture of 
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encapsulated and unencapsulated drug fractions (free drug). Therefore, to assess the free 
drug concentration as a first experimental step, the free and encapsulated drug fractions 
were separated.  
 
6.5.3.3.1 Determination of drug entrapment efficiency by column chromatography 
When a separation technique such as size-exclusion chromatography was applied 
(6.5.2.1), the percent encapsulation was described as the ratio of the unencapsulated peak 
area to that of a reference standard of the same initial concentration (Edwards and 
Baeumner, 2006). 
 
6.5.3.3.2 Determination of drug entrapment by centrifugation 
Subsequent to preparation of MLV incorporating enzyme inhibitor and the separation of 
the capsulated and unencapsulated drug by centrifugation, the pellet which contained the 
drug encapsulated liposomes was diluted with the required amount of aqueous medium. 
The encapsulated fraction of the drug was then treated with a detergent (isopropranolol 
1:1 molar ratio), vigorously shaken and incubated for a period at room temperature to 
lyse the liposomes and to completely discharge the drug from the liposomes into the 
surrounding aqueous media. Thus the exposed drug was assayed using 
spectrofluorometry. The drug entrapment was then calculated based on 
fluorometric/spectrometric analysis on a 96 well microtiter plate, using 
spectrofluorometer (Spectra Max Gemini XS) with an excitation maximum of 335 nm 
and an emission peak of 560 nm. Entrapment values of the enzyme inhibitor within 
liposomes were then calculated using the following equations (including any dilutions): 
 
 
 
To ensure reliability of entrapment values, the total recovery of drug was also calculated 
using the following equation (including any dilutions): 
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6.5.4 The effect of salt on the physico-chemical properties of liposomes 
In order to investigate the effect of salt on the physico-chemical properties of liposomes, 
liposomes composed of DSPC: chol: PS in a molar ratio of 12:1:4 or 16:1:0 were formed 
and rehydrated in phosphate buffered saline (pH 7.4), an isotonic buffer often used for in 
vivo studies and sized by sonication method. Their characteristics in terms of size and 
surface charge were measured by photon correlation spectroscopy as previously 
described. 
 
6.5.5 Stability studies in buffer and serum 
The stability of the prepared liposomes was investigated in terms of drug retention, 
particle size and zeta potential. 
 
6.5.5.1 Drug retention 
A principal feature of a successful drug delivery system is that liposomes quantitatively 
maintain their load while circulating (Gregoriadis, 1995). Accordingly, drug entrapment 
within liposome formulations, DSPC: chol: PS in molar ratios of 16:1:0 and 12:1:4, was 
measured as detailed previously. Following separation of the non-incorporated drug from 
the liposome suspension by size-exclusion chromatography, the release rate of the drug 
was determined by incubating drug-incorporated liposomes in PBS: FBS 50:50 (v/v) 
composition at 37 °C in a shaking (constant) water bath (80 rpm) at pre-set time intervals 
(0, 30, 60 and 120 minutes). At each time point, the amount of drug released was 
subsequently quantified by removing the required quantity of sample, diluting it with PBS 
as appropriate and loading it on to the column. The results were reported as the percentage 
of drug leakage from vesicles following 2 hour incubation in PBS (37 °C, pH 7.4). 
 
6.5.5.2 Liposome stability: Particle size and zeta potential  
Liposome formulations were prepared as detailed in section 6.4.1 and incubated in PBS or 
PBS: FBS 50:50 (v/v) composition in a gently shaking water bath (37 °C, 80 rpm). At 
various time points (0, 30, 60 and 120 minutes), the required quantity of sample was 
removed and subsequently the average diameter and surface charge of the liposomes were 
measured via the technique of dynamic light scattering using a ZetaPlus analyzer. 
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6.5.6 Bio-distribution of liposomes loaded with the enzyme inhibitor in mice 
Bio-distribution of liposome-encapsulated enzyme inhibitor was monitored using H3 
labelled cholesterol in the formulations as a marker. SUV were prepared using the lipid-
film hydration method previously described. In brief, weighed amounts of DSPC, 
cholesterol and PS in molar ratios of 16:1:0 or 12:1:4, in addition to the TG2 inhibitor (60 
µg/ml) and the required amount of H3 labelled cholesterol were dissolved in 
chloroform/methanol (9:1, by volume). To avoid the self-association of cholesterol in 
aqueous medium, the concentration of cholesterol was kept under the critical micelle 
concentration (25 - 40 nM at 25°) (Haberland and Reynolds, 1973). The organic solvent 
was them removed by a roto-evaporator followed by flushing with N2 to form a thin lipid 
film on the bottom of a round-bottomed flask. The lipid film was then hydrated in PBS 
(pH 7.4). The size of produced MLVs was reduced by sonictaion for about 30 second or 5 
minutes. The diameter of the liposome preparations used was approximately 100 nm with 
a polydispersity coefficient of not larger than 0.2 for neutral and anionic liposomes, or 500 
nm with a polydispersity coefficient of not larger than 0.3 for anionic liposomes. The 
liposomal surface was not modified in any way, hence relying on the inherent affinity of 
PC and DSPC for the liver.  
 
Experimentation strictly adhered to the 1986 Scientific Procedures Act (UK). All 
protocols have been subject to ethical review and were performed in a designated 
establishment. All the animals were housed appropriately and given a standard mouse diet 
ad-libitum.  
 
Male Outbred mice with an average body weight of 40 grams were kept one to each cage. 
They were housed in an animal room with a 12 hour light/ 12 hour dark cycle, a 
temperature 19 ± 23˚C, and a relative humidity of 55 ± 15 %. A dose of the liposomes 
incorporating drug was given by intravenous injection (I.V.) into the tail vein of 3 mice in 
each group at preset time intervals (10, 30, 60 and 120 minutes). The volume of substance 
injected was 100 µl, containing 0.4 µmole of lipid and 200 kBq radioactivity (52 ng 
cholesterol). Blood samples were collected via cardiac puncture. The mice were then 
humanely terminated and organs including the liver, lungs, kidneys and spleen were 
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removed for further investigation. All of the samples were weighed into plastic 
scintillation vials, to which one and a half milliliter SOLVABLE™ (solubilising agent) 
was added. The vials were heated to 50 ºC with frequent agitation of the tubes to enhance 
Solvable™ tissues penetration. Completely digested tissue samples were then bleached 
using 200 µl hydrogen peroxide followed by the addition of 10 ml Ultima Gold for H3 
quantification and the radioactivities were determined in a Packard Tri-Carb model 1600 
TR liquid scintillation counter (Packard Instrument Co., Meriden, CT). 
 
6.6 Results and discussion 
6.6.1 Liposomal characteristics 
Manipulation of liposomal physical and chemical characteristics may cause alterations in 
cellular affinity and in the organ disposition of liposomes. Therefore, the characteristics 
of liposomes in terms of size, surface charge and drug loading were initially investigated 
in order to determine the most suitable formulations that would provide the optimal 
mixture of properties for liver targeting. The range of liposome formulations prepared in 
this study is summarized in Table 6.2. 
 
Table 6.2 Summary of the range of liposomes formulations prepared in this study, the charge of the 
liposome, the total molar ratio and their corresponding molar ratios of the individual components. 
 
6.6.1.1 Characteristics of the TG2 inhibitor incorporated multi-lamellar vesicles  
The average size and size distribution of liposomes are essential parameters when the 
liposomes are intended for therapeutic use, particularly if they are administered by 
inhalation or the parenteral route (Vemuri et al., 1990). Moreover, a major physical 
characteristic of liposomes concerns the polydispersity of the suspensions (Grabielle-
Madelmont et al., 2003). Therefore, the series of liposome formulations prepared were 
Formulation Liposome 
charge 
The total 
molar ratio 
PC 
(µmole) 
 
DSPC 
(µmole) 
 
PS 
(µmole) 
 
Chol 
(µmole) 
 
PC: chol Neutral 17 16 - - 1 
DSPC: chol Neutral 17 16 - - 1 
         PC: chol: PS Anionic 17 12 - 4 1 
DSPC: chol: PS Anionic 17 - 12 4 1 
PC: chol: PS Anionic 17 8 - 8 1 
DSPC: chol: PS Anionic 17 - 8 8 1 
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initially characterised in terms of volume mean diameter (VMD) and particle size 
distribution (PSD). The PSDs are presented as X10, X50 and X90-values from cumulative 
undersize curves.  
 
Figure 6. 9 Volume mean diameter (VMD) and particle size distributions (PSD) of various TG2 
incorporated multi-lamellar vesicle formulations. The vesicles were prepared in d.H2O and analysed 
prior to centrifugation, at 25 °C using a Sympatec Helos. The particle size distributions are presented as 
X10, X50 and X90-values from cumulative undersize curves. Upon the incorporation of the charged lipid, 
there was a slight decrease in the z-average diameter of the liposomes. A two fold increase in the amount of 
charged lipids in the formulation resulted in a further decrease in the surface charge of anionic liposomes. 
Values denote mean ± SD from three experiments.  
 
As is evident from Figure 6.9, there was no significant difference between the X10 of all 
the formulations (~ 3-5 µm). The X50 of the anionic formulations with 12:1:4 molar ratio 
were slightly higher when compared to the X50 of the neutral preparations (with 16:1 
molar ratio) and the anionic formulations containing higher level of PS (PC: chol: PS and 
DSPC: chol: PS 8:1:8).
 
However this trend changed when considering the X90 with the 
neutral formulations, being significantly larger in size compared to anionic formulations 
(P ≤ 0.05, ANOVA).  
 
All vesicles had a volume mean diameter (VMD) in the range of about 12-17 µm. There 
was no considerable disparity (P ≥ 0.05, ANOVA) when the VMD was considered 
amongst the anionic formulations with the same molar ratio or between the two neutral 
formulations with the same molar ratio, regardless of the lipid type and the lipid 
concentration used, suggesting that the substitution of PC lipid with DSPC lipid (a longer 
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alkyl chain lipid) had no major effect on the size of multi lamellar vesicles for all the 
formulations tested (Figure 6.9). However, there was a trend of reduction in the VMD of 
the liposomes, upon the incorporation of PS to the formulations. The inclusion of small 
quantity of a negatively charged lipid such as PS in the formulation may be due to the PS 
reducing the probability of vesicular aggregation following the formation of vesicles 
leading to a reduction in the size of charged vesicles (Weiner et al., 1989; Vemuri and 
Rhodes, 1995). This is supported by the major reduction in the X90 particle sizes 
measured with the anionic formulations. For the same reason, a two fold increase in the 
amount of charged lipids in the formulation resulted in a further decrease in the surface 
charge of anionic liposomes (P ≤ 0.05, ANOVA). 
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Figure 6. 10 Zeta potential (mV) of various TG2 incorporated multi-lamellar vesicle formulations. 
The vesicles prepared in d.H2O and analysed prior to centrifugation, at 25 °C using a Brookhaven ZetaPlus. 
The inclusion of a charged lipid (PS) into the formulations has a remarkable effect on zeta potential values. 
In consequence, the surface charge was dropped significantly. Values denote mean ± SD from three 
experiments. 
 
With regard to the neutral liposomes, the formulation containing PC had a zeta potential 
in the range of -6.6 mV ± 1.78. Replacement of PC lipid with DSPC lipid yielded a slight 
increase in the zeta potential values of the liposomes (0.64 mV ± 1.69) (Figure 6.10). 
However, regarding the anionic liposomes, all the formulations containing DSPC 
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demonstrated a greater negative surface charge when compared to the liposomes 
containing PC with the same molar ratio. The inclusion of 4 µmole PS, significantly (P ≤ 
0.01, ANOVA) reduced the zeta potential as expected due to its anionic nature. An 
additional increase in the amount of charged lipids in the formulation by 2-fold resulted 
in a further decrease in the measured zeta potential of anionic liposomes (P ≤ 0.05, 
ANOVA) as would be expected.  
 
6.6.1.2 Characteristics of the TG2 inhibitor incorporated small unilamellar vesicles  
6.6.1.2.1 Particle size and zeta potential of SUV 
The influence of lipid alkyl chain length and charged liposomes on z-average diameter 
and zeta potential of various formulations of SUV was investigated. The findings in terms 
of the resultant liposomes size, polydispersity and zeta potential are shown in Figures 
6.11 and 6.12. 
 
Figure 6. 11 Particle size (nm) and polydispersity of various small unilamellar vesicle formulations. 
Particle size distribution was measured following 2 minutes sonication in d.H2O, at 25 °C using a 
Brookhaven ZetaPlus. The integration of a negatively charged lipid such as PS into the formulations has a 
significant effect on the vesicle size of liposomes. The substitution of PC lipid by a longer alkyl chain lipid 
such as DSPC in the anionic and neutral preparations had no substantial effect on the size of vesicles. The 
polydispersity index for the size distribution of the entire neutral and anionic vesicle was consistently in the 
proximity of 0.2. The addition of the TG2 inhibitor into the formulations, the average size of the vesicles 
and the zeta potential decrease marginally, conversely the polydispersity index remained approximately the 
same. The data are expressed as means ± standard deviation of three independent experiments. 
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Figure 6. 12 Zeta potential (mV) of various small unilamellar vesicles formulations. Particle size 
distribution was measured following 2 minutes sonication in d.H20, at 25 °C using a Brookhaven ZetaPlus. 
The integration of a negatively charged lipid such as PS into the formulations has a significant effect on the 
surface charge of liposomes. The zeta potential of the anionic formulations incorporating DSPC lipid was 
slightly lower than their PC counterparts which can be due to the slightly negative nature of DSPC lipid. 
The data are expressed as means ± standard deviation of three independent experiments. 
 
According to Figures 6.11 and 6.12, the neutral liposomes exhibited an average particle 
size of ~ 200 nm and an average zeta potential of ~ -5 to +5 mV, whereas the anionic 
liposomes showed an average size of ~ 100 nm and an average zeta potential from ~ -40 
to -50 mV. The polydispersity index (the measurement of homogeneity of dispersion) for 
the size distribution of the entire neutral and anionic vesicle was consistently in the 
proximity of 0.2.  
 
In general, there was no significant difference (P ≥ 0.05, ANOVA) in the size of SUV 
when comparing between the four anionic formulations or between the two zwitterionic 
formulations (Figure 6.11). Hence the substitution of PC lipid with a longer alkyl chain 
lipid such as DSPC (C18 alkyl chain length) in any of the formulations tested had no 
significant effect on the size or polydispersity of vesicles.  
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Similarly, there was no difference in zeta potential between the zwitterionic formulations 
or between the various anionic formulations with all formulations containing PS being 
negatively charged. However, the difference in the zeta potential between the anionic and 
neutral liposomes was highly significant (P ≤ 0.01, ANOVA) (Figure 6.12) as would be 
expected. These findings confirmed the results obtained upon measuring the zeta 
potential of MLV integrating the TG2 inhibitor, which was approximately the same as the 
TG2 inhibitor integrated SUV. Consequently, sonication time does not have any impact 
on the surface charge of vesicles (Labhasetwar et al., 1994). 
 
Upon the incorporation of PS lipid into the formulations (4 µmole), there was a major 
decrease in the vesicle size (from a range of 200 nm to a range of 100 nm), and a 
substantial decline in the zeta potential as would be expected (from 1.51 ± 5.20 mV to ~ 
48.74 ± 1.76 mV for DSPC incorporated liposomes and from -5.82 ± 0.92 mV to 41.85 ± 
1.32 mV for PC incorporated liposomes). These results confirm that the integration of a 
negatively charged lipid (PS) into the SUV formulations similar to the MLV formulations 
has a significant effect on both the size and zeta potential of the SUV liposomes. It can be 
concluded that regardless of liposome preparation, neutral liposomes produced larger 
complexes than anionic liposomes and the difference between the two was extremely 
significant (P ≤ 0.01, ANOVA). However increasing the amount of PS added has no 
significant impact when considering the concentrations tested: increasing the PS content 
two-fold only slightly decreased vesicle sizes (from 135.13 ± 2.14 nm to 112.84 ± 11.67 
nm for the liposomes incorporating DSPC and from 124.73 ± 3.08 nm to 119.43 ± 2.11 
nm for the liposomes incorporating PC) and did not significantly influence the zeta 
potential of the formulations. This may be an outcome of the presence of a charged 
moiety in the lipid formulation which reduces the probability of vesicular aggregation 
following the formation of vesicles, thus leading to a reduction in the size of the charged 
vesicles. 
 
The addition of the TG2 inhibitor made no significant difference to the size or zeta 
potential of the formulations tested (Figure 6.11 & 6.12). The TG2 inhibitor investigated 
in this study was neutral in charge. As a result, it can be stated that the integration of 
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AM2/169 into the liposome formulations had no substantial effect on the physico-
chemical property of the liposomes. 
 
Previous studies have reported that the incorporation of charged lipids in the liposome 
formulation resulted in an increase in drug loading and the size of vesicles. The rise in 
vesicle size may be attributed to the increased drug loading in response to the presence of 
a charged lipid rather than a direct outcome of the presence of charged lipid within the 
liposome formulation alone (Mohammed et al., 2004).  
 
6.6.1.2.2 Encapsulation efficiency 
Liposomal encapsulation has been shown to have a considerable effect on the 
pharmacokinetics and tissue distribution of the administered drugs (Ranade, 1989). 
Therefore, drug entrapment within the system is a key consideration. Consequently, the 
percent encapsulation of the enzyme inhibitor in SUV was investigated and the effect of 
lipid alkyl chain length and charged liposomes on the enzyme inhibitor encapsulation was 
studied on various liposomal formulations.  
 
As shown in Figure 6.13, the measured entrapment efficiency was ~ 70 % for the neutral 
formulations with no significant difference between the PC and DSPC formulations (PC: 
Chol vs DSPC: Chol). The integration of 4 µMoles PS, into the liposome preparations 
made no significant changes to the formulations containing DSPC. However, the drug 
entrapment reduced significantly from 75 % to 45 % for the formulations containing PC. 
Upon a two-fold increase in the amount of PS (to 8 µMoles), there was no significant 
further reduction for PC and DSPC composing liposomes on the TG2 inhibitor 
incorporation. The presence of negatively charged lipids such as PS, PI, or PG has a 
tendency to increase the interlamellar distance between successive bi-layers and thus 
enhance the encapsulation efficiency (Vemuri and Rhodes, 1995). However given that the 
TG2 inhibitor should be incorporated within the bilayer it is unlikely this would have an 
effect on its incorporation. It has also been previously shown by other researchers that 
(Gregoriadis et al., 1973; Mohammed et al., 2004) longer alkyl chain lipids such as DSPC 
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could augment the drug loading due to the increased hydrophobic area within the 
liposome bi-layer. 
 
Figure 6. 13 Percentage of drug entrapment for various liposomal formulations using size-exclusion 
chromatography. The highest percentage of entrapment efficiency was ~70 % for the formulation 
amalgamating DSPC, cholesterol and PS lipid at a molar ratio of 12:1:4. The data are expressed as means ± 
standard deviation of three independent experiments. 
 
6.6.2 The formulation of choice for further in vivo studies  
In view of the micro-anatomy of the liver and previous work by other researchers, the 
liposomes selected for the bio-distribution studies were of small unilamellar vesicles and 
negatively charged to allow free passage through the endothelial fenestrations and fast 
removal. As discussed earlier, it has been established that liposome membranes 
consisting of phospholipids with long hydrogenated fatty acid esters such as DSPC are 
more rigid and display a tighter film packing compared to membranes consisting of 
phospholipids composed of fatty acids of different length and saturation such as PC. 
Thus, these liposome membranes are more stable resisting lipid exchange by serum 
proteins such as HDL. Additionally, using phospholipids such as DSPC with a phase 
transition temperature higher than body temperature (55 ˚C) makes the liposome bi-layer 
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membrane less fluid and consequently less leaky and more stable in physiological fluid 
(37˚C) (Gregoriadis, 1995; Gabizon and Papahadjopoulos, 1988; Patel, 1992; Devine et 
al., 1994; Yu and Lin, 1997). The drug loading studies in Figure 6.14 also demonstrate 
that the substitution of PC with DSPC produced drug loading equal to or higher than PC, 
thus taken together, these results indicated that DSPC could be a more effective lipid than 
PC within the liposome formulations for in vivo studies. Therefore, DSPC: Chol (16:1) 
and DSPC: Chol: PS (12:1:4) were selected as formulations of choice for further bio-
distribution investigations. 
 
6.6.3 The effect of salt on the physico-chemical properties of liposome 
In bio-distribution research, buffer solutions are utilised to keep pH at a nearly constant 
value. Furthermore, the osmolarity and ion concentrations of the solution usually match 
those of the human body (isotonic). Accordingly, phosphate buffer solution (PBS) was 
selected as the buffer of choice to proceed with.  
 
To investigate the effect of salts on physico-chemical properties of anionic and neutral 
liposomes, formulations were produces in PBS (often used as isotonic buffer for in vivo 
studies). Comparisons were then made against the previously obtained results from 
section 6.6.1.2.1. Regardless of the liposome surface charge, the rehydration media (PBS 
or d.H2O) was shown to influence both the size and zeta potential of all the formulations 
tested. Rehydration in PBS resulted in a slightly decreased zeta potential compared to 
d.H2O, decreasing from 1.51 ± 5.20 mV to -6.48 ± 3.52 mV for neutral liposomes and 
slightly increased from -49.99 ± 3.86 mV to -44.13 ± 2.35 mV for anionic liposomes 
(Table 6.3). This could be attributed to an increase in electrolyte concentration resulting 
in condensation of the double layer.  
 
In terms of the particle size, formulations in PBS yielded notably greater size than those 
produced in d.H2O (P ≤ 0.05, ANOVA), irrespective of the liposome charge. There was 
about two-fold rise for the neutral formulation and about three-fold rise for the anionic 
ones. 
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Furthermore, the polydispersity index (the measurement of homogeneity of dispersion) 
for the size distribution of liposomal formulations rehydrated in PBS (~ 0.3) was 
considerably higher than that of the formulations hydrated in distilled H2O (~ 0.2), 
suggesting that the substitution of PBS with d.H2O as rehydration media produces a less 
homogenous liposome suspension (Table 6.3).  
 
Table 6.3 The effect of various hydration media (PBS and d.H2O) on characteristics of the TG2 
inhibitor integrated small unilamellar vesicles (neutral and anionic) on the physicochemical 
characteristics. The data are expressed as means ± standard deviation of three independent experiments. 
 
 
  Formulation 
 
PBS 
 
d.H2O 
 
 
Size (nm) ± 
SD 
 
PD ± SD 
 
Zeta potential 
(mV) ± SD 
 
Size (nm) ± SD 
 
PD ±  SD 
 
Zeta potential 
(mV) ± SD 
 
DSPC: Chol 
(16:1) 
 
524.7 ±  65.8 
 
0.38  ±  0.01 
 
-6.48  ±  3.52 
 
231.25 ±  32.31 
 
0.28 ± 0.00 
 
1.51  ±  5.20 
 
DSPC: Chol: PS 
(12:1:4) 
 
418.5 ±  33.4 
 
0.30  ±  0.02 
 
-44.13  ±  2.35 
 
139.88  ±  3.68 
 
0.22  ±  0.02 
 
-49.99  ±  3.86 
 
6.6.4 The influence of sonication time on physico-chemical characteristics of neutral 
and anionic liposomes 
The influence of sonication time on z-average diameter, polydispersity and zeta potential 
of neutral and anionic liposomes within DSPC based SUV prepared in PBS was also 
investigated. Liposomes were formulated using DSPC (12 µmol or 16 µmole), cholesterol 
(1 µmol) and with or devoid of 4 µmol of the negatively charged PS. 
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Figure 6. 14 The influence of sonication time on z-average diameter and polydispersity of the neutral 
liposomes. Liposomes were composed of DSPC: Chol at 16:1 molar ratio, with a requisite amount of 
enzyme inhibitor were formed in PBS and sonicated. Samples were then taken at various time points (1, 2, 
3, 4 and 5 minutes). Upon increasing the sonication time, the size and polydispersity of the vesicles were 
considerably decreased. The polydispersity of the vesicles after 5 minutes sonication was in the proximity 
of 0.2, which is characteristic of such liposome based samples. Results denote mean ± SD, n = 3.  
 
 
Figure 6. 15 The influence of sonication time on zeta potential of the neutral liposomes. Liposomes 
were composed of DSPC: Chol at 16:1 molar ratio, with a requisite amount of enzyme inhibitor were 
formed in PBS and sonicated. Samples were then taken at various time points (1, 2, 3, 4 and 5 minutes). In 
contrast to the particles size diameter, the zeta potential values remained constant for the duration of 
sonication. Results denote mean ± SD, n = 3. 
 
To optimize the formulation of SUV for the identified formulations, the effect of 
sonication time on z-average diameter, polydispersity and zeta potential of the TG2 
incorporated liposomes composed of DSPC: Chol at 16:1 molar ratio formed in PBS was 
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investigated at a fixed frequency of 5 amplitude for 1, 2, 4 and 5 minutes and displayed in 
Figures 6.14 and 6.15. The particle size and polydispersity index of the vesicles 
demonstrated a progressive decline with an increase in the time of sonication as was 
expected. In terms of the particle size, vesicles were shown to reduce in size, from ~1400 
nm to ~190 nm and in polydispersity index from ~ 0.5 to ~ 0.2. This decrease in particle 
size was extremely significant (P < 0.01, ANOVA). In term of surface charge, there was 
no substantial alteration (P > 0.05, ANOVA) during the sonication time and the zeta 
potential remained at around ~ – 4 mV in all cases (Figure 6.15).  
 
Figure 6.16 The influence of sonication time on z-average diameter and polydisperisty of anionic 
liposomes. Liposomes composed of DSPC: Chol: PS at 12:1: 4 molar ratio, with a requisite amount of 
enzyme inhibitor were formed in PBS and sonicated. Samples were then taken at various time points (1, 2, 
3, 4 and 5 minutes). Upon increasing the sonication time, the size and polydispersity of the vesicles were 
considerably decreased. Contrariwise, in the case of surface charge, there was no substantial change (P > 
0.05, ANOVA) during the sonication time. Results denote mean ± SD, n = 3. 
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Figure 6. 17 The influence of sonication time on zeta potential of anionic liposomes. Liposomes 
composed of DSPC: Chol: PS at 12:1:4 molar ratio, with a requisite amount of enzyme inhibitor were 
formed in PBS and sonicated. Samples were then taken at various time points (1, 2, 3, 4 and 5 minutes). 
The same trend as with the neutral liposomes was observed. Once again, with the increased sonication time, 
both the polydispersity and particle size of the liposomes were significantly reduced. In contrast to the 
particles size diameter, the zeta potential values remained constant for the duration of sonication. Results 
denote mean ± SD, n = 3. 
 
The incorporation of PS lipid into the formulation and preparation of anionic liposomes, 
demonstrated the same trend as with the neutral liposomes. Once again with the increased 
sonication time, the polydispersity and particle size of the liposomes were significantly 
reduced (P < 0.01, ANOVA) from 0.34 ± 0.025 to 0.21 ± 0.024 and from 1004.4 ± 78.2 
nm to 134.9 ± 0.6 nm respectively. The zeta potential values remained constant for the 
duration of sonication at around -45.03  ±  2.95 mV (P > 0.05, ANOVA), implying that 
irrespective of the liposome composition, the sonication time has no influence on the zeta 
potential of vesicles (Figures 6.16 and 6.17) (Labhasetwar et al., 1994). 
 
6.6.5 Stability studies in serum 
Stability in serum is one of the important parameters of liposome construction which can 
be affected by fatty acid chain length, saturation state of the phospholipids and the 
existence of cholesterol. Liposome stability depends on four categories of physical 
processes: loss of bi-layer components caused by desorption, loss of entrapped material 
caused by leakage, vesicle fusion, and vesicle aggregation. The fusion and aggregation of 
liposomes will result in alterations in liposome size distribution (Wu et al., 2003). 
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Accordingly, the stability of the liposome formulations was assessed by determining the 
quantity of drug retained within the liposomes, vesicle aggregation and any alterations in 
physicochemical characteristics (particle size and surface charge).  
 
6.6.5.1 Liposome stability: drug retention  
The ultimate efficacy of a liposomal dosage form will be judged on the ability of the 
formulator to reliably control the amount of free drug that reaches the site of action over a 
given period of time (Wiener et al., 1989, Gregoriadis, 1995). Previous work by other 
researchers has indicated that the drug retention for liposomes prepared from DSPC lipid 
is higher than that of liposomes produced from PC lipids. It is recognized that the ability 
of liposomes to retain drug during incubation in PBS at 37 °C could be affected by the 
lipid chain length and subsequently the lipid phase transition temperature (Senior and 
Gregoriadis, 1982). Alkyl hydrocarbon chain length is one of several factors which 
directly affect the phase transition temperature. As the hydrocarbon chain length is 
increased, van der Waals’ interactions between the lipid chains get stronger, thus 
requiring more energy to disrupt the stable lipid bi-layer, and consequently the phase 
transition temperature increases. Therefore at 37 °C, PC liposomes (Tc = 0 °C) will be in 
the fluid state resulting in increased drug loss compared with a higher transition 
temperature lipid, such as DSPC (Tc = 55 °C), that will be in the ordered gel phase and 
retain a stable bi-layer (Mohammed et al., 2004). As a consequence these stable and 
strong bi-layers decrease the efflux of drugs from liposomes and thus impede the ability 
of these liposomes to retain drug during incubation (Massing and Fuxius 2000). 
Additionally, studies have shown that excess cholesterol in certain types of liposomes 
greatly improves bi-layer stability in the presence of blood and reduces their permeability 
(Gregoriadis, 1979). The inclusion of cholesterol impedes the diffusion of water deep into 
the lipid membrane, hence enhancing liposome stability by reducing hydrolytic 
degradation (Simon and McIntosh, 1986). Accordingly, the drug retention within the 
liposome bilayer was investigated for the two of the formulations tested in vivo; DSPC: 
Chol: PS in a molar ratio of 16:1:0 and 12:1:4 formed in PBS, for a period of 2 hours. 
According to the results, liposomes did not exhibit significant leakage of entrapped 
contents for the formulations tested. The percentage of drug leakage for the anionic 
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formulation was measured at 19.5 % ± 3.53 and the neutral formulation was measured at 
23 % ± 0.70. The discrepancy in drug retention between anionic and neutral liposomes 
found in this study is not in accordance with the study by Mohammed et al. (2004), in 
which the addition of charged lipids to the liposome formulation resulted in increased 
drug release, signifying that the presence of charged lipids within the liposome bi-layer 
increased the permeability of the bi-layer or lipid drug binding.  
 
6.6.5.2 Liposome stability: vesicle size and zeta potential studies 
As previously discussed, using phospholipids such as DSPC with long hydrogenated fatty 
acid esters and a phase transition temperature higher than body temperature (55 ˚C) makes 
the liposome bi-layer membrane more rigid and demonstrates a tighter film packing in 
physiological fluid (37 ˚C) compared with membranes consisting of PC with shorter and 
less saturated hydrogenated fatty acid esters. As a consequence, these liposome 
membranes are more resistant to lipid exchange by serum proteins such as HDL. In view 
of this, particle size and surface charge of the two liposome formulations (DSPC: Chol 
and DSPC: Chol: PS in a molar ratio of 16:1 and 12:1:4 respectively) were measured over 
intervals of 2 hours incubation in PBS or PBS: FBS 50:50 (v/v) in a shaking water bath 
(37 °C, 80 rpm) at various time points (0, 30, 60 and 120 minutes). 
 
The liposome formulations developed for intravenous administrations should demonstrate 
no sign of aggregation in serum, for reasons of safety and to ensure their ability to cross 
the fenestrations of liver endothelium (Longmuir et al, 2006). According to Figures 6.18 
and 6.19, the formulations tested remained relatively stable in PBS with regard to size and 
zeta potential during the observation period; however, these characteristics modified 
notably when placed in serum. A significant preliminary increase in liposome size (vesicle 
aggregation) from ~ 170 nm to ~ 340 nm for the neutral formulation and from ~ 140 nm to 
~ 320 nm for the anionic formulation was observed in serum. Subsequent to the initial 
increase, the size of liposomes remained constant for the remainder of testing intervals for 
both formulations tested. Regarding the surface charge, an apparently common trend was 
that with an increase in incubation time in serum, the surface charge decreased gradually 
from the range of about -5 mV to about -20 mV for neutral liposomes and changed from 
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the range of about -40 mV to about -30 mV for anionic liposomes. The anionic lipid is not 
adding any protection against the effect of plasma with both types of formations 
interacting with plasma. 
 
 
 
Figure 6. 18 Vesicle stability (size and zeta potential) of the neutral liposomes in serum. Liposomes 
were composed of DSPC: Chol (16:1) incubated in PBS or PBS: FBS 50:50 (v/v) in a gently shaking water 
bath (37 °C, 80 rpm) at various time points (0, 30, 60 and 120 minutes). The formulations tested remained 
relatively stable in PBS with regard to the size and zeta potential during the observation period. However, 
these characteristics changed notably when placed in serum. The data are expressed as means ± standard 
deviation of three independent experiments. 
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Figure 6. 19 Vesicle stability (size and zeta potential) of the anionic liposomes in serum. The liposomes 
were composed of DSPC: Chol: PS (12:1:4) incubated in PBS or PBS: FBS 50:50 (v/v) in a gently shaking 
water bath (37 °C, 80 rpm) at various time points (0, 30, 60 and 120 minutes). The formulations tested 
remained relatively stable in PBS with regard to the size and zeta potential during the observation period. 
However, these characteristics changed notably when placed in serum. The data are expressed as means ± 
standard deviation of three independent experiments. 
 
6.6.6 Bio-distribution studies of the liposome-TG2 inhibitor system in mice 
Given liposomes could be formulated to incorporate the TG2 inhibitor, the next stage was 
to investigate their bio-distribution in vivo to assess their ability to deliver the drug target 
to the liver target site. Liposome composed of DSPC: chol: PS in a molar ratio of 16:1:0 
with a mean particle size of 100 nm or 12:1:4 with a mean particle size of 100 nm or 500 
nm used as drug carrier systems. To study the organ distribution of the liposome-TG2 
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inhibitor system subsequent to I.V. injection in mice, various types of organs were 
isolated and analyzed for radioactivity as described in the Material & Method section. 
 
Figurer 6.20 a-c illustrates the percentage of organ distribution of the liposomes-TG2 
inhibitor system at various time points following I.V. injection. On a per organ basis, the 
uptake of the liposomal-drug delivery system by the liver was significantly higher (P < 
0.01, ANOVA), than that taken up by other organs at all time points measured, 
independent of the formulation used. The percentage dose per organ for the liver was 
about 10 % to 18 % for the neutral formulation, about 4 % to 12 % for the anionic 
formulation with an average vesicle diameter of 500 nm and about 10 % to 18 % for the 
anionic formulation with an average vesicle diameter of 100 nm. Following the liver, the 
spleen demonstrated a higher liposome distribution amongst organs tested (P < 0.05, 
ANOVA). The dose percentage per spleen was at approximately of 1.30 %, 0.4 % and 
0.96 % for the neutral preparation, anionic formulation with large and small vesicle size 
respectively. The inherent affinity of the liposomes for the liver is due to its being the 
largest internal organ in the body and Kupffer cells in the liver are part of the reticular 
endothelial system (Wu et al., 2003). Moreover, fenestrated capillaries in the liver and 
spleen could be another cause of liposome concentration in these organs following 
intravenous injection (Terwogt et al., 1999).  
 
The liposomes with a mean particle size of 100 nm demonstrated a significantly higher 
concentration in the liver and spleen when compared with the liposomes of a larger 
particle size (500 nm), in terms of dose percent. These results are not in clear agreement 
with previous studies and suggest a higher uptake of small liposomes compared with 
larger liposomes, by the RES system. However, this could be attributed to the narrow 
range of vesicle size in the anionic formulations. 
 
The uptake of negatively charged liposomes by the liver was not greater than that of 
neutral liposomes. As previously mentioned, the addition of negatively charged lipids 
(PS) increases the process of opsonization and thus the uptake by MPS-cells (Massing 
and Fuxius, 2000). The exposure of negatively charged lipid is thought to serve as a 
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signal for the removal of liposomes (Huong et al., 2001). Liposomes composed of DSPC 
have a relatively negative nature in PBS (~ -5 mV), the incubation of these liposomes in 
plasma affects the zeta potential and yields a higher negative charge (~ -20 mV). 
Therefore, these liposomes would not be considered to be neutral in the physiologic fluid 
and there would be less difference between the charges of the two formulations tested. 
This could account for the same level of organ uptake in neutral liposomes and in 
negatively charged ones.  
 
The distribution of the liposomes in the kidney was insignificant for all the formulations 
tested (~ 0 %; Figure 6.18). The liposome accumulation in the lung was only detectable 
for the larger (500 nm) liposome (~ 1.85 %), suggesting that the larger sizes are filtered 
our rapidly in the lung capillaries. Due to the destabilization of liposomes in blood 
circulation and consequent rapid clearance of from the blood, only negligible amounts of 
radioactivity were found in the plasma at any time point subsequent to injection (results 
are not presented). 
 
There was no apparent trend regarding the uptake of liposomes at different time points 
for any of the organs; this could be a result of employing short time points in the study.  
 
Lack of significant differences in organ concentration of the three liposome formulations 
was most likely due to the same Tc of the lipids and a narrow range of vesicle size. These 
results suggest that the vesicle size could be one of the important factors affecting the fate 
of liposomes in vivo, but only with regards to a much wider size distribution than chosen 
for this study. However, there must clearly be a minimum size for the effective uptake of 
liposomes by RES. If they are below the minimum effective uptake size, the liposomes 
will most likely remain in higher concentration in circulation. In terms of future work, in 
order to investigate the effect of particle size on organ distribution of liposomes, a 
broader range of vesicle size and longer time points are recommended. 
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Figure 6. 20 Organ distribution of the liposomes-TG2 inhibitor system in mice at various time points following I.V. injection. Liposome were composed 
of DSPC: chol: PS in a molar ratio of 16:1:0 with a mean particle size of 100 nm (a) or 12:1:4 with a mean particle size of 100 nm (b) or 500 nm (c) used as drug 
carrier systems. Bio-distribution of liposome-encapsulated enzyme inhibitor was monitored using H3 labeled cholesterol in the formulations as a marker. The 
uptake of liposomes by the liver was considerably higher than for other organs due to the inherent affinity of liposomes for the liver. Values denote mean ± SD 
(n=3). 
a b 
c 
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6.6.7 Conclusion  
The presented results within this chapter indicate that the group of TG inhibitors used can 
be successfully incorporated into designed liposomes and delivered to the liver with very 
little distribution to the organs tested in this study. Upon I.V. administration of the TG 
inhibitor incorporated liposomes, the liver demonstrated relatively higher liposome 
distribution amongst all the organs tested. Therefore, liposomes can potentially be 
employed as a carrier system for site-specific delivery of this group of TG inhibitors into 
the liver, offering a potential new strategy for treating liver fibrosis and its end stage 
disease cirrhosis. 
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7.1 Summary and Implications of Research Findings 
The aim of this thesis was to investigate the therapeutic potential of a novel group of 
inhibitors of the enzyme TG for the treatment of catheter related complications such 
as bacterial infection and thrombosis, in addition to fibrotic diseases characterised by 
increased ECM deposition and cross linking such as liver fibrosis. 
 
The low molecular weight, non-toxic FXIIIa inhibitors could prevent stabilisation of 
blood clots by inhibiting fibrin stabilisation by FXIIIa and consequently increase 
thrombolysis. Furthermore, they could reduce colonisation of catheters by 
staphylococci by inhibiting their FXIIIa dependant cross-linking to host proteins 
(fibrin and fibronectin) on the central venous catheter surface, preventing the release 
of bacteria into the blood where they would be susceptible to antibiotic action and 
host defences. The first part of this research was focused on incorporating of the 
FXIIIa inhibitor into catheters and other medical devices with the aim of prevention of 
thrombus formation and reduction in the associated incidence of bacterial infection. 
However, the release of FXIIIa inhibitor as a low soluble drug from the matrix 
systems is considered to be challenging. Therefore, various approaches were 
employed to improve its release profile from various systems. Silicone and 
polyurethane (PU) central venous catheters are amongst the most widely used central 
venous catheters in intensive care and in general medical wards. The FXIIIa inhibitor 
was incorporated into the polymer base coating of the PU strips. Optimum release of 
the FXIIIa inhibitor from the polyurethane catheters could be achieved by employing 
a blend solution of polymers for coating. It was deemed that utilization of the polymer 
blend (PVP and PLGA) for coating of the PU strips increased the amount of drug 
release significantly. With regard to silicone central venous catheters, initially the 
conventional silicone elastomer strips integrated the FXIIIa inhibitor were prepared 
for sustained release of the enzyme inhibitor. It was found that the release profile of 
the inhibitor could be enhanced by employing bicarbonate (SB) and citric acid (CA) 
as additives in the silicone formulations. From these findings it could be suggested 
that the FXIIIa inhibitor incorporated catheters could offer. 
 
Further studies investigated the application of the TG2 inhibitors in treating of liver 
fibrosis and its end stage disease cirrhosis. Contrary to the conventional view that 
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cirrhosis is an irreversible process, recent evidence suggest that even advanced 
fibrosis is reversible (Friedman, 2000 ; Arthur, 2002 ; Bataller & Brenner, 2005). 
However, there is no efficient pharmaceutical intervention for liver fibrosis at present. 
Liver fibrosis is characterized by increased synthesis and decreased degradation of the 
extracellular matrix. Transglutaminase-mediated covalent cross-linking has been 
implicated in the stabilization and accumulation of ECM in number of fibrotic 
diseases. Thus, the use of tissue transglutaminase (TG2) inhibitors has potential in the 
treatment of liver fibrosis. It has been stated that pharmacological inhibition of TG2 
may have adverse side effects, since TG2 demonstrates a protective role in liver injury 
by enhancing tissue stability and repair. However, it can be argued that intracellular 
and extracellular TG2 is catalytically inactive under normal physiological conditions, 
however physical or certain types of chemical injury can lead to rapid enzymatic 
activation. Therefore, the catalytic activity of TG2 must be activated rapidly when 
required, and inactivated almost immediately after its task is complete. Evidence 
shows that the tissue transglutaminase non-specific inhibitor (cystamine) ameliorates 
carbon tetrachloride (CCl4) induced liver fibrosis via inhibition of TG2. A novel 
group of specific tissue transglutaminase inhibitors has been described recently, which 
has the advantage of targeting TG2 in the extracellular environment this limiting cell 
toxicity. These inhibitors have already indicated that they are successful candidates in 
the cure of kidney fibrosis in animal models. The ultimate aim of the work was to 
develop a drug delivery system which can be applied in the delivery of site-directed 
irreversible transglutaminase inhibitors to the liver which can then be further studied 
for the treatment of liver fibrosis in animal models. In an initial study carried out 
regarding in-vivo pharmacokinetics and biodistribution of these TG2 inhibitors in rats, 
the inhibitor demonstrated a rapid clearance and short half life. Hence, an appropriate 
carrier system was required to improve delivery and targeting of the inhibitor to the 
required side of action i.e. liver. Therefore, liposomes were used as drug delivery 
system for site specific delivery of these inhibitors of transglutaminase to the liver. 
Upon I.V. administration of the TG2 inhibitor-incorporated liposomes, on a per organ 
basis, the uptake of the liposomal-drug delivery system by the liver was significantly 
higher than that taken up by other organs at all time points measured, independent of 
the formulation used. The inherent biodistribution of the liposomes to the liver is due 
to the fenestrated capillaries in the liver, allowing the liposomes to escape from the 
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circulation and be taken up by cells of the MPS.  Thus, liposomes incorporating TG 
inhibitor could potentially offer a novel strategy for treating of liver fibrosis and its 
end stage disease cirrhosis. 
 
7.2 Future directions 
 
• Determining the amount of FXIIIa sequestrated by the inhibitor-and polymer-
coated PU catheters and the inhibitor-incorporated silicone catheters.  
 
• Production of fibrin clots on the inhibitor and polymer coated PU catheters 
and the inhibitor incorporated silicone catheters, assessing the inhibition of 
FXIIIa-mediated fibrin cross-linking and quantitative determination of 
fibrinolysis rate. 
 
• Investigation of the effect of FXIIIa inhibitor integrated catheter on release of 
Staphylococcus aureas from human thrombi 
 
• Inducing liver fibrosis by intraperitoneal (IP) injection of carbon tetrachloride 
(CCl4) in mice and studying the efficacy of TG2 inhibitors (prior to and after 
incorporation into liposomes) in amelioration of liver fibrosis. 
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